Branched linkers for conjugates

Branched linkers with multiple attachment points address the challenges of current conjugate systems by enhancing therapeutic efficacy and pharmacokinetic properties through stable and homogeneous conjugate delivery.

WO2026234447A1PCT designated stage Publication Date: 2026-11-12LIGACHEM BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/000254
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current linker technologies in conjugate systems face challenges such as reduced efficacy, off-target effects, solubility issues, stability concerns, and heterogeneous drug-to-antibody ratios, impacting reproducibility and pharmacokinetics.

Method used

Development of branched linkers with multiple attachment points for conjugates, allowing for the delivery of multiple payloads or synergistic agents, enhancing therapeutic efficacy and pharmacokinetic properties, and utilizing various conjugation methods like maleimide conjugation, cysteine re-bridging, NHS ester conjugation, click chemistry, enzymatic conjugation, and others to achieve stable and homogeneous conjugates.

Benefits of technology

The branched linkers enhance therapeutic efficacy, improve pharmacokinetic properties, and enable co-delivery of synergistic agents, resulting in improved stability and controlled release of payloads.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2026000254_12112026_PF_FP_ABST
    Figure IB2026000254_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are antibody-drug conjugates comprising a structure represented by formula (I) and formula (Ia), or a pharmaceutically acceptable salt thereof, and methods of treating a disorder in a subject, comprising administering a conjugate or composition to the subject: Formulae (I) & (Ia).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No.: LCH-03925

[0002] BRANCHED LINKERS FOR CONJUGATES RELATED APPLICATIONS

[0003] This application claims the benefit of U. S. Provisional Application No. 63 / 802,493, filed May 8, 2025, the contents of which are hereby incorporated by reference herein.

[0004] BACKGROUND

[0005] Conjugate technology allows for the selective targeting of specific cells or tissues by linking a targeting moiety to a functional payload, an approach that enhances the efficacy of the payload while potentially reducing off-target effects. Conjugates can be designed for various applications, such as therapeutics, diagnostics, and research tools.

[0006] One example of conjugate technology is antibody-drug conjugates (ADCs) used in cancer therapy. ADCs combine the specificity of antibodies with potent cytotoxic agents. Another example is folate-drug conjugates, which utilize the overexpression of folate receptors on certain cancer cells to deliver therapeutic payloads. However, conjugate technology extends beyond the aforementioned examples, encompassing various targeting moieties (e.g., peptides, aptamers, small molecules) and payloads (e.g., drugs, imaging agents, nucleic acids).

[0007] The basic structure of a conjugate comprises a “moiety-linker-payload” arrangement. The linker plays a crucial role in connecting the moiety (e.g., a targeting moiety) and the payload, often designed to release the payload under specific conditions. Once a linker is selected for a particular application, typically many methods are available to couple that linker to any desired moiety and payload. The efficacy, safety, and systemic effects of conjugates depend significantly on the stability and properties of the linker.

[0008] Linkers may be classified as non-cleavable or cleavable. When non-cleavable linkers are used, the entire conjugate complex provides the needed activity. Cleavable linkers can be designed to respond to various stimuli, such as pH changes, enzymatic activity, or reducing environments, and may be cleavable inside or outside of a cell. Then, the payload is preferentially released in a target environment. Each type of linker has its advantages and challenges in different applications.

[0009] Current linker technologies face several challenges. Non-cleavable linkers may suffer from reduced efficacy if the conjugate is not efficiently internalized or processed by target cells. Cleavable linkers, while offering controlled release, may be susceptible to premature cleavage in

[0010] -1- FH13323832.11Attorney Docket No.: LCH-03925

[0011] circulation, leading to off-target effects. Some linkers may affect the solubility, stability, or immunogenicity of the conjugate. Additionally, certain conjugation methods may result in heterogeneous products with varying drug-to-antibody ratios, impacting reproducibility and pharmacokinetics. In view of the foregoing, there is an ongoing need for new linker technologies.

[0012] SUMMARY OF THE INVENTION

[0013] In certain aspects, the present disclosure provides conjugates comprising a structure represented by formula I or a pharmaceutically acceptable salt thereof:

[0014]

[0015] I

[0016] wherein

[0017] L1comprises an alkylene (e.g., an alkylene substituted with a reactive group, such as amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl);

[0018] Y1and Y3are each independently O, N(R3), or S;

[0019]

[0020] R1, R2, and R3are each independently H, alkyl, aryl, or aralkyl;

[0021] z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

[0022] Lg is a ligand, an active agent, or a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl such as isoprenyl, or alkynyl).

[0023] In certain aspects, the present disclosure provides conjugates comprising a structure represented by formula la or a pharmaceutically acceptable salt thereof:

[0024] -2- FH13323832.11Attorney Docket No.: LCH-03925

[0025]

[0026] la

[0027] wherein

[0028] L1comprises an alkylene (e.g., an alkylene substituted with a reactive group, such as amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl);

[0029] Y1, Y2, and Y3are each independently O, N(R!), or S;

[0030] X1is -N(R2)C(O)-, -C(O)N(R2)-, -C(O)N(R2)(CH2)Z-, -(CH2)ZC(O)N(R2) -, -C(O)-, -C(O)O-, -OC(O)-, -S(O2)N(R2)-, -N(R2)S(O2)-, -P(O)(R2)N(R3)-, -N(R3)P(O)(R2)-, -P(O)2N(R3)-, or -N(R3)P(O)2-;

[0031] R1, R2, and R3are each independently H, alkyl, aryl, or aralkyl;

[0032] z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

[0033] Lg is a ligand, an active agent, or a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl such as isoprenyl, or alkynyl).

[0034] In certain aspects, the present disclosure provides methods of treating a disease or disorder in a subject, comprising administering a conjugate or composition, or a pharmaceutically acceptable salt thereof, to the subject.

[0035] In certain aspects, the present disclosure provides methods of conjugating an agent (e.g., a ligand) to a branched linker comprising contacting the agent with a conjugate disclosed herein, wherein Lg is a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, aldehyde, ester, amido, alkenyl, or alkynyl).

[0036] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows a graph illustrating the in vivo anti-cancer efficacy and dose-dependent tumor growth inhibition of a CEACAM5 antibody-drug conjugate (ADC1) in a HPAF-II pancreatic cancer xenograft mouse model compared to a control group.

[0037] -3- FH13323832.11Attorney Docket No.: LCH-03925

[0038] FIG. 2 shows a graph illustrating the in vivo anti-cancer efficacy and dose-dependent tumor growth inhibition of a Lewis Y antibody-drug conjugate (ADC1) in an HCT15 colorectal cancer xenograft mouse model compared to a control group.

[0039] FIG. 3 shows a graph illustrating the in vivo anti-cancer efficacy and dose-dependent tumor growth inhibition of a Lewis Y antibody-drug conjugate (ADC2) in an OVCAR3 ovarian cancer xenograft mouse model compared to a control group.

[0040] FIG. 4 shows a graph illustrating the in vivo tumor growth inhibition of a Lewis Y antibody-immune modulator drug conjugate (ADIC1) in an HCT15 colorectal cancer xenograft mouse model compared to a control group.

[0041] FIG. 5 shows a graph illustrating the in vivo anti-cancer efficacy of a Lewis Y antibodydrug conjugate in a tumor xenograft mouse model.

[0042] FIG. 6 shows a graph illustrating the in vivo anti-cancer efficacy of a Lewis Y antibodydrug conjugate in a tumor xenograft mouse model.

[0043] FIG. 7 shows a graph illustrating the in vivo anti-cancer efficacy of a Lewis Y antibodydrug conjugate or antibody-immune modulator drug conjugate in a tumor xenograft mouse model.

[0044] FIG. 8 shows a graph illustrating the in vivo anti-cancer efficacy of a Lewis Y antibodydrug conjugate or antibody-immune modulator drug conjugate in a tumor xenograft mouse model.

[0045] FIG. 9 shows a graph illustrating the in vivo anti-cancer efficacy of a CEACAM5 antibodydrug conjugate in a colon cancer patient-derived xenograft mouse model.

[0046] FIG. 10 shows a graph illustrating the in vivo anti-cancer efficacy of a CEACAM5 antibody-drug conjugate in a colon cancer patient-derived xenograft mouse model.

[0047] FIG. 11 shows a graph illustrating the pharmacokinetic profile of a CEACAM5 antibodydrug conjugate in a Sprague Dawley rat model.

[0048] FIG. 12 shows a graph illustrating the in vivo anti-cancer efficacy and dose-dependent tumor growth inhibition of a Lewis Y antibody-drug conjugate (ADC4) in an HCT15 colorectal cancer xenograft mouse model.

[0049] FIG. 13 shows a graph illustrating the in vivo anti-cancer efficacy of a Lewis Y antibodydrug conjugate (ADC7) in an HCT15 colorectal cancer xenograft mouse model.

[0050] FIG. 14 shows a graph illustrating the in vivo anti-cancer efficacy and dose-dependent tumor growth inhibition of a Lewis Y antibody-drug conjugate (ADC7) in an OVCAR3 ovarian cancer xenograft mouse model.

[0051] -4- FH13323832.11Attorney Docket No.: LCH-03925

[0052] FIG. 15 shows a graph illustrating the in vivo tumor growth inhibition of Lewis Y antibody-drug conjugates (ADC6, ADC8, and ADC9) in an OVCAR3 ovarian cancer xenograft mouse model.

[0053] FIG. 16 shows a graph illustrating the in vivo anti-cancer efficacy of Lewis Y antibodydrug conjugates (ADC6 and ADC9) in an HCT15 colorectal cancer xenograft mouse model.

[0054] FIG. 17 shows a graph illustrating the in vivo anti-tumor activity of Lewis Y antibodydrug conjugates (ADC6, ADC8, and ADC9) in an NCI-N87 gastric cancer xenograft mouse model.

[0055] FIG. 18 shows a graph illustrating the in vivo tumor growth inhibition of a Lewis Y antibody-immune modulator drug conjugate (ADIC2) in an HCT15 colorectal cancer xenograft mouse model.

[0056] FIG. 19 shows a graph illustrating the in vivo anti-cancer efficacy of Lewis Y antibody-immune modulator drug conjugates (ADIC6 and ADIC7) in an HCT15 colorectal cancer xenograft mouse model.

[0057] FIG. 20 shows a graph illustrating the in vivo dose-dependent tumor growth inhibition and anti-tumor activity of a Lewis Y antibody-immune modulator drug conjugate (ADIC7) in an SNU840 ovarian cancer xenograft mouse model.

[0058] FIG. 21 shows a graph illustrating the in vivo tumor growth inhibition of Lewis Y antibody-immune modulator drug conjugates (ADIC8, ADIC11, ADIC12, ADIC13, and ADIC14) in an OVCAR3 ovarian cancer xenograft mouse model.

[0059] FIG. 22 shows a graph illustrating the in vivo anti-cancer efficacy of Lewis Y antibody-immune modulator drug conjugates (ADIC8, ADIC12, and ADIC14) in an HCT15 colorectal cancer xenograft mouse model.

[0060] FIG. 23 shows a graph illustrating the in vivo anti-tumor activity of Lewis Y antibody-immune modulator drug conjugates (ADIC8, ADIC11, ADIC12, ADIC13, and ADIC14) in an NCI-N87 gastric cancer xenograft mouse model.

[0061] FIG. 24 shows a graph illustrating the in vivo anti-tumor activity of a BCMA antibodydrug conjugate (ADC1) in an OPM2-Luc multiple myeloma xenograft mouse model.

[0062] FIG. 25 shows a graph illustrating the in vivo anti-tumor activity of a BCMA antibodydrug conjugate (ADC2) in an OPM2-Luc multiple myeloma xenograft mouse model.

[0063] -5- FH13323832.11Attorney Docket No.: LCH-03925

[0064] FIG. 26 shows a graph illustrating the in vitro tumor cell cytotoxicity of a PD-L1 antibody-immune modulator conjugate in co-cultures of human breast cancer cells and peripheral blood mononuclear cells.

[0065] FIG. 27 shows a graph illustrating the in vitro cancer cell cytotoxicity of a TROP2 antibody-immune modulator drug conjugate (ADIC1) in human breast cancer cell lines.

[0066] FIG. 28 shows a graph illustrating the in vitro cancer cell cytotoxicity of a TROP2 antibody-immune modulator drug conjugate (ADIC2) in human breast cancer cell lines.

[0067] DETAILED DESCRIPTION OF THE INVENTION

[0068] In various aspects, the present disclosure provides linkers, and conjugates comprising those linkers, as well as methods for their synthesis and for their use in therapeutic applications. In particular, the disclosure describes conjugates comprising a structure represented by formula la. That structure incorporates multiple attachment points for coupling to active agents, allowing for the delivery of multiple payloads or the combination of different functionalities within a single conjugate. The branched structure may enhance the therapeutic efficacy, improve pharmacokinetic properties, or allow for the co-delivery of synergistic agents. The conjugates described herein may be particularly useful in the context of antibody-drug conjugates, but the technology is broadly applicable to various targeting moieties and payloads. Indeed, the linkers disclosed herein may be used with existing linker technology in multiple ways, as it sits within a well-developed field with numerous available techniques for assembly of conjugates:

[0069] 1. Maleimide conjugation: This method utilizes the reaction between maleimide groups and thiol groups. For example, antibodies can be partially reduced to expose cysteine residues, which then react with maleimide-functionalized linkers or payloads.

[0070] 2. Cysteine Re-bridging: This technology creates homogeneous and stable ADCs by rebridging reduced interchain disulfide bonds with bifunctional linkers, without the need for antibody engineering.

[0071] 3. N-Hydroxysuccinimide (NHS) ester conjugation: NHS esters react with primary amines, such as lysine residues on proteins. This method is commonly used for attaching linkers or payloads to antibodies or other targeting moieties.

[0072] 4. Click chemistry: Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and strain- promoted azide-alkyne cycloaddition (SPAAC) are widely used for bioorthogonal conjugation. These reactions allow for site-specific attachment of payloads to modified -6- FH13323832.11Attorney Docket No.: LCH-03925

[0073] targeting moieties. Click chemistry offers high specificity and can be performed under mild conditions, making it suitable for a wide range of biomolecules. Recently, metal- free SPAAC cycloaddition reactions have been investigated, including dibenzocyclooctyne (DBCO)-derived molecules covalently linked to the azide group of a functionalized phenylalanine such as para-azidophenylalanine (pAzF) or para- azidomethylphenylalanine (pAMF). Metal-free SPAAC reactions have been shown as promising conjugation reactions for homogeneous, highly stable conjugates with desirable pharmacokinetics and controlled delivery of the potent payload. See e.g., Xenobiotica 2024, Vol. 54, No. 8, 469^191.

[0074] 5. Enzymatic conjugation: Methods such as sortase- mediated ligation or transglutaminase-catalyzed conjugation enable site-specific attachment of payloads to targeting moieties under mild conditions. Sortase A (SrtA) catalyzes trans peptidation to insert recognition peptides at the C-terminus of antibody chains, followed by payload attachment. Bacterial transglutaminases (BTGs) form amide bonds between lysine and glutamine residues, enabling stable payload attachment. Additional examples include (i) conjugation via formyl glycine-generating enzyme, which inserts a specific sequence, converting cysteine to formyl glycine, that can then be conjugated to aldehyde-containing payloads; and (ii) prenyltransferase-mediated conjugation, wherein farnesyl transferase attaches a ketone-functionalized isoprenoid to a C- terminal CaaX motif, which is then linked to a hydroxylamine-bearing payload via oxime ligation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408.

[0075] 6. Hydrazone and oxime ligation: These methods involve the reaction between aldehydes or ketones with hydrazides or aminooxy groups, respectively. Exemplary methods include using amino-terminal engineered serine at the N-terminus, which is oxidized to an aldehyde for oxime ligation.

[0076] 7. Thiol-ene and thiol-yne reactions: These photoinitiated reactions allow for the conjugation of thiol-containing molecules to alkene or alkyne-functionalized components. These methods offer rapid reaction kinetics and can be performed under mild conditions, making them suitable for sensitive biomolecules.

[0077] -7- FH13323832.11Attorney Docket No.: LCH-03925

[0078] 8. Diels- Alder cycloaddition: This reaction between a diene and a dienophile can be used for bioconjugation, particularly when using cyclic dienes like trans-cyclooctene. The reaction proceeds rapidly and specifically under physiological conditions.

[0079] 9. Standing er ligation: This method involves the reaction between an azide and a phosphine to form an amide bond; the method offers high chemoselectivity and can be performed in aqueous media, making it suitable for bioconjugation.

[0080] 10. Photoclick chemistry: Light-induced cycloadditions, such as the reaction between tetrazoles and alkenes, provide spatiotemporal control over the conjugation process. This can be particularly useful for in situ labeling or activation of conjugates. 11. Ligation to Fab nucleotide-binding sites: A method which uses indole-based linkers to target lysine residues in the Fab region’s nucleotide-binding pocket for site-specific conjugation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408. Each conjugation method offers unique advantages and presents specific challenges, and the choice of conjugation method may depend on factors, as readily appreciated by the skilled artisan, such as the nature of the targeting moiety, the payload, and the desired properties of the final conjugate. In many cases, the targeting moiety or payload may be modified to introduce specific functional groups that facilitate conjugation. For example, antibodies may be engineered to incorporate non-natural amino acids with bioorthogonal reactive groups, allowing for conjugation.

[0081] The assembly of conjugates, including antibody-drug conjugates, is a well-established process in the art which can readily be adapted and applied to the embodiments disclosed herein. Those of ordinary skill in the art can readily employ various existing chemistry methods to assemble conjugates efficiently and reliably; such methods allow for the controlled attachment of payloads to targeting moieties through linkers. Several known chemistry methods for assembling conjugates include:

[0082] The skilled artisan can modulate reaction conditions, such as pH, temperature, and reagent concentrations, to achieve desired conjugation efficiencies and product homogeneity. The use of organic co-solvents, catalysts, or additives may be employed to enhance reaction rates or selectivity. In some cases, multiple conjugation steps may be used to assemble complex conjugates with multiple payloads or functionalities.

[0083] -8- FH13323832.11Attorney Docket No.: LCH-03925

[0084] Simply put, notwithstanding the challenges associated with particular linker designs, the conjugation chemistry used to assemble targeting moieties, linkers, and payloads into functional conjugates is a mature field. Indeed, numerous well-characterized methods, such as the methods mentioned above (e.g., maleimide-thiol reactions, click chemistry, NHS ester conjugation, and enzymatic ligation) are available and routinely employed by those of skill in the art. Thus, once the structure and properties of a linker and a synthetic route to the linker are established, the selection and application of appropriate conjugation chemistry to assemble a conjugate is generally routine and predictable.

[0085] In certain aspects, the present disclosure provides a conjugate comprising a structure represented by formula I or a pharmaceutically acceptable salt thereof:

[0086]

[0087] wherein

[0088] L1comprises an alkylene (e.g., an alkylene substituted with a reactive group, such as amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl,

[0089] or alkynyl (

[0090]

[0091] Y1and Y3are each independently O, N(R3), or S;

[0092]

[0093] -N(R3)P(O)2-;

[0094] R1, R2, and R3are each independently H, alkyl, aryl, or aralkyl;

[0095] z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

[0096] -9- FH13323832.11Attorney Docket No.: LCH-03925

[0097] Lg is a ligand, an active agent, or a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl such as isoprenyl, or alkynyl).

[0098] In certain embodiments, an alkenyl is a monovalent straight-chain or branched hydrocarbon radical containing at least one carbon-carbon double bond. In certain embodiments, an alkenyl contains 2 to 20 carbon atoms (C2-C20 alkenyl), 2 to 10 carbon atoms (C2-C10 alkenyl), or 2 to 6 carbon atoms (C2-C6 alkenyl). Representative alkenyl groups include, but are not limited to, vinyl (ethenyl), allyl (prop-2-en-l-yl), propenyl, isopropenyl, butenyl, pentenyl, hexenyl, and prenyl (3-methylbut-2-en-l-yl). In certain embodiments, an alkenyl may have more than one double bond (e.g., dienyl or trienyl). Alkenyl groups may be substituted or unsubstituted. Unless otherwise specified, alkenyl groups may be in either the cis (Z) or trans (E) configuration.

[0099] In certain embodiments, an isoprenyl is an alkenyl group derived from an isoprene unit, having the formula C5H9- and characterized by a branched five-carbon structure containing one carbon-carbon double bond. In certain embodiments, an isoprenyl includes 3-methyl-2-butenyl (also known as prenyl or dimethylallyl), as well as higher isoprenoid-derived groups such as geranyl (C10), farnesyl (C15), and geranylgeranyl (C20). Isoprenyl groups are useful as reactive functionalities for bioconjugation strategies, including prenyltransferase-mediated conjugation. In

[0100] certain embodiments, isoprenyl represents

[0101]

[0102] . In certain embodiments, Y2is H.

[0103] In certain embodiments, the conjugate comprises a structure represented by formula la or a pharmaceutically acceptable salt thereof:

[0104]

[0105] wherein

[0106] L1comprises an alkylene (e.g., an alkylene substituted with a reactive group, such as amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl such as isoprenyl, or alkynyl);

[0107] Y1, Y2, and Y3are each independently O, N(R!), or S;

[0108] -10- FH13323832.11Attorney Docket No.: LCH-03925

[0109] X1is -N(R2)C(O)-, -C(O)N(R2)-, -C(O)N(R2)(CH2)Z-, -(CH2)ZC(O)N(R2) -C(O)-, - C(O)O-, -OC(O)-, -S(O2)N(R2)-, -N(R2)S(O2)-, -P(O)(R2)N(R3)-, -N(R3)P(O)(R2)-, -P(O)2N(R3), or -N(R3)P(O)2-;

[0110] R1, R2, and R3are each independently H, alkyl, aryl, or aralkyl;

[0111] z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

[0112] Lg is a ligand, an active agent, or a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl). In certain

[0113] embodiments, isoprenyl represents

[0114]

[0115] In certain embodiments, the conjugate has a structure represented by formula lb or a pharmaceutically acceptable salt thereof:

[0116]

[0117] lb

[0118] wherein

[0119] L2, L3, and L4each independently comprise an alkylene;

[0120] V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;

[0121] T1, T2, and T3are each independently a bond, -O-, or a self-immolative moiety;

[0122] B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamide, aryl, heteroaryl, or heterocyclyl; or

[0123] V1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety; and ml, m2, and m3 are each independently 1, 2, or 3.

[0124] Those of skill in the art will recognize that variables V1and ml, V2and m2, and V3and m3 are related. For example, those of skill in the art will understand that if ml is 3, then V3will have 3 open valencies. Likewise, if ml is 1, then V1will have at least one open valency. Simply

[0125] -11- FH13323832.11Attorney Docket No.: LCH-03925

[0126] put, the skilled artisan will understand that V1and ml, V2and m2, and V3and m3 will be combined in such a way that stable configurations are obtained based on the valencies required.

[0127] In certain preferred embodiments, Lg is an antibody. In certain embodiments, the antibody is a humanized antibody or a human antibody. In certain embodiments, the antibody is selected from a monoclonal antibody, a domain antibody (dAb), a single chain antibody (scAb), a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single chain variable fragment (scFv), an scFv-Fc fragment, a single domain heavy chain antibody, a single domain light chain antibody, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.

[0128] In certain embodiments, Lg is a reactive group. In certain embodiments, Lg is amino, azido, hydroxylamino, halo, keto, aldehyde, ester, amido, alkenyl, or alkynyl. In certain embodiments,

[0129] Lg is

[0130]

[0131] In other embodiments, Lg is vinylpyridyl. In yet other embodiments, Lg is maleimidyl. In certain embodiments, Lg is azido. In other embodiments, Lg is alkynyl (e.g.,

[0132]

[0133] In certain embodiments, Y1is O.

[0134] In certain embodiments, Y2is O.

[0135] In certain embodiments, Y3is O.

[0136] In certain embodiments, X1is -N(R2)C(O)-. In other embodiments, X1is -C(O)N(R2)-. In certain embodiments, R3is H.

[0137] In certain embodiments, L1comprises a C1-C100 alkylene. In certain embodiments, L1comprises a C1-C50 alkylene. In certain embodiments, L1further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). A glycol - moiety refers to the following unit, 'n, wherein n is an integer from 1 to 15. In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, L1is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro,

[0138] -12- FH13323832.11Attorney Docket No.: LCH-03925

[0139] azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide. In certain embodiments, L1is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino). In certain embodiments, L1further comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In certain preferred embodiments, the amido moieties have a structure O O

[0140] represented by

[0141]

[0142] , wherein the wavy lines represent connections to the remainder of L1. In certain embodiments, L1further comprises a structure represented by formula Ila:

[0143]

[0144] Ila

[0145] wherein

[0146] A1represents a linkage to X1;

[0147] A2represents a linkage to Lg;

[0148] X4and X5are each independently O, S, or N(R7);

[0149] R4and R5are each H or alkyl; or R4and R5combine to form a cycloalkyl;

[0150] R6is H or alkyl; and

[0151] R7is H, alkyl, aryl, or aralkyl.

[0152] In certain embodiments, L1further comprises a structure represented by formula lib:

[0153]

[0154] lib

[0155] wherein

[0156] -13- FH13323832.11Attorney Docket No.: LCH-03925

[0157] A1represents a linkage to X1;

[0158] A2represents a linkage to Lg;

[0159] R4and R5are each H or alkyl; or R4and R5combine to form a cycloalkyl; and

[0160] R6is H or alkyl.

[0161] In certain embodiments, X4is N(R7). In certain embodiments, R7is H.

[0162] In certain embodiments, X5is O.

[0163] In certain embodiments, R4is alkyl (e.g., methyl).

[0164] In certain embodiments, R5is H. In other embodiments, R5is alkyl (e.g., methyl).

[0165] In certain embodiments, R4and R5combine to form a cycloalkyl (e.g., cyclobutyl).

[0166] In certain embodiments, R6is H. In other embodiments, R6is alkyl.

[0167] In certain embodiments, L1further comprises a structure represented by formula lie:

[0168]

[0169] wherein

[0170] A1represents a linkage to X1;

[0171] A2represents a linkage to Lg; and

[0172] R6is H or alkyl, preferably H.

[0173] In certain embodiments, L1further comprises a vinyl pyridine moiety. In other embodiments, L1further comprises a maleimide moiety. In yet other embodiments, L1further comprises a structure represented by formula Illa, Illb or IIIc:

[0174]

[0175] Illa Illb IIIc

[0176] wherein

[0177] each A1represents a linkage to X1;

[0178] each A2represents a linkage to Lg.

[0179] -14- FH13323832.11Attorney Docket No.: LCH-03925

[0180] In certain embodiments, L1further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L1further comprises a structure represented by formula IVa or IVb:

[0181]

[0182] IVa IVb

[0183] wherein

[0184] each A1represents a linkage to X1; and

[0185] each A2represents a linkage to Lg.

[0186] In certain embodiments, L1further comprises a structure represented by formula V:

[0187]

[0188] V

[0189] wherein nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;

[0190] each A1represents a linkage to X1; and

[0191] each A2represents a linkage to Lg.

[0192] In certain preferred embodiments, nl is 1, 2, 3, 4, or 5.

[0193] In certain embodiments, L1further comprises at least one amino acid. In certain embodiments, L1comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In certain embodiments, L1comprises 1 amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid is arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, serine, or threonine. In certain embodiments, the amino acid is arginine, aspartate, glutamate, histidine, lysine, or ornithine. In certain preferred embodiments, the amino acid is aspartate or glutamate. In certain embodiments, L1further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine,

[0194] -15- FH13323832.11Attorney Docket No.: LCH-03925

[0195] and ornithine. In certain embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine. In certain embodiments, L1further comprises a polypeptoid (e.g., polysarcosine).

[0196] In certain embodiments, a polypeptoid comprises repeating N-substituted glycine units having the general structure -[N(R)-CH2-C(O)]n-, wherein R is independently selected for each repeating unit and represents a side chain substituent attached to the backbone nitrogen, and n represents the number of repeating units. In certain embodiments, R is C1-C10 alkyl (e.g., methyl, ethyl, propyl, or butyl). In certain preferred embodiments, the polypeptoid is polysarcosine (poly(N-methylglycine)), wherein each R is methyl. In various embodiments, n is 5 to 200, 10 to 100, 20 to 80, or 30 to 50.

[0197] In certain embodiments, L2comprises a Ci-Cioo alkylene. In certain embodiments, L2comprises a C1-C50 alkylene. In certain embodiments, L2further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties.

[0198] In certain embodiments, L2further comprises amidoalkoxy (e.g., amidomethoxy) or carboxyalkoxy (e.g., carboxymethoxy). In certain embodiments, L2further comprises at least one amido moiety. In certain embodiments, L2further comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain preferred embodiments, L2comprises 1 or 2 amido moieties. In certain preferred

[0199]

[0200] In certain embodiments, L2comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl). In certain embodiments, L2further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L2further comprises a structure represented by formula Via or VIb:

[0201]

[0202] Vla VIb

[0203] wherein

[0204] each Ax1represents a linkage to T1; and

[0205] -16- FH13323832.11Attorney Docket No.: LCH-03925

[0206] each Ax2represents a linkage to V1.

[0207] In certain embodiments, L2is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0208] In certain embodiments, L2further comprises an amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, L2further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. In certain embodiments, L2comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In certain embodiments, L2further comprises at least one amino acid. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine. In certain embodiments, L2further comprises a polypeptoid (e.g., poly sarcosine).

[0209] In certain embodiments, ml is 1. In other embodiments, ml is 2. In yet other embodiments, ml is 3.

[0210] In certain embodiments, V1is a bond.

[0211] In certain embodiments, V1is a bond and ml is 1.

[0212] In certain embodiments, V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by formula Vila or a pharmaceutically acceptable salt thereof:

[0213]

[0214] Vila

[0215] wherein

[0216] Ax3represents a linkage to L2;

[0217] Lx1and Lx2each independently comprise an alkylene;

[0218] -17- FH13323832.11Attorney Docket No.: LCH-03925

[0219] Tx1and Tx2are each independently a bond or a self-immolative moiety; and

[0220] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0221] In certain embodiments, V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula Vllb or a pharmaceutically acceptable salt thereof:

[0222]

[0223] Vllb

[0224] wherein

[0225] Ax3represents a linkage to L2;

[0226] Lx1and Lx2each independently comprise an alkylene;

[0227] Tx1and Tx2are each independently a bond or a self-immolative moiety; and

[0228] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0229] In certain embodiments, V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula Vile or a pharmaceutically acceptable salt thereof:

[0230]

[0231] Vile

[0232] wherein

[0233] Ax3represents a linkage to L2;

[0234] Lx1and Lx2each independently comprise an alkylene;

[0235] Gx1, Gx2, and Gx3are each independently an alkylene,

[0236]

[0237] each Rx1is independently H, alkyl, or aralkyl;

[0238] -18- FH13323832.11Attorney Docket No.: LCH-03925

[0239] Tx1and Tx2are each independently a bond or a self-immolative moiety; and

[0240] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0241] In certain embodiments, V1is C and V1, T1, and B1together represent a branched moiety having a structure represented by formula Vlld or a pharmaceutically acceptable salt thereof:

[0242]

[0243] Vlld

[0244] wherein

[0245] Ax3represents a linkage to L2;

[0246] Lx1, Lx2, and Lx3each independently comprise an alkylene;

[0247] Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; and

[0248] Bx1, Bx2, and Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0249] In certain embodiments, the heteroaryl of Bx1, Bx2, or Bx3is further substituted with alkylene or amido. In certain embodiments, the amido of Bx1, Bx2, or Bx3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

[0250] In certain embodiments, Lx1comprises a C1-C100 alkylene. In certain embodiments, Lx1comprises a C1-C50 alkylene. In certain embodiments, Lx1further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lx1further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain preferred embodiments, the oligoethylene glycol comprises 4 ethylene glycol moieties.

[0251] In certain embodiments, Lx2comprises a C1-C100 alkylene. In certain embodiments, Lx2comprises a C1-C50 alkylene. In certain embodiments, Lx2further comprises an oligoethylene glycol. In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8,

[0252] -19- FH13323832.11Attorney Docket No.: LCH-03925

[0253] 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, Lx2further comprises a heteroaryl (e.g., triazolyl).

[0254] In certain embodiments, Lx3comprises a Ci-Cioo alkylene. In certain embodiments, Lx3comprises a C1-C50 alkylene. In certain embodiments, Lx3further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lx3further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain preferred embodiments, the oligoethylene glycol comprises 4 ethylene glycol moieties.

[0255] In certain embodiments, T1, Tx1, Tx2, or Tx3have a structure represented by formula VIII or a pharmaceutically acceptable salt thereof:

[0256]

[0257] VIII

[0258] wherein

[0259] each Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0260] -, -*C(O)O-,

[0261]

[0262] )N(Rx7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula VIII,

[0263] -20- FH13323832.11Attorney Docket No.: LCH-03925

[0264] Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0265] Ja1is H or alkyl;

[0266] Ja2is H or alkyl; or

[0267] Ja1and Ja2combine to form an oxo;

[0268] tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0269] nxl is 0, 1, 2, or 3;

[0270] Ax4represents a linkage to B1, Bx Bx2, or Bx3; and

[0271] Ax5represents a linkage to L2, Lx1, Lx2, or Lx3.

[0272] In certain embodiments, Rx2is H.

[0273] In certain embodiments, Rx3is H.

[0274] In certain embodiments, Rx4is H.

[0275] In certain embodiments, Rx5is H.

[0276] In certain embodiments, nxl is 0.

[0277] In certain embodiments, Wx1is -*C(O)N(Rx7)-. In certain embodiments, Rx7is alkyl optionally substituted with heteroaryl (e.g., triazolyl). In certain embodiments, when substituted, the heteroaryl of Rx7is substituted with oligoethylene glycol. In certain embodiments, Rx7is substituted with oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl. In certain embodiments, the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol. In other embodiments, the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine). In certain embodiments, the polypeptoid is substituted with an acyl. In certain embodiments, the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol. In certain embodiments, the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

[0278] In certain embodiments, Rx7is H.

[0279] In certain embodiments, Ja1is H.

[0280] In certain embodiments, Ja2is H.

[0281] In other embodiments, Ja1and Ja2combine to form oxo.

[0282] -21- FH13323832.11Attorney Docket No.: LCH-03925

[0283] In certain embodiments, B1is an active agent. In other embodiments, B1is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0284] In certain embodiments, each T1is a bond.

[0285] In certain embodiments, each B1, Bx Bx2, and Bx3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0286] In certain embodiments, L3comprises a C1-C100 alkylene. In certain embodiments, L3comprises a C1-C50 alkylene. In certain embodiments, L3further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 5 or 6 ethylene glycol moieties. In certain embodiments, L3further comprises at least one amido moiety. In certain embodiments, L3comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain embodiments, L3comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxylamido). In certain preferred embodiments, the amido moieties have a structure

[0287]

[0288] In certain embodiments, L3comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl). In certain embodiments, L3further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

[0289] In certain embodiments, L3further comprises a structure represented by formula IXa or IXb:

[0290]

[0291] IXa IXb

[0292] wherein

[0293] each Ay1represents a linkage to T2; and

[0294] each Ay2represents a linkage to V2.

[0295] -22- FH13323832.11Attorney Docket No.: LCH-03925

[0296] In certain embodiments, L3is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0297] In certain embodiments, L3further comprises an amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, L3further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. In certain embodiments, L3comprises 1 amino acid. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine. In certain embodiments, L3further comprises a polypeptoid (e.g., polysarcosine).

[0298] In certain embodiments, V2is a bond. In certain embodiments, V2is a bond and m2 is 1. In certain embodiments, V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by formula Xa or a pharmaceutically acceptable salt thereof:

[0299]

[0300] Xa

[0301] wherein

[0302] Ay3represents a linkage to L3;

[0303] Ly1and Ly2each independently comprise an alkylene;

[0304] Ty1and Ty2are each independently a bond, or a self-immolative moiety; and

[0305] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0306] -23- FH13323832.11Attorney Docket No.: LCH-03925

[0307] In certain embodiments, V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula Xb or a pharmaceutically acceptable salt thereof:

[0308]

[0309] Xb

[0310] wherein

[0311] Ay3represents a linkage to L3;

[0312] Ly1and Ly2each independently comprise an alkylene;

[0313] Ty1and Ty2are each independently a bond or a self-immolative moiety; and

[0314] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0315] In certain embodiments, V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula Xc or a pharmaceutically acceptable salt thereof:

[0316]

[0317] Xc

[0318] wherein:

[0319] Ay3represents a linkage to L3;

[0320] Ly1and Ly2each independently comprise an alkylene;

[0321] Gy1, Gy2, and Gy3are each independently an alkylene,

[0322]

[0323] each Ry1is independently H, alkyl, or aralkyl;

[0324] Ty1and Ty2are each independently a bond or a self-immolative moiety; and

[0325] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0326] -24- FH13323832.11Attorney Docket No.: LCH-03925

[0327] In certain embodiments, V2is C and V2, T2, and B2together represent a branched moiety having a structure represented by formula Xd or a pharmaceutically acceptable salt thereof:

[0328]

[0329] Xd

[0330] wherein:

[0331] Ay3represents a linkage to L3;

[0332] Ly1, Ly2, and Ly3each independently comprise an alkylene;

[0333] Ty1, Ty2, and Ty3are each independently a bond or a self-immolative moiety; and

[0334] By1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0335] In certain embodiments, the heteroaryl of By1, By2, or By3is further substituted with alkylene or amido. In certain embodiments, the amido of By1, By2, or By3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

[0336] In certain embodiments, Ly1comprises a C1-C100 alkylene. In certain embodiments, Ly1comprises a C1-C50 alkylene. In other embodiments, Ly1further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Ly1further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0337] In certain embodiments, Ly2comprises a C1-C100 alkylene. In certain embodiments, Ly2comprises a C1-C50 alkylene. In certain embodiments, Ly2further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In other embodiments, Ly2further comprises a heteroaryl (e.g., triazolyl).

[0338] -25- FH13323832.11Attorney Docket No.: LCH-03925

[0339] In certain embodiments, Ly3comprises a C1-C100 alkylene. In certain embodiments, Ly3comprises a C1-C50 alkylene. In certain embodiments, Ly3further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In other embodiments, Ly3further comprises a heteroaryl (e.g., triazolyl).

[0340] In certain embodiments, T2, Ty1, Ty2, or Ty3has a structure represented by formula XI or a pharmaceutically acceptable salt thereof:

[0341]

[0342] wherein

[0343] each Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0344] each Wy1is independently - -*C(O)O-, -*S(O2)N

[0345]

[0346] wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XI,

[0347] Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0348] Jb1is H or alkyl;

[0349] -26- FH13323832.11Attorney Docket No.: LCH-03925

[0350] Jb2is H or alkyl; or

[0351] Jb1and Jb2combine to form an oxo;

[0352] ty1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0353] ny1 is 0, 1, 2, or 3;

[0354] Ay4represents a linkage to B1, By1, By2, or By3; and

[0355] Ay5represents a linkage to L3, Ly1, Ly2, or Ly3.

[0356] In certain embodiments, each Ry2is H.

[0357] In certain embodiments, each Ry3is H.

[0358] In certain embodiments, each Ry4is H.

[0359] In certain embodiments, each Ry5is H.

[0360] In certain embodiments, each nyl is 0.

[0361] In certain embodiments, each Wy1is -*C(O)N(Ry7)-. In certain embodiments, Ry7is alkyl optionally substituted with heteroaryl (e.g., triazolyl). In certain embodiments, when substituted, the heteroaryl of Ry7is substituted with oligoethylene glycol. In certain embodiments, Ry7is substituted with oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl. In certain embodiments, the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol. In other embodiments, the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine). In certain embodiments, the polypeptoid is substituted with an acyl. In certain embodiments, the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol. In certain embodiments, the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

[0362] In certain embodiments, each Ry7is H.

[0363] In certain embodiments, Jb1is H.

[0364] In certain embodiments, Jb2is H.

[0365] In other embodiments, Jb1and Jb2combine to form an oxo.

[0366] In certain embodiments, B2is an active agent.

[0367] In certain embodiments, m2 is 1. In other embodiments, m2 is 2. In yet other embodiments, m2 is 3.

[0368] In certain embodiments, each T2is a bond.

[0369] -27- FH13323832.11Attorney Docket No.: LCH-03925

[0370] In certain embodiments, each B2, By1, By2, and By3is independently H, hydroxyl, guanidyl, sulfate, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0371] In certain embodiments, each B2is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0372] In certain embodiments, B2is alkyl (e.g., ethyl) substituted with phosphonatyl. In other embodiments, B2is alkyl (e.g., ethyl) substituted with phosphatyl. In yet other embodiments, B2is alkyl substituted with hydroxyl (e.g., 1, 2,3, 4, 5, or 6 hydroxyl groups). In certain embodiments, B2is amido (e.g., piperazineamido). In certain embodiments, B2is heterocyclyl (e.g., piperazyl). In certain embodiments, B2is alkoxy (e.g., methoxy). In certain embodiments, B2is carboxyl. In certain embodiments, B2is heteroaryl (e.g., tetrazolyl). In certain embodiments, B2is hydroxyl. In certain embodiments, B2is amino (e.g., dimethyl amino).

[0373] In certain embodiments, L4comprises a Ci-Cioo alkylene. In certain embodiments, L4comprises a C1-C50 alkylene. In certain embodiments, L4further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 6 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol further comprises at least one amido moiety. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain embodiments, L4comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl). In certain embodiments, L4further comprises a heteroaryl (e.g., pyrazolyl, triazolyl).

[0374] In certain embodiments, the oligoethylene glycol further comprises 1 or 2 amido moieties.

[0375]

[0376] In certain preferred embodiments, the amido moieties have a structure represented by H

[0377] O

[0378]

[0379] , wherein the wavy lines represent connections to the remainder of L.

[0380] In certain embodiments, L4further comprises a structure represented by formula Xlla or Xllb:

[0381] -28- FH13323832.11Attorney Docket No.: LCH-03925

[0382]

[0383] Xlla Xllb

[0384] wherein

[0385] each Az1represents a linkage to T3; and

[0386] each Az2represents a linkage to V3.

[0387] In certain embodiments, L2is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0388] In certain embodiments, L4further comprises an amino acid. In certain embodiments, L4further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In certain embodiments, L4comprises 1 amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine. In certain embodiments, L4further comprises a polypeptoid (e.g., polysarcosine).

[0389] In certain embodiments, V3is a bond. In certain embodiments, V3is a bond and m3 is 1. In certain embodiments, V3is N and V3, T3, and B3together represent a branched moiety having a structure represented by formula Xllla or a pharmaceutically acceptable salt thereof:

[0390]

[0391] -29- FH13323832.11Attorney Docket No.: LCH-03925

[0392] Xllla

[0393] wherein

[0394] Az3represents a linkage to L4;

[0395] Lz1and Lz2each independently comprise an alkylene;

[0396] Tz1and Tz2are each independently a bond or a self-immolative moiety; and

[0397] Bz1and Bz2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0398] In certain embodiments, V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula Xlllb or a pharmaceutically acceptable salt thereof:

[0399]

[0400] Xlllb

[0401] wherein

[0402] Az3represents a linkage to L4;

[0403] Lz1and Lz2each independently comprise an alkylene;

[0404] Tz1and Tz2are each independently a bond or a self-immolative moiety; and

[0405] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0406] In certain embodiments, V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula XIIIc or a pharmaceutically acceptable salt thereof:

[0407]

[0408] XIIIc

[0409] wherein

[0410] Az3represents a linkage to L4;

[0411] Lz1and Lz2each independently comprise an alkylene;

[0412] -30- FH13323832.11Attorney Docket No.: LCH-03925

[0413] Gz1, Gz2, and Gz3are each independently an alkylene,

[0414]

[0415] each Rz1is independently H, alkyl, or aralkyl;

[0416] Lz1and Lz2each independently comprise an alkylene;

[0417] Tz1and Tz2are each independently a bond or a self-immolative moiety; and

[0418] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin).

[0419] In certain embodiments, V3is C and V3, T3, and B3together represent a branched moiety having a structure represented by formula XIIId or a pharmaceutically acceptable salt thereof:

[0420]

[0421] XIIId

[0422] wherein

[0423] Az3represents a linkage to L4;

[0424] Lz1, Lz2, and Lz3each independently comprise an alkylene;

[0425] Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; and

[0426] Bz1, Bz2, and Bz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0427] In certain embodiments, the heteroaryl of Bz1, Bz2, or Bz3is further substituted with alkylene or amido. In certain embodiments, the amido of Bz1, Bz2, or Bz3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

[0428] In certain embodiments, Lz1comprises a C1-C100 alkylene. In certain embodiments, Lz1comprises a C1-C50 alkylene. In certain embodiments, Lz1further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lz1further comprises an oligoethylene glycol. In certain embodiments, Lz1comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, Lz1comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0429] -31- FH13323832.11Attorney Docket No.: LCH-03925

[0430] In certain embodiments, Lz2comprises a C1-C100 alkylene. In certain embodiments, Lz2comprises a C1-C50 alkylene. In certain embodiments, Lz2further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lz2further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0431] In other embodiments, Lz2further comprises at least one amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid is arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, serine, or threonine. In certain embodiments, the amino acid is arginine, aspartate, glutamate, histidine, lysine, or ornithine. In certain embodiments, the amino acid is aspartate or glutamate. In certain embodiments, Lz2further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In certain embodiments, Lz2further comprises a heteroaryl (e.g., triazolyl).

[0432] In certain embodiments, Lz3comprises a C1-C100 alkylene. In certain embodiments, Lz3comprises a C1-C50 alkylene. In certain embodiments, Lz3further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lz3further comprises an oligoethylene glycol. In certain embodiments, Lz3comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, Lz3comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, Lz3further comprises a heteroaryl (e.g., triazolyl).

[0433] In certain embodiments, T3, Tz1, Tz2, or Tz3have a structure represented by formula XIV or a pharmaceutically acceptable salt thereof:

[0434] -32- FH13323832.11Attorney Docket No.: LCH-03925

[0435]

[0436] wherein

[0437] each Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0438] *C(O)O-,

[0439]

[0440] (Rz7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XIV, Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0441] Jc1is H or alkyl;

[0442] Jc2is H or alkyl; or

[0443] Jc1and Jc2combine to form an oxo;

[0444] tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0445] nzl is 0, 1, 2, or 3;

[0446] Az4represents a linkage to B3, Bz1, Bz2, or Bz3; and

[0447] Az5represents a linkage to L4, Lz1, Lz2, or Lz3.

[0448] In certain embodiments, Rz2is H.

[0449] In certain embodiments, Rz3is H.

[0450] In certain embodiments, Rz4is H.

[0451] -33- FH13323832.11Attorney Docket No.: LCH-03925

[0452] In certain embodiments, Rz5is H.

[0453] In certain embodiments, nzl is 0.

[0454] In certain embodiments, Wz1is -*C(O)N(Rz7)-. In certain embodiments, Rz7is alkyl optionally substituted with heteroaryl (e.g., triazolyl). In certain embodiments, the heteroaryl of Rz7is substituted with an oligoethylene glycol. In certain embodiments, Rz7is substituted with oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl. In certain embodiments, the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol. In other embodiments, the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine). In certain embodiments, the polypeptoid is substituted with an acyl. In certain embodiments, the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol. In certain embodiments, the oligoethylene glycol is substituted with alkyl (e.g., hydroxy alkyl or carboxy alkyl).

[0455] In certain embodiments, Rz7is H.

[0456] In certain embodiments, Jc1is H.

[0457] In certain embodiments, Jc2is H.

[0458] In other embodiments, Jc1and Jc2combine to form an oxo.

[0459] In certain embodiments, m3 is 1. In other embodiments, m3 is 2. In yet other embodiments, m3 is 3.

[0460] In certain embodiments, each B3, Bz1, Bz2, and Bz3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0461] In certain embodiments, each B3is an active agent. In other embodiments, each B3is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0462] In certain embodiments, each T3is a bond.

[0463] In certain embodiments, the conjugate comprises a structure selected from:

[0464] -34- FH13323832.11Attorney Docket No.: LCH-03925

[0465]

[0466] -35- FH13323832.11Attorney Docket No.: LCH-03925

[0467]

[0468] -36- FH13323832.11Attorney Docket No.: LCH-03925

[0469]

[0470] -37- FH13323832.11Attorney Docket No.: LCH-03925

[0471]

[0472] -38- FH13323832.11Attorney Docket No.: LCH-03925

[0473]

[0474] -39- FH13323832.11Attorney Docket No.: LCH-03925

[0475]

[0476] -40- FH13323832.11Attorney Docket No.: LCH-03925

[0477]

[0478] -41- FH13323832.11Attorney Docket No.: LCH-03925

[0479]

[0480] -42- FH13323832.11Attorney Docket No.: LCH-03925

[0481]

[0482] -43- FH13323832.11Attorney Docket No.: LCH-03925

[0483]

[0484] -44- FH13323832.11Attorney Docket No.: LCH-03925

[0485]

[0486] -45- FH13323832.11Attorney Docket No.: LCH-03925

[0487]

[0488] -46- FH13323832.11Attorney Docket No.: LCH-03925

[0489]

[0490] -47- FH13323832.11Attorney Docket No.: LCH-03925

[0491]

[0492] -48- FH13323832.11Attorney Docket No.: LCH-03925

[0493]

[0494] -49- FH13323832.11Attorney Docket No.: LCH-03925

[0495]

[0496] -50- FH13323832.11Attorney Docket No.: LCH-03925

[0497]

[0498] -51- FH13323832.11Attorney Docket No.: LCH-03925

[0499]

[0500] -52- FH13323832.11Attorney Docket No.: LCH-03925

[0501]

[0502] -53- FH13323832.11Attorney Docket No.: LCH-03925

[0503]

[0504] -54- FH13323832.11Attorney Docket No.: LCH-03925

[0505]

[0506] -55- FH13323832.11Attorney Docket No.: LCH-03925

[0507]

[0508] -56- FH13323832.11Attorney Docket No.: LCH-03925

[0509]

[0510] -57- FH13323832.11Attorney Docket No.: LCH-03925

[0511]

[0512] -58- FH13323832.11Attorney Docket No.: LCH-03925

[0513]

[0514] -59- FH13323832.11Attorney Docket No.: LCH-03925

[0515]

[0516] -60- FH13323832.11Attorney Docket No.: LCH-03925

[0517]

[0518] -61- FH13323832.11Attorney Docket No.: LCH-03925

[0519]

[0520] -62- FH13323832.11Attorney Docket No.: LCH-03925

[0521]

[0522] -63- FH13323832.11Attorney Docket No.: LCH-03925

[0523]

[0524] -64- FH13323832.11Attorney Docket No.: LCH-03925

[0525]

[0526] -65- FH13323832.11Attorney Docket No.: LCH-03925

[0527]

[0528] -66- FH13323832.11Attorney Docket No.: LCH-03925

[0529]

[0530] -67- FH13323832.11Attorney Docket No.: LCH-03925

[0531]

[0532] -68- FH13323832.11Attorney Docket No.: LCH-03925

[0533]

[0534] -69- FH13323832.11Attorney Docket No.: LCH-03925

[0535]

[0536] -70- FH13323832.11Attorney Docket No.: LCH-03925

[0537]

[0538] -71- FH13323832.11Attorney Docket No.: LCH-03925

[0539]

[0540] -72- FH13323832.11Attorney Docket No.: LCH-03925

[0541]

[0542] -73- FH13323832.11Attorney Docket No.: LCH-03925

[0543]

[0544] -74- FH13323832.11Attorney Docket No.: LCH-03925

[0545]

[0546] -75- FH13323832.11Attorney Docket No.: LCH-03925

[0547]

[0548] -76- FH13323832.11Attorney Docket No.: LCH-03925

[0549]

[0550] -77- FH13323832.11Attorney Docket No.: LCH-03925

[0551]

[0552] -78- FH13323832.11Attorney Docket No.: LCH-03925

[0553]

[0554] -79- FH13323832.11Attorney Docket No.: LCH-03925

[0555]

[0556] -80- FH13323832.11Attorney Docket No.: LCH-03925

[0557]

[0558] -81- FH13323832.11Attorney Docket No.: LCH-03925

[0559]

[0560] -82- FH13323832.11Attorney Docket No.: LCH-03925

[0561]

[0562] -83- FH13323832.11Attorney Docket No.: LCH-03925

[0563]

[0564] -84- FH13323832.11Attorney Docket No.: LCH-03925

[0565]

[0566] -85- FH13323832.11Attorney Docket No.: LCH-03925

[0567]

[0568] -86- FH13323832.11Attorney Docket No.: LCH-03925

[0569]

[0570] -87- FH13323832.11Attorney Docket No.: LCH-03925

[0571]

[0572] -88- FH13323832.11Attorney Docket No.: LCH-03925

[0573]

[0574] -89- FH13323832.11Attorney Docket No.: LCH-03925

[0575]

[0576] -90- FH13323832.11Attorney Docket No.: LCH-03925

[0577]

[0578] -91- FH13323832.11

[0579]

[0580] -854-Attorney Docket No.: LCH-03925

[0581]

[0582] -93- FH13323832.11Attorney Docket No.: LCH-03925

[0583]

[0584] -94- FH13323832.11Attorney Docket No.: LCH-03925

[0585]

[0586] -95- FH13323832.11Attorney Docket No.: LCH-03925

[0587]

[0588] -96- FH13323832.11Attorney Docket No.: LCH-03925

[0589]

[0590] -97- FH13323832.11Attorney Docket No.: LCH-03925

[0591]

[0592] -98- FH13323832.11Attorney Docket No.: LCH-03925

[0593]

[0594] -99- FH13323832.11Attorney Docket No.: LCH-03925

[0595]

[0596] -100- FH13323832.11Attorney Docket No.: LCH-03925

[0597]

[0598] -101- FH13323832.11Attorney Docket No.: LCH-03925

[0599]

[0600] -102- FH13323832.11Attorney Docket No.: LCH-03925

[0601]

[0602] -103- FH13323832.11Attorney Docket No.: LCH-03925

[0603]

[0604] -104- FH13323832.11Attorney Docket No.: LCH-03925

[0605]

[0606] -105- FH13323832.11Attorney Docket No.: LCH-03925

[0607]

[0608] -106- FH13323832.11

[0609]

[0610] FH13323832.11

[0611]

[0612] FH13323832.11Attorney Docket No.: LCH-03925

[0613]

[0614] -109- FH13323832.11Attorney Docket No.: LCH-03925

[0615]

[0616] -110- FH13323832.11Attorney Docket No.: LCH-03925

[0617]

[0618] -Ill- FH13323832.11Attorney Docket No.: LCH-03925

[0619]

[0620] -112- FH13323832.11Attorney Docket No.: LCH-03925

[0621]

[0622] -113- FH13323832.11Attorney Docket No.: LCH-03925

[0623]

[0624] -114- FH13323832.11Attorney Docket No.: LCH-03925

[0625]

[0626] -115- FH13323832.11Attorney Docket No.: LCH-03925

[0627]

[0628] -116- FH13323832.11Attorney Docket No.: LCH-03925

[0629]

[0630] -117- FH13323832.11Attorney Docket No.: LCH-03925

[0631]

[0632] -118- FH13323832.11Attorney Docket No.: LCH-03925

[0633]

[0634] -119- FH13323832.11Attorney Docket No.: LCH-03925

[0635]

[0636] -120- FH13323832.11Attorney Docket No.: LCH-03925

[0637]

[0638] -121- FH13323832.11Attorney Docket No.: LCH-03925

[0639]

[0640] -122- FH13323832.11Attorney Docket No.: LCH-03925

[0641]

[0642] -123- FH13323832.11Attorney Docket No.: LCH-03925

[0643]

[0644] -124- FH13323832.11Attorney Docket No.: LCH-03925

[0645]

[0646] -125- FH13323832.11Attorney Docket No.: LCH-03925

[0647]

[0648] -126- FH13323832.11Attorney Docket No.: LCH-03925

[0649]

[0650] -127- FH13323832.11Attorney Docket No.: LCH-03925

[0651]

[0652] -128- FH13323832.11Attorney Docket No.: LCH-03925

[0653]

[0654] FH13323832.11Attorney Docket No.: LCH-03925

[0655]

[0656] -130- FH13323832.11Attorney Docket No.: LCH-03925

[0657]

[0658] -131- FH13323832.11Attorney Docket No.: LCH-03925

[0659]

[0660] -132- FH13323832.11Attorney Docket No.: LCH-03925

[0661]

[0662] FH13323832.11 -133-Attorney Docket No.: LCH-03925

[0663]

[0664] -134- FH13323832.11Attorney Docket No.: LCH-03925

[0665]

[0666] -135- FH13323832.11Attorney Docket No.: LCH-03925

[0667]

[0668] -136- FH13323832.11Attorney Docket No.: LCH-03925

[0669]

[0670] -137- FH13323832.11Attorney Docket No.: LCH-03925

[0671]

[0672] -138- FH13323832.11Attorney Docket No.: LCH-03925

[0673]

[0674] FH13323832.11 -139-Attorney Docket No.: LCH-03925

[0675]

[0676] -140- FH13323832.11Attorney Docket No.: LCH-03925

[0677]

[0678] -141- FH13323832.11Attorney Docket No.: LCH-03925

[0679]

[0680] -142- FH13323832.11Attorney Docket No.: LCH-03925

[0681]

[0682] -143- FH13323832.11Attorney Docket No.: LCH-03925

[0683]

[0684] -144- FH13323832.11Attorney Docket No.: LCH-03925

[0685]

[0686] -145- FH13323832.11Attorney Docket No.: LCH-03925

[0687]

[0688] -146- FH13323832.11Attorney Docket No.: LCH-03925

[0689]

[0690] -147- FH13323832.11Attorney Docket No.: LCH-03925

[0691]

[0692] -148- FH13323832.11Attorney Docket No.: LCH-03925

[0693]

[0694] -149- FH13323832.11Attorney Docket No.: LCH-03925

[0695]

[0696] -150- FH13323832.11Attorney Docket No.: LCH-03925

[0697]

[0698] -151- FH13323832.11Attorney Docket No.: LCH-03925

[0699]

[0700] -152- FH13323832.11Attorney Docket No.: LCH-03925

[0701]

[0702] -153- FH13323832.11Attorney Docket No.: LCH-03925

[0703]

[0704] -154- FH13323832.11Attorney Docket No.: LCH-03925

[0705]

[0706] -155- FH13323832.11Attorney Docket No.: LCH-03925

[0707]

[0708] -156- FH13323832.11Attorney Docket No.: LCH-03925

[0709]

[0710] -157- FH13323832.11Attorney Docket No.: LCH-03925

[0711]

[0712] -158- FH13323832.11Attorney Docket No.: LCH-03925

[0713]

[0714] -159- FH13323832.11Attorney Docket No.: LCH-03925

[0715]

[0716] -160- FH13323832.11Attorney Docket No.: LCH-03925

[0717]

[0718] -161- FH13323832.11Attorney Docket No.: LCH-03925

[0719]

[0720] -162- FH13323832.11Attorney Docket No.: LCH-03925

[0721]

[0722] -163- FH13323832.11Attorney Docket No.: LCH-03925

[0723]

[0724] -164- FH13323832.11Attorney Docket No.: LCH-03925

[0725]

[0726] -165- FH13323832.11Attorney Docket No.: LCH-03925

[0727]

[0728] -166- FH13323832.11Attorney Docket No.: LCH-03925

[0729]

[0730] -167- FH13323832.11Attorney Docket No.: LCH-03925

[0731]

[0732] -168- FH13323832.11Attorney Docket No.: LCH-03925

[0733]

[0734] -169- FH13323832.11Attorney Docket No.: LCH-03925

[0735]

[0736] -170- FH13323832.11Attorney Docket No.: LCH-03925

[0737]

[0738] -171- FH13323832.11Attorney Docket No.: LCH-03925

[0739]

[0740] -172- FH13323832.11Attorney Docket No.: LCH-03925

[0741]

[0742] -173- FH13323832.11Attorney Docket No.: LCH-03925

[0743]

[0744] -174- FH13323832.11Attorney Docket No.: LCH-03925

[0745]

[0746] -175- FH13323832.11Attorney Docket No.: LCH-03925

[0747]

[0748] -176- FH13323832.11Attorney Docket No.: LCH-03925

[0749]

[0750] -177- FH13323832.11Attorney Docket No.: LCH-03925

[0751]

[0752] -178- FH13323832.11Attorney Docket No.: LCH-03925

[0753]

[0754] -179- FH13323832.11Attorney Docket No.: LCH-03925

[0755]

[0756] -180- FH13323832.11Attorney Docket No.: LCH-03925

[0757]

[0758] -181- FH13323832.11Attorney Docket No.: LCH-03925

[0759]

[0760] -182- FH13323832.11Attorney Docket No.: LCH-03925

[0761]

[0762] -183- FH13323832.11Attorney Docket No.: LCH-03925

[0763]

[0764] -184- FH13323832.11Attorney Docket No.: LCH-03925

[0765]

[0766] -185- FH13323832.11Attorney Docket No.: LCH-03925

[0767]

[0768] -186- FH13323832.11Attorney Docket No.: LCH-03925

[0769]

[0770] -187- FH13323832.11Attorney Docket No.: LCH-03925

[0771]

[0772] -188- FH13323832.11Attorney Docket No.: LCH-03925

[0773]

[0774] -189- FH13323832.11Attorney Docket No.: LCH-03925

[0775]

[0776] -190- FH13323832.11Attorney Docket No.: LCH-03925

[0777]

[0778] -191- FH13323832.11Attorney Docket No.: LCH-03925

[0779]

[0780] -192- FH13323832.11Attorney Docket No.: LCH-03925

[0781]

[0782] -193- FH13323832.11Attorney Docket No.: LCH-03925

[0783]

[0784] -194- FH13323832.11Attorney Docket No.: LCH-03925

[0785]

[0786] -195- FH13323832.11Attorney Docket No.: LCH-03925

[0787]

[0788] -196- FH13323832.11Attorney Docket No.: LCH-03925

[0789]

[0790] ; or a pharmaceutically acceptable salt thereof.

[0791] In certain embodiments, the compound is selected from:

[0792] -197- FH13323832.11Attorney Docket No.: LCH-03925

[0793]

[0794] -198- FH13323832.11Attorney Docket No.: LCH-03925

[0795]

[0796] -199- FH13323832.11Attorney Docket No.: LCH-03925

[0797]

[0798] -200- FH13323832.11Attorney Docket No.: LCH-03925

[0799]

[0800] -201- FH13323832.11Attorney Docket No.: LCH-03925

[0801]

[0802] -202- FH13323832.11Attorney Docket No.: LCH-03925

[0803]

[0804] -203- FH13323832.11Attorney Docket No.: LCH-03925

[0805]

[0806] -204- FH13323832.11Attorney Docket No.: LCH-03925

[0807]

[0808] -205- FH13323832.11Attorney Docket No.: LCH-03925

[0809]

[0810] -206- FH13323832.11Attorney Docket No.: LCH-03925

[0811]

[0812] -207- FH13323832.11Attorney Docket No.: LCH-03925

[0813]

[0814] -208- FH13323832.11Attorney Docket No.: LCH-03925

[0815]

[0816] -209- FH13323832.11Attorney Docket No.: LCH-03925

[0817]

[0818] -210- FH13323832.11Attorney Docket No.: LCH-03925

[0819]

[0820] -211- FH13323832.11Attorney Docket No.: LCH-03925

[0821]

[0822] -212- FH13323832.11Attorney Docket No.: LCH-03925

[0823]

[0824] -213- FH13323832.11Attorney Docket No.: LCH-03925

[0825]

[0826] -214- FH13323832.11Attorney Docket No.: LCH-03925

[0827]

[0828] -215- FH13323832.11Attorney Docket No.: LCH-03925

[0829]

[0830] -216- FH13323832.11Attorney Docket No.: LCH-03925

[0831]

[0832] -217- FH13323832.11Attorney Docket No.: LCH-03925

[0833]

[0834] -218- FH13323832.11Attorney Docket No.: LCH-03925

[0835]

[0836] -219- FH13323832.11Attorney Docket No.: LCH-03925

[0837]

[0838] -220- FH13323832.11Attorney Docket No.: LCH-03925

[0839]

[0840] -221- FH13323832.11Attorney Docket No.: LCH-03925

[0841]

[0842] -222- FH13323832.11Attorney Docket No.: LCH-03925

[0843]

[0844] -223- FH13323832.11Attorney Docket No.: LCH-03925

[0845]

[0846] -224- FH13323832.11Attorney Docket No.: LCH-03925

[0847]

[0848] -225- FH13323832.11Attorney Docket No.: LCH-03925

[0849]

[0850] -226- FH13323832.11Attorney Docket No.: LCH-03925

[0851]

[0852] or a pharmaceutically acceptable salt thereof.

[0853] In certain embodiments, the conjugate is selected from:

[0854] -227- FH13323832.11Attorney Docket No.: LCH-03925

[0855]

[0856] -228- FH13323832.11Attorney Docket No.: LCH-03925

[0857]

[0858] -229- FH13323832.11Attorney Docket No.: LCH-03925

[0859]

[0860] -230- FH13323832.11Attorney Docket No.: LCH-03925

[0861]

[0862] -231- FH13323832.11Attorney Docket No.: LCH-03925

[0863] In certain embodiments, each active agent is independently a chemotherapeutic agent or a toxin, or a combination thereof. In certain embodiments, each active agent is a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, an antiparasitic agent, and a combination thereof. In certain embodiments, each of B1, B2, B3, Bx1, Bx2, By1, By2, Bz1, or Bz2

[0864]

[0865] -232- FH13323832.11Attorney Docket No.: LCH-03925

[0866]

[0867] In certain embodiments, each active agent is a cytotoxic compound selected from a mitotic inhibitor, a DNA alkylating agent, an RNA targeting agent and a topoisomerase inhibitor, or a combination thereof. In certain embodiments, the cytotoxic compound is a thailanstatin or an amatoxin. In certain embodiments, the cytotoxic compound is selected from an auristatin, a maytansinoid, a tubulysin, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine, and a camptothecin, or a combination thereof.

[0868] In other embodiments, the active agent is selected from:

[0869] -233- FH13323832.11Attorney Docket No.: LCH-03925

[0870] (a) erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, ethylenimine, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, topotecan, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotoxin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomysins, actinomycin, antimycin, azaserine, bleomycins, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L- norleucine, doxorubicin, morpholinodoxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, liposomal doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6- mercaptopurine, thiamiprine, thioguanine, ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatrexate, demecolcine, diaziquone, eflornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidanmol, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2, 2’, 2” -trichlorotriethylamine, T-2 toxin, verracurin A, roridin A, and anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol,

[0871] -234- FH13323832.11Attorney Docket No.: LCH-03925

[0872] pipobroman, arabinoside, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, docetaxel, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, vincristine, vinorelbine, novantrone, teniposide, daunomycin, aminopterin, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, or pharmaceutically acceptable salts, solvates, or acids of any of the foregoing;

[0873] (b) monokine, a lymphokine, a traditional polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a, tumor necrosis factor-p, Mullerian inhibiting substance, mouse gonadotropin associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, an osteoinductive factor, an interferon, interferon-oc, interferon-P, interferon-y, a colony stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, an interleukin (IL), IL- 1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, polypeptide factor, LIF, kit ligand, or a combination of any of the foregoing;

[0874] (c) diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, amanitin a- amanitin, pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, an auristatin, tubulysin, geldanamycin, maytansinoid, SG2285, cryptophycin, an enediyne antibiotic, epothilone, taltobulin, azonafide, a toxoid, or a combination of any of the foregoing;

[0875] (d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, or a combination of any of the foregoing;

[0876] (e) a radioactive label,32P,35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination of any of the foregoing;

[0877] (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, and an anti-parasitic agent, or a combination of any of the foregoing;

[0878] (g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, LY117018, onapristone, or toremifene;

[0879] -235- FH13323832.11Attorney Docket No.: LCH-03925

[0880] (h) 4(5)-imidazoles, megestrol acetate, exemestane, or anastrozole;

[0881] (i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine;

[0882] (j) an aromatase inhibitor;

[0883] (k) a protein kinase inhibitor;

[0884] (l) a lipid kinase inhibitor;

[0885] (m) an antisense oligonucleotide;

[0886] (n) a ribozyme;

[0887] (o) a vaccine; and

[0888] (p) an anti-angiogenic agent.

[0889] In certain embodiments, the active agent is pyrrolobenzodiazepine. In other embodiments, each active agent is selected from GENZ-644282, exatecan, monomethyl auristatin (e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FLU 8, Dxd derivative (e.g., Dxd2), a stimulator of interferon genes agonist, and Toll-like receptor agonist (e.g., TER7 / 8), or a combination thereof.

[0890] In certain embodiments, each active agent is selected from exatecan, monomethyl auristatin (e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FE118, Dxd derivative (e.g., Dxd2), a stimulator of interferon genes agonist, and Toll-like receptor agonist (e.g., TER7 / 8), or a combination thereof. In certain embodiments, the active agent is exatecan. In certain embodiments, each active agent is monomethyl auristatin such as monomethyl auristatin E (MMAE). In certain embodiments, each active agent is monomethyl auristatin F (MMAF). In certain embodiments, each active agent is FE118. In certain embodiments, each active agent is Dxd2. In certain embodiments, each active agent is a stimulator of interferon genes agonist (STINGa). In certain embodiments, the Toll-like receptor agonist is a TER7 / 8 agonist. In other embodiments, the Toll-like receptor agonist is a TER7 agonist. In yet other embodiments, the Tolllike receptor agonist is a TER8 agonist.

[0891] In certain embodiments, a first active agent is exatecan and a second active agent is a STINGa. In certain embodiments, a first active agent is MMAE and a second active agent is a STINGa. In certain embodiments, a first active agent is MMAF and a second active agent is a STINGa. In certain embodiments, a first active agent is

[0892] -236- FH13323832.11Attorney Docket No.: LCH-03925

[0893]

[0894] second active agent is a STINGa. In certain embodiments, a first active agent is MMAE and a second active agent is exatecan. In certain embodiments, a first active agent is GENZ-644282 and a second active agent is a STINGa. In certain embodiments, a first active agent is taltobulin and a second active agent is a STINGa.

[0895] In certain embodiments, the conjugate comprises at least 3 active agents. In certain embodiments, a first active agent is STINGa and a second active agent and a third active agent are each exatecan. In certain embodiments, a first active agent is STINGa and a second active agent and a third active agent are each MMAE. In certain embodiments, a first active agent is STINGa and a second active agent and a third active agent are each MMAF. In certain embodiments, a first active agent is MMAE and a second active agent and a third active agent are each exatecan. In certain embodiments, a first active agent is MMAF and a second active agent and a third active agent are each exatecan. In certain embodiments, a first active agent is MMAE and a second active agent and a third active agent are each a TLR7 / 8 agonist.

[0896] In certain embodiments, a first active agent is MMAE and a second active agent and a third

[0897] active agent are each

[0898]

[0899] . In certain embodiments, a first active agent is MMAF and a second active agent and a third active agent are each a TLR7 / 8 agonist.

[0900] In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a conjugate disclosed herein and a pharmaceutically acceptable excipient.

[0901] -237- FH13323832.11Attorney Docket No.: LCH-03925

[0902] In certain embodiments, the present disclosure provides a method of treating a disease or disorder in a subject, comprising administering a conjugate or composition disclosed herein. In certain embodiments, the disease or disorder is cancer.

[0903] In certain embodiments, the present disclosure provides a method of conjugating an agent (e.g., a ligand) to a branched linker comprising contacting the agent with a conjugate disclosed herein, wherein Lg is a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, aldehyde, ester, amido, alkenyl, or alkynyl).

[0904] Pharmaceutical Compositions

[0905] The compositions and methods of the present invention may be utilized to treat an individual in need thereof. In certain embodiments, the individual is a mammal such as a human, or a non-human mammal. When administered to an animal, such as a human, the composition or the conjugate is preferably administered as a pharmaceutical composition comprising, for example, a conjugate of the invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration (z.e., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution is pyrogen-free, or substantially pyrogen-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition can also be present in a transdermal delivery system, e.g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as a lotion, cream, or ointment.

[0906] A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a conjugate such as a conjugate of the invention. Such physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent,

[0907] -238- FH13323832.11Attorney Docket No.: LCH-03925

[0908] depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a self-emulsifying drug delivery system or a selfmicroemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a conjugate of the invention. Liposomes, for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

[0909] The phrase "pharmaceutically acceptable" is employed herein to refer to those conjugates, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0910] The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

[0911] A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption

[0912] -239- FH13323832.11Attorney Docket No.: LCH-03925

[0913] through the oral mucosa (e.g., sublingually); subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin). The conjugate may also be formulated for inhalation. In certain embodiments, a conjugate may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U. S. Pat. Nos.

[0914] 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.

[0915] The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the conjugate which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.

[0916] Methods of preparing these formulations or compositions include the step of bringing into association an active conjugate, such as a conjugate of the invention, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a conjugate of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0917] Formulations of the invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of a conjugate of the present invention as an active ingredient. Compositions or conjugates may also be administered as a bolus, electuary or paste.

[0918] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules and the like), the active

[0919] -240- FH13323832.11Attorney Docket No.: LCH-03925

[0920] ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium conjugates; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) complexing agents, such as, modified and unmodified cyclodextrins; and (11) coloring agents. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

[0921] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered conjugate moistened with an inert liquid diluent.

[0922] The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying

[0923] -241- FH13323832.11Attorney Docket No.: LCH-03925

[0924] agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the abovedescribed excipients.

[0925] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[0926] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0927] Suspensions, in addition to the active conjugates, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0928] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active conjugate may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.

[0929] The ointments, pastes, creams and gels may contain, in addition to an active conjugate, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0930] Powders and sprays can contain, in addition to an active conjugate, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or

[0931] -242- FH13323832.11Attorney Docket No.: LCH-03925

[0932] mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0933] Transdermal patches have the added advantage of providing controlled delivery of a conjugate of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the active conjugate in the proper medium. Absorption enhancers can also be used to increase the flux of the conjugate across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the conjugate in a polymer matrix or gel.

[0934] The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. Pharmaceutical compositions suitable for parenteral administration comprise one or more active conjugates in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

[0935] Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0936] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.

[0937] -243- FH13323832.11Attorney Docket No.: LCH-03925

[0938] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

[0939] Injectable depot forms are made by forming microencapsulated matrices of the subject conjugates in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.

[0940] For use in the methods of this invention, active conjugates can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.

[0941] Methods of introduction may also be provided by rechargeable or biodegradable devices. Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a conjugate at a particular target site.

[0942] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0943] The selected dosage level will depend upon a variety of factors including the activity of the particular conjugate or combination of conjugates employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular conjugate(s) being employed, the duration of the treatment, other drugs, conjugates and / or materials used in combination with the particular conjugate(s) employed, the age, sex, weight,

[0944] -244- FH13323832.11Attorney Docket No.: LCH-03925

[0945] condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0946] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the pharmaceutical composition or conjugate at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the concentration of a conjugate that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the conjugate will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the conjugate, and, if desired, another type of therapeutic agent being administered with the conjugate of the invention. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison’s Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).

[0947] In general, a suitable daily dose of an active conjugate used in the compositions and methods of the invention will be that amount of the conjugate that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

[0948] If desired, the effective daily dose of the active conjugate may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain embodiments of the present invention, the active conjugate may be administered two or three times daily. In preferred embodiments, the active conjugate will be administered once daily.

[0949] The patient receiving this treatment is any animal in need, including primates, in particular humans; and other mammals such as equines, cattle, swine, sheep, cats, and dogs; poultry; and pets in general.

[0950] In certain embodiments, conjugates of the invention may be used alone or conjointly administered with another type of therapeutic agent.

[0951] -245- FH13323832.11Attorney Docket No.: LCH-03925

[0952] The present disclosure includes the use of pharmaceutically acceptable salts of conjugates of the invention in the compositions and methods of the present invention. In certain embodiments, contemplated salts of the invention include, but are not limited to, alkyl, dialkyl, trialkyl or tetraalkyl ammonium salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, L-arginine, benethamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, IH-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyljmorpholine, piperazine, potassium, l-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, 1 -hydroxyl-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, 1-ascorbic acid, 1-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, d-glucoheptonic acid, d-gluconic acid, d-glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, 1-malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, 1-pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, 1-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid acid salts.

[0953] The pharmaceutically acceptable acid addition salts can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent.

[0954] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

[0955] -246- FH13323832.11Attorney Docket No.: LCH-03925

[0956] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alphatocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0957] Definitions

[0958] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.

[0959] The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. “Principles of Neural Science”, McGraw-Hill Medical, New York, N. Y. (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, W. H. Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed.”, W. H. Freeman & Co., N. Y. (1999); and Gilbert et al., “Developmental Biology, 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).

[0960] Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, C. A. (1985).

[0961] All of the above, and any other publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.

[0962] The term “agent” is used herein to denote a chemical compound (such as an organic or inorganic compound, a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g., a peptide, a lipid, a

[0963] -247- FH13323832.11Attorney Docket No.: LCH-03925

[0964] carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. Agents include, for example, agents whose structure is known, and those whose structure is not known.

[0965] A “patient,” “subject,” or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).

[0966] “Treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.

[0967] The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and / or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and / or clinically significant amount.

[0968] “Administering” or “administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent.

[0969] -248- FH13323832.11Attorney Docket No.: LCH-03925

[0970] Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.

[0971] Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age and / or the physical condition of the subject and the chemical and biological properties of the compound or agent (e.g., solubility, digestibility, bioavailability, stability and toxicity). In some embodiments, a compound or an agent is administered orally, e.g., to a subject by ingestion. In some embodiments, the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.

[0972] As used herein, the phrase “conjoint administration” refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body (e.g., the two agents are simultaneously effective in the patient, which may include synergistic effects of the two agents). For example, the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic agents.

[0973] A “therapeutically effective amount” or a “therapeutically effective dose” of a drug or agent is an amount of a drug or an agent that, when administered to a subject will have the intended therapeutic effect. The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. The precise effective amount needed for a subject will depend upon, for example, the subject’s size, health and age, and the nature and extent of the condition being treated, such as cancer or MDS. The skilled worker can readily determine the effective amount for a given situation by routine experimentation.

[0974] As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not. For example, “optionally substituted alkyl” refers to the alkyl may be substituted as well as where the alkyl is not substituted.

[0975] It is understood that substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skill in the art to result chemically stable compounds

[0976] -249- FH13323832.11Attorney Docket No.: LCH-03925

[0977] which can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.

[0978] As used herein, the term “optionally substituted” refers to the replacement of one to six hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH2-O-alkyl, -OP(O)(O-alkyl)2 or -CH2-OP(O)(O-alkyl)2. Preferably, “optionally substituted” refers to the replacement of one to four hydrogen radicals in a given structure with the substituents mentioned above. More preferably, one to three hydrogen radicals are replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.

[0979] As used herein, the term “alkyl” refers to saturated aliphatic groups, including but not limited to C1-C10 straight-chain alkyl groups or C1-C10 branched-chain alkyl groups. Preferably, the “alkyl” group refers to Ci-Ce straight-chain alkyl groups or Ci-Ce branched-chain alkyl groups. Most preferably, the “alkyl” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkyl groups. Examples of “alkyl” include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 1-octyl, 2-octyl, 3-octyl or 4-octyl and the like. Moreover, the term “alkyl” as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.

[0980] As used herein, the term “alkylene” refers to a bivalent saturated aliphatic groups, including but not limited to C1-C10 straight-chain alkylene groups or C1-C10 branched-chain alkylene groups. Preferably, the “alkylene” group refers to Ci-Ce straight-chain alkylene groups or Ci-Ce branched-chain alkylene groups. Most preferably, the “alkylene” group refers to C1-C4 straight-chain alkylene groups or C1-C4 branched-chain alkylene groups. Examples of “alkylene” include, but are not limited to, methylene, ethylene, 1 -propylene, 2-propylene, n-butylene, sec -butylene, tertbutylene, 1-pentylene, 2-pentylene, 3-pentylene, neo-pentylene, 1-hexylene, 2-hexylene, 3-

[0981] -250- FH13323832.11Attorney Docket No.: LCH-03925

[0982] hexylene, 1-heptylene, 2-heptylene, 3-heptylene, 4-heptylene, 1-octylene, 2-octylene, 3-octylene or 4-octylene and the like. The “alkylene” group may be optionally substituted.

[0983] The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.

[0984] The term “acylamino” is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.

[0985] The term “acyloxy” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.

[0986] The term “alkoxy” refers to an alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.

[0987] The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O- alkyl.

[0988] The term “Cx.y” or “Cx-Cy”, when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. A Cnealkyl group, for example, contains from one to six carbon atoms in the chain.

[0989] The term “alkylamino”, as used herein, refers to an amino group substituted with at least one alkyl group.

[0990] The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.

[0991] The term “amido”, as used herein, refers to a group such as

[0992]

[0993] wherein R9and R10each independently represent a hydrogen or hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0994] The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by

[0995] -251- FH13323832.11Attorney Docket No.: LCH-03925

[0996]

[0997] ?

[0998] wherein R9, R10, and R10’ each independently represent a hydrogen or a hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0999] The term “aminoalkyl”, as used herein, refers to an alkyl group substituted with an amino group.

[1000] The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group. The term “aryl” as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.

[1001] The term “carbamate” is art-recognized and refers to a group

[1002]

[1003] wherein R9and R10independently represent hydrogen or a hydrocarbyl group.

[1004] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

[1005] The term “carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic. Exemplary “carbocycles” include -252- FH13323832.11Attorney Docket No.: LCH-03925

[1006] cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-lH-indene and bicyclo[4.1.0]hept-3-ene. “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.

[1007] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

[1008] The term “carbonate” is art-recognized and refers to a group -OCO2-.

[1009] The term “carboxy”, as used herein, refers to a group represented by the formula -CO2H. The term “cycloalkyl” includes substituted or unsubstituted non-aromatic single ring structures, preferably 4- to 8-membered rings, more preferably 4- to 6-membered rings. The term “cycloalkyl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is cycloalkyl and the substituent (e.g., R100) is attached to the cycloalkyl ring, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, benzodioxane, tetrahydroquinoline, and the like.

[1010] The term “ester”, as used herein, refers to a group -C(O)OR9wherein R9represents a hydrocarbyl group.

[1011] The term “ether”, as used herein, refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.

[1012] The term “guanidinyl”, as used herein, refers to a group of the formula -NRa-C(=NRb)-NRbRc, wherein Ra, Rb, and Rcare each independently H or hydrocarbyl.

[1013] The terms “halo” and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.

[1014] The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.

[1015] -253- FH13323832.11Attorney Docket No.: LCH-03925

[1016] The terms “heteroaryl” and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heteroaryl” and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.

[1017] The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.

[1018] The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.

[1019] The terms “heterocyclyl”, “heterocycle”, and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heterocyclyl” and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

[1020] The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a carbon atom that does not have a =O or =S substituent, and typically has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a =O substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.

[1021] -254- FH13323832.11Attorney Docket No.: LCH-03925

[1022] The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a hydroxy group.

[1023] The term “hydroxylamino” is art-recognized and refers to a group

[1024]

[1025] l

[1026] Rx, wherein Rx, Ry, and Rzindependently represent hydrogen or a hydrocarbyl group.

[1027] The term “lower” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer. A “lower alkyl”, for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).

[1028] The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain embodiments, each ring of the poly cycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.

[1029] The term “sulfate” is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.

[1030] The term “sulfonamide” is art-recognized and refers to the group represented by the general formulae

[1031]

[1032] wherein R9and R10independently represents hydrogen or hydrocarbyl.

[1033] The term “sulfoxide” is art-recognized and refers to the group-S(O)-.

[1034] The term “sulfonate” is art-recognized and refers to the group SO3H, or a pharmaceutically acceptable salt thereof.

[1035] -255- FH13323832.11Attorney Docket No.: LCH-03925

[1036] The term “sulfone” is art-recognized and refers to the group -S(O)2-.

[1037] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamide, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.

[1038] The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol group. The term “thioester”, as used herein, refers to a group -C(O)SR9or -SC(O)R9wherein R9represents a hydrocarbyl.

[1039] The term “thioether”, as used herein, is equivalent to an ether, wherein the oxygen is replaced with a sulfur.

[1040] The term “urea” is art-recognized and may be represented by the general formula

[1041]

[1042] wherein R9and R10independently represent hydrogen or a hydrocarbyl.

[1043] -256- FH13323832.11Attorney Docket No.: LCH-03925

[1044] The term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.

[1045] The phrase “pharmaceutically acceptable” is art-recognized. In certain embodiments, the term includes compositions, excipients, adjuvants, polymers and other materials and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[1046] “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.

[1047] The term “pharmaceutically acceptable acid addition salt” as used herein means any nontoxic organic or inorganic salt of any base compounds represented by Formula la. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono or di- acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds of Formula la are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts, e.g., oxalates, may be used, for example, in the isolation of compounds of Formula la for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.

[1048] The term “pharmaceutically acceptable basic addition salt” as used herein means any nontoxic organic or inorganic base addition salt of any acid compounds represented by Formula la or any of their intermediates. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.

[1049] -257- FH13323832.11Attorney Docket No.: LCH-03925

[1050] Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01 / 062726.

[1051] Furthermore, certain compounds which contain alkenyl groups may exist as Z (zusammen) or E (entgegen) isomers. In each instance, the disclosure includes both mixture and separate individual isomers.

[1052] “Prodrug” or “pharmaceutically acceptable prodrug” refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host after administration to form the compound of the present disclosure (e.g., compounds of formula la). Typical examples of prodrugs include compounds that have biologically labile or cleavable (protecting) groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. Examples of prodrugs using ester or phosphoramidate as biologically labile or cleavable (protecting) groups are disclosed in U. S. Patents 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference. The prodrugs of this disclosure are metabolized to produce a compound of Formula la. The present disclosure includes within its scope, prodrugs of the compounds described herein. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in “Design of Prodrugs” Ed. H. Bundgaard, Elsevier, 1985.

[1053] The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filter, diluent, excipient, solvent or encapsulating material useful for formulating a drug for medicinal or therapeutic use.

[1054] The term “Log of solubility”, “LogS” or “logS” as used herein is used in the art to quantify the aqueous solubility of a compound. The aqueous solubility of a compound significantly affects its absorption and distribution characteristics. A low solubility often goes along with a poor absorption. LogS value is a unit stripped logarithm (base 10) of the solubility measured in mol / liter.

[1055] -258- FH13323832.11Attorney Docket No.: LCH-03925

[1056] EXAMPLES

[1057] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and are not intended to limit the invention.

[1058] Synthesis of Exemplary Con jugates

[1059] Abbreviations

[1060] Ac: acetyl

[1061] aq: aqueous

[1062] Bu: butyl

[1063] Boc: / -butoxycarbonyl

[1064] Bn: benzyl

[1065] brine: saturated aq. sodium chloride solution

[1066] Cbz: benzyloxycarbonyl

[1067] DMAP: 4-(dimethylamino)pyridine

[1068] DMSO: dimethyl sulfoxide

[1069] Et: ethyl

[1070] HCl: hydrogen chloride

[1071] HPLC: high performance liquid chromatography

[1072] Me: methyl

[1073] MMAE: monomethyl auristatin E

[1074] MMAF: monomethyl auristatin F

[1075] MMAF-OMe: monomethyl auristatin F methyl ester

[1076] NaHCO3: sodium bicarbonate

[1077] NaOH: sodium hydroxide

[1078] NH4Cl: ammonium chloride

[1079] PMB: 4-methoxybenzyl

[1080] Ts: -toluenesulfonyl

[1081] TIPS: triisopropylsilyl

[1082] Teoc: 2-(trimethylsily l)ethoxycarbonyl

[1083] THPTA: tris(3-hydroxypropyltriazolymethyl)amine

[1084] -259- FH13323832.11Attorney Docket No.: LCH-03925

[1085] TBAF: tetrabutylammonium fluoride

[1086] wt: weight

[1087] Example 1: Preparation of Compound 1-5

[1088]

[1089] Preparation of Compound 1-1

[1090] To a mixture of hexaethylene glycol (30 g, 106 mmol), silver (I) oxide (29.55 g, 128 mmol) and potassium iodide (1.76 g, 10.6 mmol) in dichloromethane (2 L) was added p-toluenesulfonyl chloride (20.26 g, 106 mmol) at 0 °C. The reaction mixture was warmed to room temperature under N2. After 16 hours, the reaction mixture was filtered through a celite pad, concentrated under reduced pressure and purified by column chromatography to afford Compound 1-1 (28.5 g, 61%) as a colorless oil. ESI-MS m / z: [M+H]+437.79. 'H-NMR (400 MHz, CDCl3) 87.80 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 4.16 (m, 2H), 3.72-3.58 (m, 22H), 2.97 (br, 1H), 2.45 (s, 3H).

[1091] Preparation of Compound 1-2

[1092] Compound 1-1 (28 g, 64.1 mmol) and sodium azide (6.25 g, 96.2 mmol) were dissolved in N,N-dimethylformamide (70 mL). Then the reaction mixture was heated to 100 °C. After stirring for 3 hours, the reaction mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-2 (11.3 g, 57%) as a colorless oil. ESI-MS m / z: [M+H]+308.65.1H-NMR (400 MHz, CDCl3) 83.77-3.69 (m, 2H), 3.71-3.63 (m, 18H), 3.67-3.58 (m, 2H), 3.40 (t, J = 5.1 Hz, 2H).

[1093] Preparation of Compound 1-3

[1094] To a solution of Compound 1-2 (10 g, 32.5 mmol) in tetrahydrofuran (60 mL) were added triphenylphosphine (9.39 g, 35.8 mmol) and distilled water (5.9 mL, 325 mmol) at 0 °C under N2.

[1095] -260- FH13323832.11Attorney Docket No.: LCH-03925

[1096] The reaction mixture was heated to 85 °C and stirred for 4 hours. After the completion of reaction, the reaction mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-3 (7.7 g, 84%) as a colorless oil. ESIMS m / z: [M+H]+282.34.1H-NMR (400 MHz, CDC13) 83.75-3.57 (m, 22H), 3.56-3.49 (m, 2H), 2.92-2.83 (m, 2H).

[1097] Preparation of Compound 1-4

[1098] To a solution of Compound 1-3 (7.7 g, 27.4 mmol) in acetonitrile (50 mL) were added benzyl chloroformate (4.7 mL, 32.8 mmol) and a solution of sodium bicarbonate (6.9 g, 82.1 mmol) in distilled water (60 mL). After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (100 mL) and washed with distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-4 (9.27 g, 82%). ESI-MS m / z: [M+H]+416.34.1H-NMR (400 MHz, CDCl3) 87.35 (d, J = 4.7 Hz, 5H), 5.10 (d, J = 3.8 Hz, 2H), 3.77-3.50 (m, 22H), 3.40 (t, J = 5.6 Hz, 2H), 3.01 (d, 7 = 6.5 Hz, 1H).

[1099] Preparation of Compound 1-5

[1100] To a solution of Compound 1-4 (2.2 g, 5.30 mmol) in dichloromethane (50 mL) were added triethylamine (2.23 mL, 15.89 mmol) and p-toluenesulfonyl chloride (1.31 g, 6.88 mmol) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with aq. 10% citric acid solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-5 (1.9 g, 63%) as a colorless oil. ESI-MS m / z: [M+H]+570.07.

[1101] Example 2: Preparation of Compound 1-7

[1102]

[1103] Preparation of Compound 1-6

[1104] -261- FH13323832.11Attorney Docket No.: LCH-03925

[1105] To a solution of hexaethylene glycol (65.37 g, 232 mmol) in tetrahydrofuran (100 mL) was added sodium hydride (60% dispersion in mineral oil, 151 mg, 6.29 mmol) at 0 °C. After stirring at 0 °C for 30 minutes, tert-butyl acrylate (10 mL, 68.7 mmol) was added to the reaction mixture. After stirring at room temperature for 16 hours, the reaction mixture was quenched by the addition of acetic acid (1 mL) and concentrated under reduced pressure. Then, the resulting residue was diluted with distilled water (500 mL) and extracted with ethyl acetate (500 mL x 4). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-6 (28 g, 100%) as a colorless oil, which was used for the next step without further purification. ESI-MS m / z: [M+Na]+433.18.

[1106] Preparation of Compound 1-7

[1107] To a solution of Compound 1-6 (900 mg, 2.19 mmol) in dichloromethane (20 mL) were added triethylamine (0.92 mL, 6.58 mmol) and p-toluenesulfonyl chloride (627 mg, 3.29 mmol) at 0 °C. After stirring at room temperature for 25 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4Cl solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-7 (900 mg, 73%) as a pale yellow oil. ESI-MS m / z: [M+Na]+587.33. ’H-NMR (400 MHz, CDCl3) 87.83-7.76 (m, 2H), 7.37-7.31 (m, 2H), 4.19-4.12 (m, 2H), 3.75-3.66 (m, 4H), 3.66-3.43 (m, 22H), 2.50 (t, J= 6.6 Hz, 2H), 2.45 (s, 4H), 1.45 (s, 9H).

[1108] Example 3: Preparation of Compound 1-15

[1109] -262- FH13323832.11Attorney Docket No.: LCH-03925

[1110]

[1111] 1-11

[1112] -263- FH13323832.11Attorney Docket No.: LCH-03925

[1113]

[1114] Preparation of Compound 1-8

[1115] To a solution of methyl 3,4,5-trihydroxybenzoate (methyl gallate, 70 g, 380.1 mmol) in A-dimethylformamide (600 mL) were added 4-methoxybenzyl chloride (51.8 mL, 380.1 mmol), potassium bicarbonate (114.17 g, 1140.4 mmol), and potassium iodide (0.38 g, 2.28 mmol). The reaction mixture was heated to 60 °C under N2. After 16 hours, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting mixture was diluted

[1116] -264- FH13323832.11Attorney Docket No.: LCH-03925

[1117] with water (300 mL) and extracted with dichloromethane (300 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-8 (58.17 g, 50%) as a white solid. ESI-MS m / z: [M+H]+305.31. 'H-NMR (400 MHz, CDC13) 8 7.30 (d, J = 8.0 Hz, 2H), 7.19 (s, 2H), 6.90 (d, J = 8.0 Hz, 2H), 5.40 (s, 2H), 5.05 (s, 2H), 3.88 (s, 3H), 3.82 (s, 3H).

[1118] Preparation of Compound 1-9

[1119] To a solution of Compound 1-8 (1.5 g, 4.93 mmol) in A. A-dimethylformamide (10 mL) were added potassium bicarbonate (3.41 g, 24.6 mmol) and Compound 1-5 (6.46 g, 11.34 mmol) under N2. After stirring at 80 °C for 17 hours, the reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 1-9 (5.6 g, quant.) as a yellow oil. ESI-MS m / z: [M+H]+1100.46.

[1120] Preparation of Compound 1-10

[1121] To a solution of Compound 1-9 (3.6 g, 3.28 mmol) in dichloromethane (30 mL) were added anisole (5.3 mL, 49.1 mmol) and trifluoroacetic acid (1.3 mL) at 0 °C under N2. After stirring at room temperature for 40 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-10 (3.6 g, quant.) as a pale yellow oil. ESI-MS m / z: [M+H]+979.45.

[1122] Preparation of Compound 1-11

[1123] To a solution of Compound 1-10 (2.0 g, 2.04 mmol) in A. A-dimethylformamide (10 mL) were added potassium bicarbonate (1.02 g, 10.21 mmol) and Compound 1-7 (1.6 g, 2.86 mmol) under N2. The reaction mixture was stirred at 65 °C for 12 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4Cl solution (10 mL x 3), saturated aq. NaHCCh solution (10 mL x 3), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography to afford Compound 1-11 (1.9 g, 68%) as a pale yellow oil. ESI-MS m / z: [M+H]+1371.69.

[1124] -265- FH13323832.11Attorney Docket No.: LCH-03925

[1125] Preparation of Compound 1-12

[1126] To a solution of Compound 1-11 (1.8 g, 1.31 mmol) in methanol (12 mL) was added 1 N aq. NaOH solution (6.56 mL, 6.56 mmol) at 0 °C under N2. After 7 hours, the reaction mixture was titrated with 1 N aq. HC1 solution to pH 3-4 at 0 °C, and the reaction mixture was extracted with dichloromethane (30 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 1-12 (914 mg, 51%) as a yellow oil. ESI-MS m / z:

[1127] [M+Na]+1379.60.

[1128] Preparation of Compound 1-14

[1129] To a solution of Compound 1-12 (200 mg, 0.15 mmol) in A, N,N-dimethylformamide (5 mL) were added Compound 1-13 (terLbutyl-A-[2-[2-(2-aminoethoxy)ethoxy]-ethoxy]carbamate, 51 mg, 0.19 mmol; prepared by the method described in US Patent No. 11,173,214 B2), N, N, N’, N’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 73 mg, 0.19 mmol), and AUV-diisopropylethylamine (0.07 mL, 0.38 mmol) under N2. After stirring at room temperature for 18 hours, the reaction mixture was concentrated under reduced pressure and diluted with ethyl acetate (20 mL). The organic layer was washed with saturated aq. NH4Cl solution (20 mL), saturated aq. NaHCCL solution (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-14 (150 mg, 64%) as a colorless oil. ESI-MS m / z: [M+H]+1605.16.

[1130] Preparation of Compound 1-15

[1131] To a solution of Compound 1-14 (258 mg, 0.16 mmol) in methanol (9 mL) was added palladium / charcoal (10 wt. %, 40 mg) under hydrogen atmosphere. After stirring at room temperature for 1 hour, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 1-15 (178 mg, 83%) as a colorless oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1336.10.

[1132] Example 4: Preparation of Compound 1-19

[1133] -266- FH13323832.11Attorney Docket No.: LCH-03925

[1134]

[1135] Preparation of Compound 1-17

[1136] To a solution of Compound 1-16 (5 g, 8.70 mmol; prepared by the method described in US Patent No. 11,173,214 B2) in dichloromethane (100 mL) were added bis(pentafluorophenyl)carbonate (4.11 g, 10.44 mmol) and N, / V-di isopropylethyl amine (1.35 ml, 10.44 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with distilled water (70 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-17 (6.4 g, 94%). ESI-MS m / z: [M+Na]+806.79.

[1137] Preparation of Compound 1-18

[1138] To a solution of Compound 1-17 (6.4 g, 8.16 mmol) in M / V-dimethylformamide (20 mL) were added exatecan mesylate (5.20 g, 9.79 mmol) and M / V-diisopropylethylamine (3.41 mL, 19.58 mmol). After stirring at room temperature for 1 hour, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (70 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure.

[1139] -267- FH13323832.11Attorney Docket No.: LCH-03925

[1140] The resulting residue was purified by column chromatography to afford Compound 1-18 (7.66 g, 90%). ESI-MS m / z: [M+H]+1035.85.

[1141] Preparation of Compound 1-19

[1142] To a solution of Compound 1-18 (6.6 g, 6.37 mmol) in dichloromethane (5 mL) and methanol (20 mL) were added palladium / charcoal (10 wt. %, 330 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-19 (4.7 g, 77%). ESI-MS m / z: [M+H]+945.78. 'H-NMR (400 MHz, DMSO-d6) 88.07 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 11.2 Hz, 1H), 7.65 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.52 (s, 1H), 5.76 (s, 1H), 5.61 (d, J = 8.0 Hz, 1H), 5.49-5.39 (m, 3H), 5.31-5.22 (m, 3H), 5.18-5.03 (m, 4H), 4.74 (d, J = 9.6 Hz, 1H), 3.63 (s, 3H), 3.3-3.05 (m, 3H), 2.38 (s, 3H), 2.35-2.15 (m, 2H), 2.02 (s, 3H), 1.98 (s, 6H), 0.88 (t, J = 7.2 Hz, 3H).

[1143] Example 5: Preparation of Compound 1-22

[1144] -268- FH13323832.11Attorney Docket No.: LCH-03925

[1145]

[1146] -269- FH13323832.11Attorney Docket No.: LCH-03925

[1147]

[1148] Preparation of Compound 1-20

[1149] To a solution of Compound 1-15 (200 mg, 0.15 mmol) and Compound 1-19 (289 mg, 0.30 mmol) in 7V, / V-di methylformamide (6 mL) were added M / V. / V’. A’-tetramethyl-D-i 17 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 174 mg, 0.45 mmol) and N, N-diisopropylethylamine (0.133 mL, 0.76 mmol) at 0 °C. After stirring at room temperature for 6 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium -270- FH13323832.11Attorney Docket No.: LCH-03925

[1150] sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-20 (240 mg, 49%). ESI-MS m / z:

[1151] [M / 2+H]+1581.45, [M / 3+H]+1054.70.

[1152] Preparation of Compound 1-21

[1153] To a solution of Compound 1-20 (160 mg, 0.05 mmol) in tetrahydrofuran / methanol (2 mL / 2 mL) was added lithium hydroxide monohydrate (21 mg, 0.50 mmol) in distilled water (3 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 2 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-21 (66 mg, 45%). ESI-MS m / z: [M / 2+H]+1455.50, [M / 3+H]+970.33.

[1154] Preparation of Compound 1-22

[1155] To a solution of Compound 1-21 (65 mg, 0.028 mmol) in acetonitrile (3 mL) was added phosphoric acid (85%, 2.5 mL) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 1-22 (54 mg, 86%) as a yellow solid. ESI- MS m / z: [M / 2+H]+1377.43, [M / 3+H]+918.70.

[1156] Example 6: Preparation of Compound 1-28

[1157] -271- FH13323832.11Attorney Docket No.: LCH-03925

[1158]

[1159] Preparation of Compound 1-23

[1160] To a solution of Compound 1-1 (7.0 g, 16.04 mmol) in dichloromethane (50 mL) was added imidazole (2.4 g, 35.28 mmol) and triisopropylsilyl chloride (4.08 mL, 19.24 mmol) at 0

[1161] -272- FH13323832.11Attorney Docket No.: LCH-03925

[1162] °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with dichloromethane (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-23 (14.6 g, 91%).1H-NMR (400 MHz, CDCl3) 87.79 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.16 (t, J = 4.8 Hz, 2H), 3.83 (t, J = 5.6 Hz, 2H), 3.69-3.58 (m, 20H), 2.45 (s, 3H), 1.12-1.06 (m, 21H).

[1163] Preparation of Compound 1-24

[1164] To a solution of methyl 3,4,5-trihydroxybenzoate (methyl gallate, 1.5 g, 8.15 mmol), potassium iodide (135.2 mg, 0.81 mmol) and potassium carbonate (2.2 g, 16.29 mmol) in N, N-dimethylformamide (5 mL) was added Compound 1-23 (8.2 g, 13.03 mmol) in N, N-dimethylformamide (6 mL). After stirring at 80 °C for 16 hours under N2, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-24 (1.0 g, 19%). ESI-MS m / z: [M+H]+605.16, [M+Na]+627.10.

[1165] Preparation of Compound 1-25

[1166] To a solution of Compound 1-24 (1.0 g, 0.71 mmol) in A. A-dimethylformamide (5 mL) was added Compound 1-5 (8.2 g, 13.03 mmol) in N, A-dimethylformamide (5 mL). After stirring at 80 °C for 16 hours under N2, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-25 (2.1 g, 93%). ESI-MS m / z: [M+H]+1400.07, [M / 2+H]+700.54.

[1167] Preparation of Compound 1-26

[1168] To a solution of Compound 1-25 (1.0 g, 0.71 mmol) in tetrahydrofuran / methanol (9 mL / 3 mL) was added 1 N aq. NaOH solution (8 mL, 8 mmol) at 0 °C under N2. The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was adjusted to pH 6 with 3 N aq. HO solution and extracted with ethyl acetate (100 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure,

[1169] -273- FH13323832.11Attorney Docket No.: LCH-03925

[1170] Compound 1-26 (1.0 g, 99%) was obtained, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1386.20, [M / 2+H]+693.48.

[1171] Preparation of Compound 1-27

[1172] To a solution of Compound 1-26 (1.0 g, 0.72 mmol) and Compound 1-13 (191 mg, 0.72 mmol) in / V. / V-di methylformamide (5 mL) were added M / V. / V’. A’-tetramethyl-O-f I / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 410 mg, 1.08 mmol) and N, N-diisopropylethylamine (0.38 mL, 2.16 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-27 (817mg, 69%). ESI-MS m / z:

[1173] [M+H]+1632.30, [M+Na]+1653.92.

[1174] Preparation of Compound 1-28

[1175] To a solution of Compound 1-27 (446 mg, 0.27 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 100 mg). The reaction mixture was stirred at room temperature for 4 hours under hydrogen atmosphere. Then the reaction mixture was filtered through a celite pad and washed with methanol (100 mL). The filtrate was concentrated to afford Compound 1-28 (320 mg, 85%), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1363.12, [M+Na]+1385.18.

[1176] Example 7: Preparation of Compound 1-31

[1177] -274- FH13323832.11Attorney Docket No.: LCH-03925

[1178]

[1179] -275- FH13323832.11Attorney Docket No.: LCH-03925

[1180]

[1181] Preparation of Compound 1-29

[1182] To a solution of Compound 1-28 (170 mg, 0.12 mmol) and Compound 1-19 (253 mg, 0.27 mmol) in / V. / V-di methylformamide (3 mL) were added M / V. / V’. A’-tetramethyl-O-i 17 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 115 mg, 0.30 mmol) and N, N- diisopropylethylamine (0.08 mL, 0.49 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with

[1183] -276- FH13323832.11Attorney Docket No.: LCH-03925

[1184] distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-29 (235 mg, 59%). ESI-MS m / z:

[1185] [M / 2+H]+1609.64, [M / 3+H]+1073.45.

[1186] Preparation of Compound 1-30

[1187] To a solution of Compound 1-29 (235 mg, 0.073 mmol) in tetrahydrofuran / methanol (1 mL / 1 mL) was added lithium hydroxide monohydrate (24 mg, 0.58 mmol) in distilled water (1 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-30 (43 mg, 20%). ESI-MS m / z: [M / 2+H]+1470.89, [M / 3+H]+981.01.

[1188] Preparation of Compound 1-31

[1189] To a solution of Compound 1-30 (42 mg, 0.014 mmol) in acetonitrile (1 mL) was added phosphoric acid (85%, 1 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-31 (23 mg, 60%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1341.47, [M / 3+H]+897.73.

[1190] Example 8: Preparation of Compound 1-35

[1191] -277- FH13323832.11Attorney Docket No.: LCH-03925

[1192]

[1193] -278- FH13323832.11Attorney Docket No.: LCH-03925

[1194] Preparation of Compound 1-32

[1195] To a solution of Compound 1-27 (1.3 g, 0.81 mmol) in tetrahydrofuran (3 mL) was added tetrabutylammonium fluoride (1 M in tetrahydrofuran, 1.2 mL, 1.2 mmol) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with sat. NH4Cl solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-32 (1.0 g, 83%). ESI-MS m / z: [M+H]+1476.05, [M+Na]+1497.98.

[1196] Preparation of Compound 1-33

[1197] To a solution of Compound 1-32 (107 mg, 0.072 mmol) in dichloromethane (1 mL) at 0 °C under N2 were added -toluenesulfonyl chloride (40 mg, 0.21 mmol) and triethylamine (0.036 mL, 0.26 mmol). After stirring at room temperature for 2 days, the reaction mixture was diluted with dichloromethane (30 mL) and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-33 (87 mg, 74%). ESI-MS m / z: [M / 2+H]+815.45, [M+Na]+1651.75.

[1198] Preparation of Compound 1-34

[1199] To a solution of Compound 1-33 (897 mg, 0.55 mmol) in methanol (10 mL) was added dimethylamine (2 M in methanol, 1.1 mL, 2.20 mmol). After stirring at 80 °C for 9 hours in sealed tube, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-34 (650 mg, 73%). ESI-MS m / z:

[1200] [M+H]+1503.07, [M+Na]+1524.96.

[1201] Preparation of Compound 1-35

[1202] To a solution of Compound 1-34 (173 mg, 0.11 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 30 mg). The reaction mixture was stirred at room temperature for 1 hour under hydrogen atmosphere. Then the reaction mixture was filtered through a celite pad and washed with methanol (100 mL). The filtrate was concentrated to provide Compound 1-35 (145 mg, 99%), which was used for the next step without further purification. ESI-MS m / z:

[1203] [M+H]+1234.07, [M+Na]+1256.03.

[1204] Example 9: Preparation of Compound 1-38

[1205] -279- FH13323832.11Attorney Docket No.: LCH-03925

[1206]

[1207] -280- FH13323832.11Attorney Docket No.: LCH-03925

[1208] Preparation of Compound 1-36

[1209] To a solution of Compound 1-35 (145 mg, 0.11 mmol) and Compound 1-19 (223 mg, 0.24 mmol) in / V. / V-di methylformamide (5 mL) were added M / V. / V’. A’-tetramethyl-O-f I / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 102 mg, 0.27 mmol) and N, N-diisopropylethylamine (0.07 mL, 0.43 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NaHCO3 solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-36 (213 mg, 64%). ESI-MS m / z:

[1210] [M / 2+H]+1545.00, [M / 3+H]+1030.41.

[1211] Preparation of Compound 1-37

[1212] To a solution of Compound 1-36 (213 mg, 0.069 mmol) in tetrahydrofuran / methanol (1 mL / 1 mL) was added lithium hydroxide monohydrate (23 mg, 0.55 mmol) in distilled water (1 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-37 (84 mg, 43%). ESI-MS m / z: [M / 2+H]+1404.92, [M / 3+H]+937.00.

[1213] Preparation of Compound 1-38

[1214] To a solution of Compound 1-37 (84 mg, 0.030 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-38 (57 mg, 88%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1355.03, [M / 3+H]+903.67.

[1215] Example 10: Preparation of Compound 1-40

[1216]

[1217] Preparation of Compound 1-39

[1218] To a solution of Compound 1-3 (6.9 g, 24.5 mmol) in dichloromethane (50 mL) were added A, A-diisopropylethylamine (6.4 mL, 36.7 mmol) and (4-nitrophenyl)-2-trimethylsilylethyl carbonate (7.6 g, 26.9 mmol) at 0 °C. After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. NH4Cl solution

[1219] -281- FH13323832.11Attorney Docket No.: LCH-03925

[1220] (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-39 (9 g, 86%). ESI-MS m / z: [M+H]+426.21.

[1221] Preparation of Compound 1-40

[1222] To a solution of Compound 1-39 (5.59 g, 13.1 mmol) in dichloromethane (50 mL) were added triethylamine (5.5 mL, 39.4 mmol) and p-toluenesulfonyl chloride (3.2 g, 17.0 mmol) at 0 °C. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with aq. 10% citric acid solution (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-40 (7.3 g, 95%). ESI-MS m / z: [M+H]+580.07.

[1223] Example 11: Preparation of Compound 1-42

[1224]

[1225] 1-42

[1226] Preparation of Compound 1-41

[1227] To a solution of pentaethylene glycol (150 g, 629 mmol) in tetrahydrofuran (900 mL) was added potassium terLbutoxide (1.7 M in tetrahydrofuran, 180 mL, 307 mmol) at 0 °C. After stirring at 0 °C for 30 minutes under N2, propargyl bromide (80% in toluene, 34.8 mL, 315 mmol) was added slowly at 0 °C. Then the reaction mixture was gradually warmed to 50 °C. After stirring for 16 hours, the solid was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-41 (57 g, 65 %). ESI-MS m / z: [M+H]+277.39, [M+Na]+299.39.

[1228] Preparation of Compound 1-42

[1229] To a solution of Compound 1-41 (57 g, 206 mmol) in dichloromethane (300 mL) were added 4-(dimethylamino)pyridine (DMAP, 5.0 g, 41 mmol) and -toluenesulfonyl chloride (79 g, 412 mmol). Then triethylamine (58 mL, 412 mmol) was added slowly at 0 °C. The reaction mixture was gradually warmed to room temperature. After stirring for 16 hours, the reaction mixture was

[1230] -282- FH13323832.11Attorney Docket No.: LCH-03925

[1231] diluted with dichloromethane (200 mL) and washed with distilled water (200 mL), and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-42 (75 g, 85 %). ESI-MS m / z: [M+H]+431.43, [M+Na]+453.42.

[1232]

[1233] Preparation of Compound 1-43

[1234] To a solution of Compound 1-8 (1.2 g, 3.94 mmol) in A, A-dimethylformamide (15 mL) were added potassium carbonate (3.8 g, 27.6 mmol) and Compound 1-40 (4.57 g, 7.88 mmol)

[1235] -283- FH13323832.11Attorney Docket No.: LCH-03925

[1236] under N2. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with dichloromethane (30 mL). The organic layer was washed with saturated aq. NH4Cl solution (10 mL x 3), saturated aq. NaHCO3 solution (10 mL x 3), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 1-43 (4.5 g, quant.). ESI-MS m / z: [M+H]+1120.10.

[1237] Preparation of Compound 1-44

[1238] To a solution of Compound 1-43 (3.5 g, 3.12 mmol) in methanol (10 mL) was added palladium / charcoal (10 wt. %, 1.05 g) under hydrogen atmosphere. After stirring at room temperature for 3 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 1-44 (2.5 g, 80%). ESI-MS m / z: [M+H]+1000.20.

[1239] Preparation of Compound 1-45

[1240] To a solution of Compound 1-44 (1.2 g, 1.20 mmol) in A. A-dimethylformamide (15 mL) were added potassium bicarbonate (240 mg, 2.40 mmol) and Compound 1-42 (567 mg, 1.32 mmol) under N2. After stirring at 50 °C for 48 hours, the reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4Cl solution (10 mL x 3), saturated aq. NaHCO3 solution (10 mL x 3), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 1-45 (1.5 g, 99%). ESI-MS m / z: [M+Na]+1280.00.

[1241] Preparation of Compound 1-46

[1242] To a solution of Compound 1-45 (1.0 g, 0.79 mmol) in tetrahydrofuran (6 mL) was added 1 N aq. NaOH solution (7 mL, 0.795 mmol) at 0 °C under N2. After 7 hours, the reaction mixture was titrated with 1 N aq. HCl solution to pH 3-4 at 0 °C, and the crude product was extracted with dichloromethane (10 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 1-46 (850 mg, 85%). ESI-MS m / z: [M+Na]+1244.08 Preparation of Compound 1-47

[1243] To a solution of Compound 1-46 (820 mg, 0.65 mmol) in A, A-dimethylformamide (8 mL) were added Compound 1-13 (174 mg, 0.65 mmol), A, A, A’, A’-tetramethyLO-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 375 mg, 0.98 mmol), and A. A-diisopropylethylamine

[1244] -284- FH13323832.11Attorney Docket No.: LCH-03925

[1245] (0.34 mL, 1.97 mmol) under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with ethyl acetate (50 mL). The organic layer was washed with saturated aq. NH4Cl solution (50 mL), saturated aq. NaHCO3 solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-47 (700 mg, 71%). ESI-MS m / z: [M+H]+1490.14.

[1246] Preparation of Compound 1-48

[1247] To a solution of Compound 1-47 (520 mg, 0.34 mmol) in tetrahydrofuran (4 mL) was added tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 1.7 mL, 1.74 mmol). After stirring at 50 °C for 48 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by reversed phase column chromatography to afford Compound 1-48 (400 mg, 95%). ESI-MS m / z: [M+H]+1201.07.

[1248] Example 13: Preparation of Compound 1-50

[1249]

[1250] 1-49 1-50 Preparation of Compound 1-49

[1251] To a solution of 2-bromoethanol (3 g, 24.01 mmol) in distilled water (30 mL) was added sodium azide (4.68 g, 72.02 mmol) at room temperature under N2. After stirring at 80 °C for 16 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-49 (1.75 g, 83%), which was used for the next step without further purification.1H-NMR (400 MHz, CDCl3) 83.92 (s, 2H), 3.55 (s, 2H), 1.99 (bs, 1H).

[1252] Preparation of Compound 1-50

[1253] To a solution of l-bromo-2,3,4-tri-O-acetyl-a-D-glucuronic acid methyl ester (300 mg, 0.76 mmol) in dichloromethane (5 mL) were added 4 A molecular sieve (450 mg), Compound 1-49 (131 mg, 1.51 mmol), and silver (I) carbonate (312 mg, 1.13 mmol) at 0 °C under N2. After

[1254] -285- FH13323832.11Attorney Docket No.: LCH-03925

[1255] stirring at room temperature for 16 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-50 (201 mg, 66%) as a white solid.1H-NMR (400 MHz, CDC13) 85.31-5.23 (m, 2H), 5.04 (t, J = 7.6 Hz), 4.65 (d, J = 7.2 Hz, 1H), 4.12-4.03 (m, 2H), 3.76 (s, 3H), 3.75-3.64 (m, 1H), 3.55-3.48 (m, 1H), 3.33-3.24 (m, 1H), 2.05 (s, 3H), 2.02 (s, 6H).

[1256] Example 14: Preparation of Compound 1-54

[1257] -286- FH13323832.11Attorney Docket No.: LCH-03925

[1258]

[1259] -287- FH13323832.11Attorney Docket No.: LCH-03925

[1260]

[1261] Preparation of Compound 1-51

[1262] To a solution of Compound 1-48 (120 mg, 0.10 mmol) in / V. / V-dimethylformamide (5 mL) were added Compound 1-19 (198 mg, 0.21 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 95 mg, 0.25 mmol), and / V. / V-diisopropylethylamine (0.09 mL, 0.50 mmol) under N2. After stirring at room temperature for 6 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCCL solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The

[1263] -288- FH13323832.11Attorney Docket No.: LCH-03925

[1264] resulting residue was purified by column chromatography to afford Compound 1-51 (169 mg, 55%) as a brown oil. ESI-MS m / z: [M / 2+H]+1528.51, [M / 3+H]+1019.43.

[1265] Preparation of Compound 1-52

[1266] To a solution of Compound 1-51 (164 mg, 0.05 mmol) and Compound 1-50 (24 mg, 0.06 mmol) in dichloromethane (1 mL) and ethanol (2 mL) was added a solution of tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 7 mg, 0.05 mmol), copper (II) sulfate pentahydrate (10.8 mg, 0.04 mmol) and sodium L-ascorbate (16.1 mg, 0.08 mmol) in distilled water (3 mL) under N2. After stirring at room temperature for 6 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 1-52 (200 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1153.71.

[1267] Preparation of Compound 1-53

[1268] To a solution of Compound 1-52 (200 mg, 0.05 mmol) in methanol (2 mL) and tetrahydrofuran (2 mL) was added lithium hydroxide monohydrate (29.6 mg, 0.71 mmol) in distilled water (3 mL) at -50 °C. After stirring for 4 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-53 (100 mg, 60%). ESI-MS m / z:

[1269] [M / 3+H]+1013.86.

[1270] Preparation of Compound 1-54

[1271] To a solution of Compound 1-53 (100 mg, 0.033 mmol) in acetonitrile (3 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 1-54 (70.8 mg, 70%). ESI-MS m / z:

[1272] [M / 2+H]+1583.31.

[1273] Example 15: Preparation of Compound 1-58

[1274]

[1275] -289- FH13323832.11Attorney Docket No.: LCH-03925

[1276] Preparation of Compound 1-56

[1277] To a solution of Compound 1-55 (5.0 g, 50.97 mmol) in acetonitrile (100 mL) were added ethyl propiolate (2.74 mL, 26.85 mmol) and / V-methy I morpholine (0.30 mL, 2.68 mmol). After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-56 (4.0 g, 79%) as a brown oil.1H-NMR (400 MHz, CDC13) 87.60 (d, J = 7.60 Hz, 1H), 7.39-7.23 (m, 5H), 5.21 (d, J = 12.8 Hz, 1H), 4.57 (s, 2H), 4.23-4.13 (m, 2H), 3.99 (bs, 2H), 3.75 (bs, 2H), 3.66-3.58 (m, 20H), 1.27 (t, J = 7.2 Hz, 3H).

[1278] Preparation of Compound 1-57

[1279] To a solution of Compound 1-56 (4.8 g, 10.20 mmol) in methanol (75 mL) was added palladium / charcoal (10 wt. %, 500 mg) under hydrogen atmosphere. After stirring at room temperature for 16 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 1-57 (2.56 g, 65%) as a pale yellow oil. ESI-MS m / z: [M+H]+1352.20. ‘H-NMR (400 MHz, CDCl3) 84.19-4.11 (m, 2H), 3.80-3.53 (m, 26H), 2.59 (t, J = 6.8 Hz, 2H), 1.26 (t, J = 7.2 Hz, 3H).

[1280] Preparation of Compound 1-58

[1281] To a solution of Compound 1-57 (230 mg, 0.60 mmol) in dichloromethane (5 mL) were added triethylamine (0.25 mL, 1.80 mmol) and p-toluenesulfonyl chloride (137 mg, 0.72 mmol) at 0 °C. After stirring at room temperature for 20 hours, the reaction mixture was diluted with dichloromethane (20 mL) and washed with aq. 10% citric acid solution (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 1-58 (223 mg, 69%) as a pale yellow oil. ESI-MS m / z: [M+H]+537.12.!H- NMR (400 MHz, CDCl3) 87.85-7.77 (m, 2H), 7.34 (d, J = 7.8 Hz, 2H), 4.23-4.08 (m, 4H), 3.84-3.53 (m, 28H), 2.58 (t, 7 = 6.3 Hz, 2H), 2.45 (s, 3H), 1.34-1.21 (m, 3H).

[1282] Example 16: Preparation of Compound 1-65

[1283] -290- FH13323832.11Attorney Docket No.: LCH-03925

[1284]

[1285] Preparation of Compound 1-59

[1286] To a solution of Compound 1-43 (1.94 g, 1.73 mmol) in tetrahydrofuran (12 mL) and methanol (6 mL) was added 1 N aq. NaOH solution (17 mL, 17.0 mmol) at 0 °C under N2. After 3 hours, the reaction mixture was titrated with 1 N aq. HC1 solution to pH 3-4, and extracted with ethyl acetate (10 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-59 (1.93

[1287] -291- FH13323832.11Attorney Docket No.: LCH-03925

[1288] g, quant.) as a yellow oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1105.07.

[1289] Preparation of Compound 1-60

[1290] To a solution of Compound 1-59 (473 mg, 0.43 mmol) in / V-dimethylformamide (10 mL) were added Compound 1-13 (136 mg, 0.51 mmol), W ^N’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 244 mg, 0.64 mmol), and N, N-diisopropylethylamine (0.18 mL, 1.28 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with aq. 10% citric acid solution (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-60 (484 mg, 84%) as a yellow oil. ESI-MS m / z: [M+H]+1352.21.

[1291] Preparation of Compound 1-61

[1292] To a solution of Compound 1-60 (484 mg, 0.36 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 50 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 1-61 (393 mg, 89%) as a brown oil. ESI-MS m / z:

[1293] [M+H]+1231.17.

[1294] Preparation of Compound 1-62

[1295] To a solution of Compound 1-61 (393 mg, 0.32 mmol) in A. A-dimethylformamide (5 mL) were added potassium bicarbonate (160 mg, 1.60 mmol) and Compound 1-58 (240 mg, 0.45 mmol) under N2. After stirring at 65 °C for 17 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 1-62 (467 mg, 92%) as a yellow oil. ESI-MS m / z: [M+H]+798.64.

[1296] Preparation of Compound 1-63

[1297] To a solution of Compound 1-62 (550 mg, 0.35 mmol) in ethanol (5 mL) was added 1 N aq. NaOH solution (3.5 mL, 3.5 mmol) at 0 °C under N2. After 8 hours, the reaction mixture was titrated with 1 N aq. HC1 solution to pH 3-4 at 0 °C and extracted with ethyl acetate (10 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate

[1298] -292- FH13323832.11Attorney Docket No.: LCH-03925

[1299] was concentrated under reduced pressure to afford Compound 1-63 (550 mg, quant.) as a pale yellow oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1568.15.

[1300] Preparation of Compound 1-64

[1301] To a solution of Compound 1-63 (300 mg, 0.19 mmol) in A, N,N-dimethylformamide (5 mL) were added l-(tert-butoxycarbonyl)piperazine (43 mg, 0.23 mmol), A. A. A’. A’-tetramethyl-D-(IH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 87 mg, 0.23 mmol), and N, N-diisopropylethylamine (0.07 mL, 0.46 mmol) under N2. After stirring at room temperature for 15 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCCh solution (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-64 (256 mg, 77%) as a pale yellow oil. ESI-MS m / z: [M+H]+1736.20.

[1302] Preparation of Compound 1-65

[1303] To a solution of Compound 1-64 (256 mg, 0.15 mmol) in tetrahydrofuran (5 mL) was added tetrabutylammonium fluoride (1 M in tetrahydrofuran, 0.22 mL, 0.75 mmol) at 65 °C. After stirring for 9 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by reversed phase column chromatography to afford Compound 1-65 (191 mg, 88%) as a pale yellow oil. ESI-MS m / z: [M+H]+1447.37.

[1304] Example 17: Preparation of Compound 1-68

[1305]

[1306] -293- FH13323832.11Attorney Docket No.: LCH-03925

[1307]

[1308] -294- FH13323832.11Attorney Docket No.: LCH-03925

[1309] Preparation of Compound 1-66

[1310] To a solution of Compound 1-65 (94 mg, 0.065 mmol) and Compound 1-19 (129 mg, 0.14 mmol) in / V, / V-di methylformamide (4 mL) were added M / V. / V’. A’-tetramethyl-O-f 17 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 61 mg, 0.16 mmol) and N, N-diisopropylethylamine (0.057 mL, 0.32 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 1-66 (116 mg, 54%). ESI-MS m / z:

[1311] [M / 2+H]+1651.75, [M / 3+H]+1101.57.

[1312] Preparation of Compound 1-67

[1313] To a solution of Compound 1-66 (116 mg, 0.035 mmol) in tetrahydrofuran / methanol (1 mL / 1 mL) was added lithium hydroxide monohydrate (12 mg, 0.28 mmol) in water (1 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. The reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. The reaction mixture was purified by HPLC to afford Compound 1-67 (72 mg, 68%). ESI-MS m / z: [M / 2+H]+1512.18, [M / 3+H]+1008.51.

[1314] Preparation of Compound 1-68

[1315] To a solution of Compound 1-67 (72 mg, 0.024 mmol) in acetonitrile (1.5 mL) was added phosphoric acid (85%, 1.5 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-68 (54 mg, 81%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1411.94, [M / 3+H]+941.65.

[1316] Example 18: Preparation of Compound 1-69

[1317]

[1318] Preparation of Compound 1-69

[1319] -295- FH13323832.11Attorney Docket No.: LCH-03925

[1320] To a solution of tris(hydroxymethyl)aminomethane (5 g, 41.2 mmol) in dimethyl sulfoxide (20 mL) was added aq. 5 M NaOH solution (1.05 mL, 5.25 mmol) at 0 °C. Then tert-butyl acrylate (60 mL, 412 mmol) was added slowly at 0 °C. The reaction mixture was gradually warmed to room temperature. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 1-69 (12.8 g, 61 %). ESIMS m / z: [M+H]+506.62.1H-NMR (400 MHz, CDC13) 83.64 (t, J = 4.2 Hz, 6H), 3.32 (s, 6H), 2.45 (t, J = 4.1 Hz, 6H), 1.45 (s, 27H).

[1321] Example 19: Preparation of Compound 1-72

[1322] -296- FH13323832.11Attorney Docket No.: LCH-03925

[1323]

[1324] Preparation of Compound 1-70

[1325] To a solution of Compound 1-14 (858 mg, 0.54 mmol) in methanol (2 mL) was added 1 N aq. NaOH solution (4.28 mL, 4.28 mmol) at 0 °C under N2. After 12 hours, the reaction mixture was titrated with 1 N aq. HCl solution to pH 3-4 at 0 °C and extracted with ethyl acetate (10 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-70 (729 mg, 88%) as a brown oil, which was used for the next step without further purification. ESI-MS m / z: [M+Na]+1569.23.

[1326] -297- FH13323832.11Attorney Docket No.: LCH-03925

[1327] Preparation of Compound 1-71

[1328] To a solution of Compound 1-70 (729 mg, 0.47 mmol) in / V, / V-di methylformamide (5 mL) were added Compound 1-69 (357 mg, 0.71 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 268 mg, 0.71 mmol), and A, A-di isopropylethylamine (0.41 mL, 2.36 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-71 (673 mg, 70%). ESI-MS m / z: [M / 2+H]+1018.13.

[1329] Preparation of Compound 1-72

[1330] To a solution of Compound 1-71 (628 mg, 0.31 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 63 mg) under hydrogen atmosphere. After stirring at room temperature for 3 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 1-72 (570 mg, quant.) as a colorless oil. ESI-MS m / z: [M / 2+H]+883.94.

[1331] Example 20: Preparation of Compound 1-75

[1332] -298- FH13323832.11Attorney Docket No.: LCH-03925

[1333]

[1334] -299- FH13323832.11Attorney Docket No.: LCH-03925

[1335] Preparation of Compound 1-73

[1336] To a solution of Compound 1-72 (100 mg, 0.06 mmol) in / V, / V-di methylformamide (5 mL) were added Compound 1-19 (118 mg, 0.12 mmol), A, A, A’, A’-tetramethyLO-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 54 mg, 0.14 mmol), and A, A-di isopropylethyl amine (0.05 mL, 0.28 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (10 mL), saturated aq. NaHCCh solution (10 mL), and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-73 (148 mg, 72%) as a pale yellow solid. ESI-MS m / z: [M / 2+H]+1813.38, [M / 3+H]+1209.29.

[1337] Preparation of Compound 1-74

[1338] To a solution of Compound 1-73 (148 mg, 0.04 mmol) in methanol (1.5 mL) and tetrahydrofuran (1.5 mL) was added lithium hydroxide monohydrate (15.4 mg, 0.37 mmol) in distilled water (2 mL) at -50 °C. After stirring for 2 hours at 5 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-74 (77 mg, 56%). ESI-MS m / z:

[1339] [M / 2+H]+1672.87. [M / 3+H]+1115.68.

[1340] Preparation of Compound 1-75

[1341] To a solution of Compound 1-74 (77 mg, 0.023 mmol) in acetonitrile (1.5 mL) was added phosphoric acid (85%, 1.5 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 1-75 (48.8 mg, 66%). ESI-MS m / z: [M / 2+H]+1583.31.

[1342] Example 21: Preparation of Compound 1-79

[1343]

[1344] 1-76

[1345] -300- FH13323832.11Attorney Docket No.: LCH-03925

[1346]

[1347] -301- FH13323832.11Attorney Docket No.: LCH-03925

[1348] To a solution of Compound 1-76 (178 mg, 0.14 mmol; prepared by the method described in US Patent No. 11,173,214 B2) in / V, / V-dimethylformamide (2 mL) were added Compound 1-15 (92 mg, 0.07 mmol), N, N, N’, N’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 65 mg, 0.17 mmol), and A, A-di isopropylethylamine (0.05 mL, 0.34 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated and the resulting residue was purified by reversed phase column chromatography to afford Compound 1-77 (132 mg, 51%) as a white solid. ESI-MS m / z: [M / 3+H]+1254.22.

[1349] Preparation of Compound 1-78

[1350] To a solution of Compound 1-77 (132 mg, 0.04 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (12 mg, 0.28 mmol) in water (1 mL) at -78 °C. After stirring at -5 °C for 6 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-78 (44 mg, 36%) as a yellow solid. ESI-MS m / z:

[1351] [M / 3+H]+1160.75.

[1352] Preparation of Compound 1-79

[1353] To a solution of Compound 1-78 (44 mg, 0.01 mmol) in acetonitrile (0.5 mL) was added phosphoric acid (85%, 0.5 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 1-79 (42 mg, 99%) as a white solid. ESI-MS m / z: [M / 3+H]+1107.73.

[1354] Example 22: Preparation of Compound 1-80

[1355]

[1356] 1-2 1-80

[1357] Preparation of Compound 1-80

[1358] To a solution of Compound 1-2 (2.0 g, 6.51 mmol) in dichloromethane (15 mL) were added triethylamine (1.37 mL, 9.76 mmol) and -toluenesulfonyl chloride (1.49 g, 7.81 mmol) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. NH4Cl solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-80 (2.04 g, 70%) as a pale yellow oil. ESI-MS m / z:

[1359] -302- FH13323832.11Attorney Docket No.: LCH-03925

[1360] [M+Na]+484.243.1H-NMR (400 MHz, CDCl3) 87.80 (m, J = 8.1, 4.3 Hz, 2H), 7.35 (m, J = 7.6, 4.2 Hz, 2H), 4.16 (d, J = 5.5 Hz, 2H), 3.84-3.48 (m, 21H), 3.39 (d, J = 5.3 Hz, 2H), 2.45 (d, J = 4.0 Hz, 3H).

[1361]

[1362] Preparation of Compound 1-81

[1363] To a solution of Compound 1-80 (1 g, 2.16 mmol) in / V, / V-di methylformamide (10 mL) were added methyl 3,4,5-trihydroxybenzoate (798 mg, 4.33 mmol), potassium bicarbonate (433mg, 4.33 mmol) and potassium iodide (17 mg, 0.10 mmol). After stirring at 50 °C for 2 days,

[1364] -303- FH13323832.11Attorney Docket No.: LCH-03925

[1365] the reaction mixture was diluted with ethyl acetate (50 mL) and washed with distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-81 (569 mg, 55%). ESI-MS m / z: [M+H]+474.14.

[1366] Preparation of Compound 1-82

[1367] To a solution of Compound 1-81 (885 mg, 1.86 mmol) in A, N,N-dimethylformamide (10 mL) were added Compound 1-5 (2.2 g, 3.92 mmol), potassium carbonate (775 mg, 5.60 mmol) and potassium iodide (31 mg, 0.18 mmol). After stirring at 60 °C for 16 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-82 (1.71 g, 72%). ESI-MS m / z: [M+H]+1268.98.

[1368] Preparation of Compound 1-83

[1369] To a solution of Compound 1-82 (1.71 g, 1.37 mmol) in tetrahydrofuran / methanol (12 mL / 4 mL) was added 1 N aq. NaOH solution (15 mL, 1.51 mmol) at 0 °C under N2. The reaction mixture was stirred at room temperature for 16 hours. Then the pH of the reaction mixture was adjusted to pH 2 with 6 N aq. HC1 solution and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure to afford Compound 1-83 (1.69 g, 99%), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1253.89.

[1370] Preparation of Compound 1-84

[1371] To a solution of Compound 1-83 (1.69 g, 1.37 mmol) and Compound 1-13 (400 mg, 1.51 mmol) in A. A-dimethylformamide (10 mL) were added A. A. A’. A’-tetramethyl-O-f I / / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 783 mg, 2.06 mmol) and N, N’-diisopropylethylamine (0.72 mL, 4.13 mmol) at 0 °C. After stirring at room temperature for 16 hours under N2, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-84 (1.31g, 64%). ESI-MS m / z:

[1372] [M+H]+1500.93.

[1373] Preparation of Compound 1-85

[1374] -304- FH13323832.11Attorney Docket No.: LCH-03925

[1375] To a solution of Compound 1-84 (300 mg, 0.20 mmol) and tert-butyl 3,6,9,12-tetraoxapentadec-14-ynoate (67 mg, 0.22 mmol), tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 88 mg, 0.20 mmol) in ethanol (3 mL) were added copper (II) sulfate pentahydrate (40.6 mg, 0.16 mmol) in distilled water (1.5 mL), and sodium L-ascorbate (60 mg, 0.30 mmol) in distilled water (1.5 mL) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-85 (218 mg, 60%). ESI-MS m / z: [M+H]+1802.91.

[1376] Preparation of Compound 1-86

[1377] To a solution of Compound 1-85 (210 mg, 0.11 mmol) in methanol (6 mL) was added palladium / charcoal (10 wt. %, 21 mg). The reaction mixture was stirred at room temperature for 3 hours under hydrogen atmosphere. The reaction mixture was filtered through a celite pad and washed with methanol (30 mL). The filtrate was concentrated to afford Compound 1-86 (170 mg, 95%), which was used without further purification. ESI-MS m / z: [M+H]+1535.21.

[1378]

[1379] -305- FH13323832.11Attorney Docket No.: LCH-03925

[1380]

[1381] Preparation of Compound 1-87

[1382] To a solution of Compound 1-86 (170 mg, 0.11 mmol) and Compound 1-19 (224 mg, 0.23 mmol) in / V. / V-di methylformamide (5 mL) were added M / V. / V’. A’-tetramethyl-O-i IH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 128 mg, 0.33 mmol) and N, N-diisopropylethylamine (0.09 mL, 0.56 mmol) at 0 °C. After stirring at room temperature for 4 hours under N2, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium

[1383] -306- FH13323832.11Attorney Docket No.: LCH-03925

[1384] sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-87 (240 mg, 24%). ESI-MS m / z:

[1385] [M / 3+H]+1130.35.

[1386] Preparation of Compound 1-88

[1387] To a solution of Compound 1-87 (230 mg, 0.06 mmol) in tetrahydrofuran / methanol (2 mL / 2 mL) was added lithium hydroxide monohydrate (28 mg, 0.67 mmol) in distilled water (4 mL) at -78 °C under N2. After stirring for 4 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-88 (120 mg, 57%). ESI-MS m / z: [M / 2+H]+1555.17. [M / 3+H]+1037.21.

[1388] Preparation of Compound 1-89

[1389] To a solution of Compound 1-88 (120 mg, 0.03 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 3 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-89 (72 mg, 63%). ESI-MS m / z:

[1390] [M / 2+H]+1476.85. [M / 3+H]+985.13.

[1391] Example 25: Preparation of Compound 1-93

[1392]

[1393] -307- FH13323832.11Attorney Docket No.: LCH-03925

[1394]

[1395] Preparation of Compound 1-90

[1396] To a solution of tert-butyl 3,6,9,12-tetraoxapentadec-14-ynoate (500 mg, 1.65 mmol) in dichloromethane (3 mL) was added hydrogen chloride solution (4 M in 1,4-dioxane, 3 mL). After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 1-90 (410 mg, quant.), which was used for the next step without further purification. ESI-MS m / z: [M+H]+247.21.

[1397] Preparation of Compound 1-91

[1398] To a solution of Compound 1-90 (407 mg, 1.65 mmol) in A. A-dimethylformamide (10 mL) were added Compound 1-69 (919 mg, 1.82 mmol), l-[bis(dimethylamino)methylene]-lH- l,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 942 mg, 2.48 mmol), and A, A-diisopropylethylamine (0.86 mL, 4.96 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCCh solution (30 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-91 (1.2 g, 98%). ESI-MS m / z: [M+H]+734.19.

[1399] Preparation of Compound 1-92

[1400] To a solution of Compound 1-84 (300 mg, 0.20 mmol) and Compound 1-91 (68 mg, 0.22 mmol) in ethanol (3 mL) were added tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 88 mg,

[1401] -308- FH13323832.11Attorney Docket No.: LCH-03925

[1402] 0.20 mmol), copper (II) sulfate pentahydrate (41 mg, 0.16 mmol), and sodium L-ascorbate (61 mg, 0.31 mmol) in distilled water (3 mL) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated distilled water (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-92 (218 mg, 60%). ESI-MS m / z: [M / 2+H]+901.97.

[1403] Preparation of Compound 1-93

[1404] To a solution of Compound 1-92 (630 mg, 0.29 mmol) in methanol (15 mL) was added palladium / charcoal (10 wt. %, 70 mg) under hydrogen atmosphere. After stirring at room temperature for 3 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 1-93 (545 mg, 98%) which was used for next step without further purification. ESI-MS m / z: [M+H]+1966.08, [M / 2+H]+983.58.

[1405]

[1406] -309- FH13323832.11Attorney Docket No.: LCH-03925

[1407]

[1408] Preparation of Compound 1-94

[1409] To a solution of Compound 1-93 (140 mg, 0.07 mmol) in A, N,N-dimethylformamide (5 mL) were added Compound 1-19 (148 mg, 0.16 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 81 mg, 0.21 mmol), and A. A-diisopropylethylamine (0.07 mL, 0.43 mmol) under N2. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by reversed phase column chromatography to afford Compound 1-94 (50 mg, 77%) as a beige foam solid. ESI-MS m / z:

[1410] [M / 2+H]+1912.56, [M / 3+H]+1275.50.

[1411] Preparation of Compound 1-95

[1412] -310- FH13323832.11Attorney Docket No.: LCH-03925

[1413] To a solution of Compound 1-94 (205 mg, 0.05 mmol) in tetrahydrofuran (2 mL) and methanol (2 mL) was added lithium hydroxide monohydrate (18 mg, 0.43 mmol) in water (3 mL) at -78 °C. After stirring at -5 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-95 (124 mg, 65%) as a yellow solid. ESI-MS m / z: [M / 3+H]+1180.77.

[1414] Preparation of Compound 1-96

[1415] To a solution of Compound 1-95 (15 mg, 0.003 mmol) in acetonitrile (1.5 mL) was added phosphoric acid (85%, 2 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-96 (7.1 mg, 60%) as a yellow solid. ESIMS m / z: [M / 2+H]+1636.32, [M / 3+H]+1091.28.

[1416] Example 27: Preparation of Compound 1-102

[1417]

[1418] -311- FH13323832.11Attorney Docket No.: LCH-03925

[1419]

[1420] -312- FH13323832.11Attorney Docket No.: LCH-03925

[1421] Preparation of Compound 1-97

[1422] To a solution of Compound 1-84 (300 mg, 0.19 mmol) in tetrahydrofuran (6 mL) were added triphenylphosphine (57 mg, 0.21 mmol) and distilled water (0.03 mL, 1.99 mmol) at 0 °C under N2. After stirring at 80 °C for 16 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-97 (180 mg, 61%). ESI-MS m / z: [M+H]+1474.13.

[1423] Preparation of Compound 1-98

[1424] To a solution of Compound 1-97 (180 mg, 0.12 mmol) in dichloromethane (7 mL) were added methyl / V. / V'-bis-boc- 1 -guanylpyrazol (41 mg, 0.13 mmol) and triethylamine (0.02 mL, 0.18 mmol). After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-98 (165 mg, 78%). ESI-MS m / z: [M+H]+1717.21.

[1425] Preparation of Compound 1-99

[1426] To a solution of Compound 1-98 (160 mg, 0.09 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 20 mg). The reaction mixture was stirred at room temperature for 3 hours under hydrogen atmosphere. The reaction mixture was filtered through a celite pad and washed with methanol (30 mL). The filtrate was concentrated to afford Compound 1-99 (133 mg, 98%), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1448.25.

[1427] Preparation of Compound 1-100

[1428] To a solution of Compound 1-99 (133 mg, 0.09 mmol) and Compound 1-19 (182 mg, 0.19 mmol) in A, / V-di methylformamide (6 mL) were added A, A, A’, A’-tetramethyl-O-(lH-benzotriazoLLyl)uronium hexafluorophosphate (HBTU, 194 mg, 0.27 mmol) and N, N-diisopropylethylamine (0.08 mL, 0.45 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with distilled water (50 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-100 (220 mg, 72%). ESI-MS m / z: [M / 3+H]+1101.17.

[1429] Preparation of Compound 1-101

[1430] -313- FH13323832.11Attorney Docket No.: LCH-03925

[1431] To a solution of Compound 1-100 (220 mg, 0.06 mmol) in tetrahydrofuran / methanol (1.5 mL / 1.5 mL) was added lithium hydroxide monohydrate (22 mg, 0.53 mmol) in distilled water (3 mL) at -78 °C under N2. After stirring for 3 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-101 (91 mg, 45%). ESI-MS m / z: [M / 2+H]+1512.15, [M / 3+H]+1008.37.

[1432] Preparation of Compound 1-102

[1433] To a solution of Compound 1-101 (91 mg, 0.03 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-102 (57 mg, 69%). ESI-MS m / z:

[1434] [M / 2+H]+1362.03, [M / 3+H]+908.41.

[1435] Example 28: Preparation of Compound 1-104

[1436]

[1437] 1-103 1-104 Preparation of Compound 1-103

[1438] To a solution of 3-butyn-l-ol (1 g, 14.2 mmol) in pyridine (5 mL) were added trimethyl phosphite (2.1 mL, 17.8 mmol) and carbon tetrabromide (5.2g, 15.6 mmol) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-103 (1.6 g, 62%). ESI-MS m / z: [M+H]+179.17.1H-NMR (400 MHz, CDCl3) 84.17-4.12 (m, 2H), 3.81 (s, 3H), 3.78 (s, 3H), 2.62-2.58 (m, 2H), 2.0 (d, J = 6.6 Hz, 1H).

[1439] Preparation of Compound 1-104

[1440] To a solution of Compound 1-103 (600 mg, 3.36 mmol) in pyridine (5 mL) were added bromotrimethylsilane (1.5 g, 10.1 mmol) and 2,4,6-collidine (1.2g, 10.1 mmol) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure and the resulting residue was treated with ethanol (6 mL) and stirred for 2 hours.

[1441] -314- FH13323832.11Attorney Docket No.: LCH-03925

[1442] The reaction mixture was concentrated under reduced pressure and triturated with ether. The resulting solid was filtered to afford Compound 1-104 (505 mg, quant.) as a white solid. ESI-MS m / z: [M+H]+150.95.

[1443] Example 29: Preparation of Compound 1-110

[1444]

[1445] -315- FH13323832.11Attorney Docket No.: LCH-03925

[1446]

[1447] Preparation of Compound 1-105

[1448] To a solution of Compound 1-61 (650 mg, 0.52 mmol) in / V. / V-dimethylformamide (7 mL) were added Compound 1-80 (267 mg, 0.58 mmol) and potassium bicarbonate (63 mg, 0.63 mmol) under N2. After stirring at 40 °C for 2 days, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (200 mL x 2). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting

[1449] -316- FH13323832.11Attorney Docket No.: LCH-03925

[1450] residue was purified by column chromatography to afford Compound 1-105 (680 mg, 84%). ESIMS m / z: [M+H]+1520.98.

[1451] Preparation of Compound 1-106

[1452] To a solution of Compound 1-105 (690 mg, 0.45 mmol) in tetrahydrofuran (5 mL) was added tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 0.39 mL, 1.36 mmol). After stirring at 70 °C for 16 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-106 (410 mg, 73%). ESIMS m / z: [M+H]+1232.22, [M / 2+H]+616.95.

[1453] Preparation of Compound 1-107

[1454] To a solution of Compound 1-106 (410 mg, 0.33 mmol) and Compound 1-19 (660 mg, 0.69 mmol) in A. A-dimethylformamide (10 mL) were added A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 378 mg, 0.99 mmol) and N, N-diisopropylethylamine (0.28 mL, 1.66 mmol) at 0 °C. After stirring at room temperature for 14 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-107 (1 g, 97%). ESI-MS m / z: [M / 2+H]+1544.08, [M / 3+H]+1029.77.

[1455] Preparation of Compound 1-108

[1456] To a solution of Compound 1-107 (500 mg, 0.16 mmol) in tetrahydrofuran / methanol (1.5 mL / 1.5 mL) was added lithium hydroxide monohydrate (54 mg, 1.29 mmol) in distilled water (3 mL) at -78 °C under N2. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-108 (320 mg, 70%). ESI-MS m / z: [M / 2+H]+1403.92, [M / 3+H]+936.47.

[1457] Preparation of Compound 1-109

[1458] To a solution of Compound 1-108 (80 mg, 0.02 mmol) and Compound 1-104 (8.5 mg, 0.05 mmol), tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 2.9 mg, 0.80 mmol) in ethanol (3 mL) were added copper (II) sulfate pentahydrate (11 mg, 0.04 mmol) in distilled water (1.5 mL), and sodium L-ascorbate (8.4 mg, 0.04 mmol) in distilled water (1.5 mL) under N2. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced

[1459] -317- FH13323832.11Attorney Docket No.: LCH-03925

[1460] pressure. The resulting residue was purified by reversed phase column chromatography to afford Compound 1-109 (80 mg, 94%). ESI-MS m / z: [M / 2+H]+1479.22, [M / 3+H]+986.58.

[1461] Preparation of Compound 1-110

[1462] To a solution of Compound 1-109 (82 mg, 0.02 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-110 (25 mg, 31%). ESI-MS m / z:

[1463] [M / 2+H]+1428.89, [M / 3+H]+953.17.

[1464] Example 30: Preparation of Compound 1-114

[1465]

[1466] -318- FH13323832.11Attorney Docket No.: LCH-03925

[1467] Preparation of Compound 1-111

[1468] To a solution of diethyl phosphite (285 mg, 2.07 mmol) in anhydrous N, N-dimethylformamide (4 mL) were added sodium hydride (60 % dispersion in mineral oil, 50 mg, 2.07 mmol) and 4-bromo-l -butyne (250 mg, 1.88 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was extracted with ethyl acetate (50 mL) and water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 1-111 (90 mg, 25%) as a yellow oil. ESI-MS m / z: [M+H]+191.03.

[1469] Preparation of Compound 1-112

[1470] To a solution of Compound 1-111 (85 mg, 0.44 mmol) in dichloromethane (1.5 mL) were added bromotrimethylsilane (0.35 mL, 2.68 mmol) and 2,4,6-collidine (0.18 mL, 1.34 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure. The residue was diluted with diethyl ether (20 mL) and filtered to afford Compound 1-112 (125 mg, quant.).1H-NMR (400 MHz, DMSO-d6) 87.27 (s, 2H), 2.82 (s, 1H), 2.51 (s, 6H), 2.38 (s, 3H), 2.35-2.26 (m, 2H), 1.79-1.66 (m, 2H).

[1471] Preparation of Compound 1-113

[1472] To a solution of Compound 1-108 (81 mg, 0.029 mmol) in ethanol (2 mL) were added Compound 1-112 (15 mg, 0.058 mmol), tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 6 mg, 0.011 mmol), copper (II) sulfate pentahydrate (21 mg, 0.086 mmol) and sodium L-ascorbate (9 mg, 0.046 mmol) in water (1 mL). After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure and purified by reversed phase column chromatography to afford Compound 1-113 (56 mg, 66 %). ESI-MS m / z: [M / 2+H]+1471.25, [M / 3+H]+981.20.

[1473] Preparation of Compound 1-114

[1474] To a solution of Compound 1-113 (56 mg, 0.019 mmol) in acetonitrile (1 mL) was added phosphoric acid (85%, 1 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-114 (32 mg, 59%) as a yellow solid. ESIMS m / z: [M / 2+H]+1421.12, [M / 3+H]+947.79.

[1475] Example 31: Preparation of Compound 1-117

[1476] -319- FH13323832.11Attorney Docket No.: LCH-03925

[1477]

[1478] Preparation of Compound 1-115

[1479] To a solution of 3-butyn-l-ol (300 mg, 4.28 mmol) in dichloromethane (5 mL) was added sulfur trioxide pyridine complex (681 mg, 4.28 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure and triturated with ether. The resulting solid was filtered to afford Compound 1-115 (1 g, crude) as a

[1480] -320- FH13323832.11Attorney Docket No.: LCH-03925

[1481] white solid. 'H-NMR (400 MHz, CDCl3) 88.99-8.95 (d, J = 12 Hz, 2H), 8.41-8.36 (m, 1H), 7.96-7.92 (m, 2H), 4.24 (dd, J= 12.0, 8.0 Hz, 2H), 2.66-2.61 (m, 1H), 1.98-1.95 (m, 1H).

[1482] Preparation of Compound 1-116

[1483] To a solution of Compound 1-108 (80 mg, 0.02 mmol) and Compound 1-115 (13 mg, 0.05 mmol), tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 1.4 mg, 0.01 mmol) in ethanol (2 mL) and dichloromethane (0.4 mL) were added copper (II) sulfate pentahydrate (21 mg, 0.08 mmol) in distilled water (1 mL), and sodium L-ascorbate (9.0 mg, 0.04 mmol) in distilled water (1 mL) under N2. After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by reversed phase column chromatography to afford Compound 1-116 (72 mg, 86%). ESI-MS m / z: [M / 2+H]+1479.66, [M / 3+H]+986.66.

[1484] Preparation of Compound 1-117

[1485] To a solution of Compound 1-116 (72 mg, 0.02 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-117 (25 mg, 35%). ESI-MS m / z:

[1486] [M / 2+H]+1429.46, [M / 3+H]+953.30.

[1487] Example 32: Preparation of Compound 1-123

[1488] -321- FH13323832.11Attorney Docket No.: LCH-03925

[1489]

[1490] 1-123

[1491] Preparation of Compound 1-118

[1492] To a solution of 4-pentynoic acid (2 g, 20.4 mmol) in tetrahydrofuran (50 mL) were added A'-dicyclohexylcarbodiimide (5 g, 24.5 mmol) and A-hydroxysuccinimide (2.3 g, 20.4 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was added acetic acid (0.25 mL) and then filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-118 (4 g, crude), which was used for the next step without further purification.1H-NMR (400 MHz, CDCl3) 82.93-2.82 (m, 6H), 2.67-2.58 (m, 2H), 2.05 (s, 1H).

[1493] Preparation of Compound 1-119

[1494] To a solution of Compound 1-118 (3.4 g, 17.6 mmol) in A-dimethylfomiamide (35 mL) were added (2R,3R,4R,5S)-6-(methylamino)hexane-l,2,3,4,5-pentol (2.65 g, 13.6 mmol) and pyridine (17 mL). After stirring at room temperature for 3 hours under N2, the reaction mixture was extracted with ethyl acetate (100 mL) and water (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 1-119 (4.8 g, quant.). ESI-MS m / z: [M+H]+276.31.

[1495] Preparation of Compound 1-121

[1496] -322- FH13323832.11Attorney Docket No.: LCH-03925

[1497] To a solution of Compound 1-120 (216 mg, 0.46 mmol; prepared by the method described in US 2022 / 0226496 Al) and Compound 1-119 (417 mg, 1.5 mmol) in ethanol (3 mL) were added tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 194 mg, 0.36 mmol), copper (II) sulfate pentahydrate (515 mg, 2.06 mmol) and sodium L-ascorbate (218 mg, 1.10 mmol) in distilled water (3 mL). After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure and purified by column chromatography to afford Compound 1-121 (596 mg, quant.). ESI-MS m / z: [M+H]+1296.35, [M / 2+H]+648.97.

[1498] Preparation of Compound 1-122

[1499] To a stirred mixture of the compound 1-121 (330 mg, 0.25 mmol) in dichloromethane (1 mL) and methanol (1 mL) was added hydrogen chloride solution (4 M in 1,4-dioxane, 1 mL) at 0 °C. After stirring at room temperature for 6 hours, the reaction mixture was concentrated to afford Compound 1-122 (310 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1196.20, [M / 2+H]+598.94.

[1500] Preparation of Compound 1-123

[1501] To a solution of 1-122 (299 mg, 0.25 mmol) in A. A-dimethylformamide (4 mL) were added Compound 1-118 (97 mg, 0.37 mmol) and triethylamine (0.05 mL, 0.37 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-123 (60 mg, 19%). ESI-MS m / z: [M+H]+1276.21, [M / 2+H]+638.93.

[1502] Example 33: Preparation of Compound 1-125

[1503] -323- FH13323832.11Attorney Docket No.: LCH-03925

[1504]

[1505] 1-125

[1506] -324- FH13323832.11Attorney Docket No.: LCH-03925

[1507] Preparation of Compound 1-124

[1508] To a solution of Compound 1-108 (81 mg, 0.029 mmol) in ethanol (2 mL) and dichloromethane (0.5 mL) were added Compound 1-123 (15 mg, 0.058 mmol), tris(3- hydroxypropyltriazolylmethyl)amine (THPTA, 6 mg, 0.011 mmol), copper (II) sulfate pentahydrate (21 mg, 0.086 mmol) and sodium L-ascorbate (9 mg, 0.046 mmol) in distilled water (2 mL). After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure and purified by column chromatography to afford Compound 1-124 (56 mg, 66 %). ESI-MS m / z: [M / 2+H]+1471.25, [M / 3+H]+981.20.

[1509] Preparation of Compound 1-125

[1510] To a solution of Compound 1-124 (56 mg, 0.019 mmol) in acetonitrile (1 mL) was added phosphoric acid (85%, 1 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-125 (32 mg, 59%) as yellow solid. ESI-MS m / z: [M / 2+H]+1421.12, [M / 3+H]+947.79.

[1511] Example 34: Preparation of Compound 1-133

[1512]

[1513] -325- FH13323832.11Attorney Docket No.: LCH-03925

[1514]

[1515] -326- FH13323832.11Attorney Docket No.: LCH-03925

[1516] Preparation of Compound 1-126

[1517] To a solution of D-glucamine (1.00 g, 5.52 mmol) in methanol (25 mL) and water (25 mL) was added di-tert-butyl dicarbonate (1.6 mL, 7.17 mmol) at 0 °C. After stirring at 23 °C for 16 hours, the reaction mixture was concentrated under reduced pressure, and isopropyl alcohol (15 mL) was added to the residue. The reaction mixture was cooled in an ice-water bath to induce precipitation, and the resulting solid was collected by filtration and dried under reduced pressure to afford Compound 1-126 (1.24 g, 80%) as a pale yellow solid. ESI-MS m / z: [M+Na]+304.31.

[1518] Preparation of Compound 1-127

[1519] Compound 1-126 (500 mg, 1.78 mmol) was dissolved in acetic anhydride (5 mL) / pyridine (5 mL). The reaction mixture was stirred at 23 °C for 2 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with IM aq. HC1 solution (30 mL x 2), saturated aq. NH4Cl solution (30 mL x 2), saturated aq. NaHCO3 solution (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under the reduced pressure to afford Compound 1-127 (377 mg, crude) as a yellow solid, which was used for the next step without further purification. ESI-MS m / z: [M+Na]+514.35.

[1520] Preparation of Compound 1-128

[1521] To a solution of Compound 1-127 (377 mg, 0.767 mmol) was added dropwise trifluoroacetic acid (0.5 mL) at 0 °C under N2. The reaction mixture was stirred for 2 hours. The reaction mixture was concentrated under reduced pressure and triturated with ether. The resulting solid was filtered to afford Compound 1-128 (100 mg, 26%) as a white solid. ESI-MS m / z:

[1522] [M+H]+392.28.

[1523] Preparation of Compound 1-129

[1524] To a solution of Compound 1-70 (150 mg, 0.097 mmol) in A, A-dimethylformamide (5 mL) were added Compound 1-128 (54 mg, 0.107 mmol), L[bis(dimethylamino)methylene]-1H-l,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 44 mg, 0.116 mmol), and A, A-diisopropylethylamine (0.084 mL, 0.485 mmol) under N2. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure, diluted with dichloromethane (30 mL) and washed with saturated aq. NH4Cl (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under the reduced pressure to afford Compound 1-129 (160 mg, crude) as a yellow oil, which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+961.62.

[1525] -327- FH13323832.11Attorney Docket No.: LCH-03925

[1526] Preparation of Compound 1-130

[1527] To a solution of Compound 1-129 (160 mg, 0.083 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 32 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 1-130 (137 mg, quant.), which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+827.42.

[1528] Preparation of Compound 1-131

[1529] To a solution of Compound 1-130 (137 mg, 0.083 mmol) in A, A-dimethylformamide (5 mL) were added Compound 1-19 (165 mg, 0.174 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 79 mg, 0.207 mmol), and N, N-diisopropylethylamine (0.072 mL, 0.414 mmol) under N2. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure, diluted with dichloromethane (30 mL) and washed with saturated aq. NH4Cl (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-131 (158 mg, 54%) as a yellow solid. ESI-MS m / z: [M / 3+H]+1170.66.

[1530] Preparation of Compound 1-132

[1531] To a solution of Compound 1-131 (158 mg, 0.045 mmol) in tetrahydrofuran (0.5 mL) and methanol (0.5 mL) was added lithium hydroxide monohydrate (19 mg, 0.45 mmol) in water (0.5 mL) at -78 °C. After stirring at 0 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-132 (78 mg, 57%) as a yellow solid. ESI-MS m / z: [M / 3+H]+1007.17.

[1532] Preparation of Compound 1-133

[1533] To a solution of Compound 1-132 (78 mg, 0.026 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 3 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-133 (44 mg, 58%) as a yellow solid. ESIMS m / z: [M / 3+H]+973.71.

[1534] Example 35: Preparation of Compound 2-2

[1535] -328- FH13323832.11Attorney Docket No.: LCH-03925

[1536] H

[1537]

[1538] Hȴ S-BK

[1539] 2-1

[1540] Preparation of Compound 2-1

[1541] To a solution of / V-Boc-hydroxylamine (5.0 g, 37.55 mmol) in / V, / V-dimethylformamide (20 mL) were added potassium carbonate (8.8 g, 63.84 mmol) and ethyl-2-bromoisobutyrate (15.38 g, 78.86 mmol). After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4Cl solution (50 mL), distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-1 (10.5 g, quant.).1H-NMR (400 MHz, CDC13) 84.21 (p, J = 6.8 Hz, 2H), 1.49 (s, 6H), 1.47 (s, 9H), 1.31 (q, J = 6.9 Hz, 3H).

[1542] Preparation of Compound 2-2

[1543] To a solution of Compound 2-1 (47 g, 190.1 mmol) in methanol (400 mL) was added lithium hydroxide monohydrate (16 g, 380 mmol) in water (100 mL). After stirring at room temperature for 3 hours, the reaction mixture was adjusted to pH 3.0 with 1 M HO solution and concentrated. Then the reaction mixture was extracted with ethyl acetate (200 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and triturated with ether. The resulting solid was filtered to afford Compound 2-2 (38 g, 91%) as a white solid. 'H-NMR (400 MHz, CDCl3) 87.32 (s, 1H), 1.53 (s, 6H), 1.49 (s, 9H).

[1544] Example 36: Preparation of Compound 2-7

[1545]

[1546] Preparation of Compound 2-3

[1547] -329- FH13323832.11Attorney Docket No.: LCH-03925

[1548] To a solution of bis(2-hydroxyethyl)ether (20 g, 188.5 mmol) in dichloromethane (400 mL) were added p-toluenesulfonyl chloride (79 g, 414.6 mmol) and potassium hydroxide (42 g, 753.9 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was washed with saturated aq. NH4Cl solution (100 mL x 2) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-3 (78 g, 99%) as a white solid. 'H-NMR (400 MHz, CDCl3) 87.79-7.77 (m, 4H), 7.36-7.34 (m, 4H), 4.10-4.08 (m, 4H), 3.62-3.60 (m, 4H), 2.45 (s, 6H).

[1549] Preparation of Compound 2-4

[1550] To a solution of Compound 2-3 (78 g, 188.2 mmol) in A, N,N-dimethylformamide (470 mL) was added sodium azide (61 g, 940.9 mmol) under N2. After stirring at 80 °C for 18 hours, the reaction mixture was diluted with ethyl acetate (1 L) and washed with saturated aq. NH4Cl solution (500 mL x 2) and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-4 (24 g, 83%) as a pale yellow oil.1H-NMR (400 MHz, CDCh) 83.70-3.67 (m, 4H), 3.43-3.40 (m, 4H).

[1551] Preparation of Compound 2-5

[1552] To a solution of Compound 2-4 (24 g, 153.7 mmol) in ethyl acetate (500 mL) were added triphenylphosphine (40 g, 153.7 mmol) and 1 M HO solution (284 mL) at 0 °C under N2. After stirring at room temperature for 17 hours, the reaction mixture was concentrated under reduced pressure and then the residue was adjusted to pH 10 with 1 M aq. sodium hydroxide solution. The residue was extracted with dichloromethane (100 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-5 (9.6 g, 48%) as a colorless oil. 'H-NMR (400 MHz, CDCl3) 83.68 (t, J = 4.8 Hz, 2H), 3.54 (t, J = 4.8 Hz, 2H), 3.40 (t, J = 4.8 Hz, 2H), 3.90 (t, J = 4.8 Hz, 2H), 1.37 (bs, 2H).

[1553] Preparation of Compound 2-6

[1554] To a solution of Compound 2-5 (8.9 g, 68.4 mmol) in dichloromethane (150 mL) were added Compound 2-2 (15 g, 68.4 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 33.8 g, 88.95 mmol), and N, A-di isopropylethyl amine (23.8 mL, 137 mmol) under N2. After stirring at room temperature for 14 hours, the reaction

[1555] -330- FH13323832.11Attorney Docket No.: LCH-03925

[1556] mixture was washed with saturated aq. NH4Cl solution (20 mL), saturated aq. NaHCO3 solution (20 mL), and brine (40 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-6 (20 g, 88%) as a yellow oil. ESI-MS m / z:

[1557] [M+H]+332.25.1H-NMR (400 MHz, CDCl3) 87.04 (s, 1H), 3.66 (t, J = 5.0 Hz, 2H), 3.58 (s, 2H), 3.47 (t, 7= 5.6 Hz, 2H), 3.41 (t, 7 = 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H).

[1558] Preparation of Compound 2-7

[1559] To a solution of Compound 2-6 (21 g, 63.3 mmol) in tetrahydrofuran (150 mL) were added triphenylphosphine (18 g, 69.7 mmol) and distilled water (22 mL) at 0 °C under N2. After stirring at 80 °C for 20 hours, the reaction mixture was concentrated and the resulting residue was purified by column chromatography to afford Compound 2-7 (15 g, 77%) as a yellow oil. ESI-MS m / z:

[1560] [M+H]+306.279.1H-NMR (400 MHz, CDCl3) 83.56 (t, 7= 5.4 Hz, 2H), 3.53-3.48 (m, 4H), 3.46 (q, 7 = 5.5 Hz, 2H), 2.90 (t, 7= 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H).

[1561] Example 37: Preparation of Compound 2-12

[1562]

[1563] -331- FH13323832.11Attorney Docket No.: LCH-03925

[1564]

[1565] -332- FH13323832.11Attorney Docket No.: LCH-03925

[1566] Preparation of Compound 2-8

[1567] To a solution of Compound 1-12 (190 mg, 0.14 mmol) in / V. / V-dimethylformamide (5 mL) were added Compound 2-7 (45 mg, 0.15 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.18 mmol), and A, A-di isopropylethyl amine (0.06 mL, 0.42 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-8 (140 mg, 61 %). ESI-MS m / z: [M+H]+1645.04, [M / 2+H]+823.39.

[1568] Preparation of Compound 2-9

[1569] To a solution of Compound 2-8 (140 mg, 0.09 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 15 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-9 (90 mg, 77%) as a yellow oil. ESI-MS m / z:

[1570] [M+H]+1376.80, [M / 2+H]+689.21.

[1571] Preparation of Compound 2-10

[1572] To a solution of Compound 2-9 (170 mg, 0.10 mmol) and Compound 1-19 (199 mg, 0.21 mmol) in N, N-dimethylformamide (4 mL) were added A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 95 mg, 0.25 mmol) and N, N-diisopropylethylamine (0.087 mL, 0.50 mmol) at 0 °C. After stirring at room temperature for 2 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL), and dried over anhydrous sodium sulfate. The organic layer was filtered, concentrated under reduced pressure, and purified by column chromatography to afford Compound 2-10 (223 mg, 71%). ESI-MS m / z: [M / 2+H]+1616.94, [M / 3+H]+1078.32.

[1573] Preparation of Compound 2-11

[1574] To a solution of Compound 2-10 (223 mg, 0.069 mmol) in tetrahydrofuran / methanol (1.5 mL / 1.5 mL) was added lithium hydroxide monohydrate (23 mg, 0.55 mmol) in water (1.5 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under

[1575] -333- FH13323832.11Attorney Docket No.: LCH-03925

[1576] reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-11 (115 mg, 56%). ESI-MS m / z: [M / 2+H]+1476.80, [M / 3+H]+937.17.

[1577] Preparation of Compound 2-12

[1578] To a solution of Compound 2-11 (115 mg, 0.039 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-12 (75 mg, 69%) as a yellow solid. ESIMS m / z: [M / 2+H]+1398.80, [M / 3+H]+932.86.

[1579]

[1580] -334- FH13323832.11Attorney Docket No.: LCH-03925

[1581]

[1582] Preparation of Compound 2-13

[1583] To a solution of Compound 1-11 (1.10 g, 0.802 mmol) in dichloromethane (2 mL) was added hydrogen chloride solution (4 M in 1,4-dioxane, 2 mL, 26.1 mmol) at 0 °C under N2. After 4 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 2-13 (1 g, 95%) as a brown oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1315.79.

[1584] Preparation of Compound 2-14

[1585] To a solution of Compound 2-13 (1 g, 0.760 mmol) in A, A-dimethylformamide (20 mL) were added 1-(tert-butoxycarbonyl)piperazine (170 mg, 0.912 mmol), A. MA’. A’-tetramethyl- -(IH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 346 mg, 0.912 mmol), and N, N-diisopropylethylamine (0.32 mL, 2.28 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4Cl solution (50 mL), saturated aq. NaHCCh solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-14 (835 mg, 74%). ESI-MS m / z: [M+H]+1485.05.

[1586] Preparation of Compound 2-15

[1587] -335- FH13323832.11Attorney Docket No.: LCH-03925

[1588] To a solution of Compound 2-14 (835 mg, 0.563 mmol) in methanol (5 mL) was added 1 N aq. NaOH solution (2.81 mL, 2.81 mmol) at 0 °C under N2. After 3 hours, the reaction mixture was titrated with 1 N aq. HCl solution to pH 3-4 at 0 °C and extracted with ethyl acetate (30 mL x 2). The organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-15 (748 mg, 90%) as a brown oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1471.00.

[1589] Preparation of Compound 2-16

[1590] To a solution of Compound 2-15 (975 mg, 0.66 mmol) and Compound 2-7 (405 mg, 1.32 mmol) in A, A-dimethylformamide (20 mL) were added A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 377 mg, 0.99 mmol) and N, N-diisopropylethylamine (0.35 mL, 1.99 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. NH4Cl solution (25 mL), saturated aq. NaHCO3 solution (25 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-16 (350 mg, 30%). ESI-MS m / z: [M / 2+H]+879.01.

[1591] Preparation of Compound 2-17

[1592] To a solution of Compound 2-16 (349 mg, 0.20 mmol) in methanol (12 mL) was added palladium / charcoal (10 wt. %, 150 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-17 (297 mg, quant.) as a pale yellow oil. ESI-MS m / z: [M / 2+H]+745.61.

[1593] Example 39: Preparation of Compound 2-20

[1594] -336- FH13323832.11Attorney Docket No.: LCH-03925

[1595]

[1596] -337- FH13323832.11Attorney Docket No.: LCH-03925

[1597] Preparation of Compound 2-18

[1598] To a solution of Compound 2-17 (297 mg, 0.20 mmol) and Compound 1-19 (415 mg, 0.44 mmol) in A-dimethylformamide (10 mL) were added A. M / V’. A’-tetramethyl-O-f I / / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 189 mg, 0.50 mmol) and N, N-diisopropylethylamine (0.17 mL, 0.20 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-18 (428 mg, 64%) as a pale yellow solid. ESI-MS m / z: [M / 2+H]+1672.06, [M / 3+H]+1115.08.

[1599] Preparation of Compound 2-19

[1600] To a solution of Compound 2-18 (428 mg, 0.13 mmol) in tetrahydrofuran (4 mL) and methanol (4 mL) was added lithium hydroxide monohydrate (42.9 mg, 1.02 mmol) in water (5 mL) at -78 °C. After stirring at 5 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-19 (250 mg, 63%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1532.03, [M / 3+H]+1021.77.

[1601] Preparation of Compound 2-20

[1602] To a solution of Compound 2-19 (120 mg, 0.04 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-20 (89 mg, 76%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1431.77, [M / 3+H]+955.00.

[1603] Example 40: Preparation of Compound 2-26

[1604]

[1605] -338- FH13323832.11Attorney Docket No.: LCH-03925

[1606]

[1607] Preparation of Compound 2-21

[1608] To a solution of Compound 1-8 (30 g, 98.6 mmol) in / V, / V-dimethylformamide (300 mL) were added cesium carbonate (70.67 g, 217 mmol) and Compound 1-80 (104.66 g, 227 mmol) under N2. The reaction mixture was stirred at 50 °C for 4 hours. The reaction mixture was concentrated under reduced pressure and the residue was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aq. NH4Cl solution (100 mL), saturated aq. NaHCO3 solution (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-21 (82 g, 94%) as a yellow oil. ESI-MS m / z: [M+H]+855.77.

[1609] Preparation of Compound 2-22

[1610] To a solution of Compound 2-21 (88 g, 99.7 mmol) in dichloromethane (250 mL) were added anisole (162 mL, 1495 mmol) and trifluoroacetic acid (38 mL) at 0 °C under N2. After stirring at room temperature for 40 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-22 (63 g, 83%) as a pale yellow oil. ESI-MS m / z: [M+H]+763.68.

[1611] Preparation of Compound 2-23

[1612] -339- FH13323832.11Attorney Docket No.: LCH-03925

[1613] To a solution of Compound 2-22 (23 g, 30.2 mmol) in / V, / V-di methylformamide (150 mL) were added cesium carbonate (14.74 g, 45.2 mmol) and Compound 1-7 (20.43 g, 36.2 mmol) under N2. The reaction mixture was stirred at 50 °C for 4 hours. The reaction mixture was concentrated under reduced pressure and the residue was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aq. NH4Cl solution (100 mL), saturated aq. NaHCO3 solution (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-23 (20 g, 57%) as a yellow oil. ESI-MS m / z: [M+Na]+1178.06.

[1614] Preparation of Compound 2-24

[1615] To a solution of Compound 2-23 (20 g, 17.3 mmol) in isopropyl alcohol / distilled water (250 mL / 250 mL) was added NaOH (1.04 g, 26.0 mmol) at 0 °C under N2. After 5 hours, the reaction mixture was titrated with 1 N aq. HC1 solution to pH 3-4 at 0 °C and extracted with ethyl acetate (250 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-24 (19 g, 96%) as a brown oil, which was used for the next step without further purification. ESI-MS m / z:

[1616] [M+Na]+1164.04.

[1617] Preparation of Compound 2-25

[1618] To a solution of Compound 2-24 (19 g, 16.6 mmol) in A, A-dimethylformamide (100 mL) were added Compound 2-7 (6.10 g, 20.0 mmol), A, A, A’, A’-tetramethyLO-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 7.58 g, 20.0 mmol), and N, N-diisopropylethylamine (14 mL, 83.2 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (300 mL) and washed with saturated aq. NH4Cl solution (200 mL), saturated aq. NaHCO3 solution (200 mL) and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-25 (19.6 g, 82%). ESI-MS m / z: [M+H]+1430.42.

[1619] Preparation of Compound 2-26

[1620] To a solution of Compound 2-25 (5.00 g, 3.50 mmol) in methanol (20 mL) was added 1 N aq. NaOH solution (28 mL, 28.0 mmol) at 0 °C under N2. After 24 hours, the reaction mixture was titrated with 1 N aq. HC1 solution to pH 3-4 at 0 °C and extracted with dichloromethane (30 mL x 2). The organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate

[1621] -340- FH13323832.11Attorney Docket No.: LCH-03925

[1622] was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-26 (5.0 g, quant.) as a yellow oil. ESI-MS m / z: [M+Na]+1395.22.

[1623] Example 41: Preparation of Compound 2-31

[1624]

[1625] -341- FH13323832.11Attorney Docket No.: LCH-03925

[1626]

[1627] Preparation of Compound 2-27

[1628] To a solution of Compound 2-26 (4.80 g, 3.50 mmol) in N,N-dimethylformamide (50 mL) were added Compound 1-69 (2.65 g, 5.25 mmol), M / V. / V’. A’-tetramethyl-O-i I H-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 1.99 g, 5.25 mmol), and A, / V-di isopropylethylamine (3 mL, 17.5 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4Cl solution (100 mL),

[1629] -342- FH13323832.11Attorney Docket No.: LCH-03925

[1630] saturated aq. NaHCO3 solution (100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-27 (4.22 g, 65%). ESI-MS m / z: [M+H]+1860.82.

[1631] Preparation of Compound 2-28

[1632] To a solution of Compound 2-27 (4.22 g, 2.27 mmol) in tetrahydrofuran (30 mL) were added triphenylphosphine (1.43 g, 5.44 mmol) and distilled water (0.82 mL, 45.4 mmol) at 0 °C under N2. The reaction mixture was stirred at 60 °C for 12 hours. After concentrated under reduced pressure, the resulting residue purified by column chromatography to afford Compound 2-28 (4.0 g, 97%). ESI-MS m / z: [M+H]+1808.21.

[1633] Preparation of Compound 2-30

[1634] To a solution of Compound 2-29 (525 mg, 1.08 mmol; prepared by the method described in US Patent No. 11,173,214 B2) in M / V-dimethylformamide (5 mL) were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC HC1, 283 mg, 1.48 mmol), 1-hydroxybenzotriazole (HOBt, 199 mg, 1.48 mmol), Compound 2-28 (890 mg, 0.49 mmol), and N-methylmorpholine (0.32 mL, 2.95 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NaHCCh solution (50 mL) and saturated aq. NH4Cl solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-30 (890 mg, 66%). ESI-MS m / z: [M / 2+H]+1370.61, [M / 3+H]+914.14.

[1635] Preparation of Compound 2-31

[1636] To a solution of Compound 2-30 (890 mg, 0.32 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (384 mg, 0.97 mmol) and pyridine (0.10 mL, 1.30 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was concentrated under reduced pressure and then was diluted with ethyl acetate (100 mL) and washed with brine (50 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-31 (1.28 g, crude), which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1580.56, [M / 3+H]+1054.06.

[1637] -343- FH13323832.11Attorney Docket No.: LCH-03925

[1638]

[1639] -344- FH13323832.11Attorney Docket No.: LCH-03925

[1640]

[1641] Preparation of Compound 2-32

[1642] To a solution of compound 2-31 (450 mg, 0.14 mmol) in N,N-dimethylformamide (2 mL) was added exatecan mesylate (159 mg, 0.30 mmol) in N,N-dimethylformamide (3 mL) and N, N- diisopropylethylamine (0.20 mL, 1.14 mmol) at room temperature under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford Compound 2-32 (550 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1831.35, [M / 3+H]+1221.44.

[1643] Preparation of Compound 2-33

[1644] To a solution of Compound 2-32 (115 mg, 0.031 mmol) in tetrahydrofuran / methanol (0.5 mL / 0.5 mL) was added lithium hydroxide monohydrate (10 mg, 0.25 mmol) in water (0.5 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. Then the resulting residue was purified by HPLC to afford Compound 2-33 (60 mg, 56%). ESI-MS m / z: [M / 2+H]+1691.42, [M / 3+H]+1128.07.

[1645] Preparation of Compound 2-34

[1646] To a solution of Compound 2-33 (60 mg, 0.018 mmol) in acetonitrile (1 mL) was added phosphoric acid (85%, 1.5 mL) at 0 °C. After stirring at room temperature for 5 hours, the reaction

[1647] -345- FH13323832.11Attorney Docket No.: LCH-03925

[1648] mixture was purified by HPLC to afford Compound 2-34 (37 mg, 67%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1558.64, [M / 3+H]+1039.39.

[1649] Example 43: Preparation of Compound 2-36

[1650]

[1651] -346- FH13323832.11Attorney Docket No.: LCH-03925

[1652] Preparation of Compound 2-35

[1653] To a solution of compound 2-9 (1.90 g, 1.38 mmol) in dichloromethane (30 mL) were added compound 2-29 (1.47 g, 4.62 mmol; prepared by the method described in WO 2017 / 089894 Al), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC HC1, 609 mg, 6.30 mmol), 1-hydroxybenzotriazole (HOBt, 448 mg, 3.31 mmol) and A-methyl morpholine (0.91 mL, 8.28 mmol) under N2. After stirring at room temperature for 12 hours, the reaction mixture was diluted with ethyl acetate (50 mL), washed with saturated aq. NaHCO3 solution (30 mL), saturated aq. NH4Cl solution (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-35 (1.3 g, 41%) as a colorless oil. ESI-MS m / z: [M+Na]+2330.22.

[1654] Preparation of Compound 2-36

[1655] To a solution of Compound 2-35 (670 mg, 0.29 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (286 mg, 0.725 mmol) and pyridine (0.093 mL, 1.16 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with dichloromethane (100 mL) and washed with saturated aq. NaHCCL solution (50 mL), aq. 0.5 N HC1 solution (50 mL), and aq. 2% NaOH solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-36 (995 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1364.73.

[1656] Example 44: Preparation of Compound 2-39

[1657] -347- FH13323832.11Attorney Docket No.: LCH-03925

[1658]

[1659] -348- FH13323832.11Attorney Docket No.: LCH-03925

[1660] Preparation of Compound 2-37

[1661] To a solution of Compound 2-36 (200 mg, 0.07 mmol) and Monomethyl auristatin F methyl ester (MMAF-OMe,109 mg, 0.15 mmol) in A, A-dimethylformamide (3 mL) were added 1-hydroxy-7-azabenzotriazole (HO At, 3 mg, 0.02 mmol) and A, A-di isopropylethylamine (0.1 mL, 0.59 mmol) at 0 °C under N2. The reaction mixture was warmed to room temperature and stirred for 12 hours. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (20 mL), distilled water (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-37 (220 mg, 78%) as a white solid. ESI-MS m / z: [M / 3+H]+1285.75.

[1662] Preparation of Compound 2-38

[1663] To a solution of Compound 2-37 (220 mg, 0.06 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (24 mg, 0.57 mmol) in water (1 mL) at -78 °C. After stirring at -5 °C for 6 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-38 (140 mg, 69%) as a white solid. ESI-MS m / z: [M / 3+H]+1183.02.

[1664] Preparation of Compound 2-39

[1665] To a solution of Compound 2-38 (140 mg, 0.04 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.3 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-39 (65 mg, 49%) as a white solid. ESI-MS m / z: [M / 3+H]+1130.82.

[1666] Example 45: Preparation of Compound 2-42

[1667] -349- FH13323832.11Attorney Docket No.: LCH-03925

[1668]

[1669] Preparation of Compound 2-40

[1670] -350- FH13323832.11Attorney Docket No.: LCH-03925

[1671] To a solution of Compound 2-36 (100 mg, 0.04 mmol) and Monomethyl auristatin E (MMAE, 57 mg, 0.08 mmol) in A. A-dimethylformamide (5 mL) were added 1-hydroxy-7-azabenzotriazole (HOAt, 1 mg, 0.01 mmol) and N, / V-di isopropylethylamine (0.1 mL, 0.4 mmol) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), distilled water (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-40 (160 mg, quant.) as a white solid, which was used for the next step without further purification. ESI-MS m / z: [M / 3+H]+1267.24.

[1672] Preparation of Compound 2-41

[1673] To a solution of Compound 2-40 (160 mg, 0.04 mmol) in tetrahydrofuran (1 mL) and methanol (0.5 mL) was added lithium hydroxide monohydrate (17 mg, 0.42 mmol) in water (4 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 5 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-41 (91 mg, 61%) as a white solid. ESI-MS m / z:

[1674] [M / 3+H]+1173.45.

[1675] Preparation of Compound 2-42

[1676] To a solution of Compound 2-41 (88 mg, 0.03 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.6 mL) at 0 °C. The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-42 (23 mg, 27%) as a white solid. ESI-MS m / z: [M / 3+H]+1121.67.

[1677] Example 46: Preparation of Compound 2-47

[1678]

[1679] 2-46 2-47

[1680] Preparation of Compound 2-43

[1681] -351- FH13323832.11Attorney Docket No.: LCH-03925

[1682] To a solution of (25)-2-bromopropanoic acid (2.0 g, 13.1 mmol) and benzyl alcohol (1.5 mL, 14.4 mmol) in toluene (4 mL) was added -toluenesulfonic acid hydrate (56 mg, 0.29 mmol). After stirring at 100 °C for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NaHCO3 solution (30 mL), distilled water (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-43 (2.9 g, 91%).1H-NMR (400 MHz, CDCl3) 87.41-7.35 (m, 5H), 5.21 (d, J = 3.8 Hz, 2H), 4.47-4.36 (m, 1H), 1.85 (d, 3H).

[1683] Preparation of Compound 2-44

[1684] To a solution of A-Boc-hydroxylamine (350 mg, 2.63 mmol) in A. A-dimethylformamide (3 mL) were added potassium carbonate (0.38 g, 2.76 mmol) and Compound 2-43 (0.67 g, 2.76 mmol). After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), distilled water (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-44 (350 mg, 45%). ESI-MS m / z: [M+Na]+318.30, [(M-Boc)+H]+196.26. 'H-NMR (400 MHz, CDCl3) 87.56 (d, 1H), 7.40-7.34 (m, 5H), 5.26-5.13 (m, 2H), 4.58-4.48 (m, 1H), 1.48 (d, J = 2.3 Hz, 12H).

[1685] Preparation of Compound 2-45

[1686] To a solution of Compound 2-44 (350 mg, 1.19 mmol) in methanol (8 mL) were added palladium / charcoal (10 wt. %, 70 mg) under hydrogen atmosphere. After stirring at room temperature for 3 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-45 (243 mg, quant.). ESI-MS m / z: [M+Na]+228.24.

[1687] Preparation of Compound 2-46

[1688] To a solution of Compound 2-45 (256 mg, 1.25 mmol) in A, N,N-dimethylformamide (5 mL) were added Compound 2-5 (150 mg, 1.15 mmol), A, A, A’, A’-tetramethyLO-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 568 mg, 1.50 mmol), and A, A-diisopropylethylamine (0.4 mL, 2.31 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCCL solution (30 mL), and brine (30 mL). The organic layer was dried over

[1689] -352- FH13323832.11Attorney Docket No.: LCH-03925

[1690] anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-46 (229 mg, 63%). ESI-MS m / z: [M+Na]+340.31. ’H- NMR (400 MHz, CDC13) 87.66 (s, 1H), 7.42 (s, 1H), 4.35-4.27 (m, 1H), 3.70-3.56 (m, 4H), 3.55-3.35 (m, 4H), 1.55-1.41 (m, 12H).

[1691] Preparation of Compound 2-47

[1692] To a solution of Compound 2-46 (229 mg, 0.72 mmol) in tetrahydrofuran (7 mL) were added triphenylphosphine (208 mg, 0.79 mmol) and distilled water (0.26 mL, 14.4 mmol) at 0 °C under N2. After stirring at 60 °C for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-47 (157 mg, 75%). ESI-MS m / z: [M+H]+292.35.1H-NMR (400 MHz, CDCl3) 87.69-7.64 (m, 1H), 4.32 (q, J = 6.5 Hz, 1H), 3.64-3.51 (m, 5H), 3.41 (s, 1H), 2.91 (d, J = 5.6 Hz, 2H), 1.51-1.41 (m, 12H).

[1693] Example 47: Preparation of Compound 2-52

[1694] -353- FH13323832.11Attorney Docket No.: LCH-03925

[1695]

[1696] -354- FH13323832.11Attorney Docket No.: LCH-03925

[1697]

[1698] Preparation of Compound 2-48

[1699] To a solution of Compound 1-12 (250 mg, 0.18 mmol) in A, N,N-dimethylformamide (5 mL) were added Compound 2-47 (59 mg, 0.20 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 83.8 mg, 0.22 mmol), and A. A-diisopropylethylamine (0.08 mL, 0.72 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (20 mL) and washed with saturated aq. NH4Cl solution (20 mL), saturated aq. NaHCCL solution (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The

[1700] -355- FH13323832.11Attorney Docket No.: LCH-03925

[1701] resulting residue was purified by column chromatography to afford Compound 2-48 (240 mg, 80%). ESI-MS m / z: [M+Na]+1653.79.

[1702] Preparation of Compound 2-49

[1703] To a solution of Compound 2-48 (240 mg, 0.15 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 50 mg) under hydrogen atmosphere. After stirring at room temperature for 1 hour, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-49 (200 mg, quant.) as a colorless oil. ESI-MS m / z: [M+H]+1362.85.

[1704] Preparation of Compound 2-50

[1705] To a solution of Compound 1-19 (297 mg, 0.31 mmol) in A, N,N-dimethylformamide (4 mL) were added Compound 2-49 (204 mg, 0.15 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 142 mg, 0.37 mmol), and A. A-diisopropylethylamine (0.13 mL, 0.75 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted under reduced pressure. The resulting residue was purified by reversed phase column chromatography to afford Compound 2-50 (430 mg, 89%) as a yellow solid. ESI-MS m / z: [M / 3+H]+1073.66.

[1706] Preparation of Compound 2-51

[1707] To a solution of Compound 2-50 (430 mg, 0.13 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (24 mg, 0.57 mmol) in water (1 mL) at -78 °C. After stirring at -5 °C for 6 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-51 (68 mg, 17%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1469.86.

[1708] Preparation of Compound 2-52

[1709] To a solution of Compound 2-51 (68 mg, 0.02 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-52 (57 mg, 85%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1391.79.

[1710] Example 48: Preparation of Compound 2-56

[1711] -356- FH13323832.11Attorney Docket No.: LCH-03925

[1712]

[1713] 2-55 2-56

[1714] Preparation of Compound 2-53

[1715] To a solution of / V-Boc-hydroxylamine (500 mg, 3.75 mmol) in / V. / V-dimethylformamide (10 mL) were added ethyl 1 -bromocyclobutanecarboxylate (0.58 mL, 3.75 mmol) and potassium carbonate (545 mg, 3.94 mmol). After stirring at room temperature for 16 hours under N2, ethyl 1-bromocyclobutanecarboxylate (1.16 mL, 7.50 mmol) was additionally added to the reaction mixture and stirred at 60 °C for 24 hours. Then the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-53 (500 mg, 51%). 'H-NMR (400 MHz, CDCl3) 87.48 (s, 1H), 4.25 (q, J = 7.2 Hz, 2H), 2.50-2.33 (m, 4H), 2.19-2.07 (m, 1H), 2.03-1.90 (m, 1H), 1.49 (s, 9H), 1.33 (t, J = 7.1 Hz, 3H).

[1716] Preparation of Compound 2-54

[1717] To a solution of Compound 2-53 (500 mg, 1.93 mmol) in tetrahydrofuran / methanol (5 mL / 5 mL) was added lithium hydroxide monohydrate (243 mg, 5.78 mmol) in distilled water (5 mL) at 0 °C under N2. After stirring at room temperature for 6 hours, the reaction mixture was adjusted to pH 3.0 with 1 M aq. HO solution and extracted with ethyl acetate (20 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure to afford Compound 2-54 (430 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M+Na]+254.31.

[1718] Preparation of Compound 2-55

[1719] To a solution of Compound 2-54 (430 mg, 1.86 mmol) and Compound 2-5 (220 mg, 1.69 mmol) in A. A-dimethylformamide (10 mL) were added A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 833 mg, 2.20 mmol) and N, N-diisopropylethylamine (0.88 mL, 5.07 mmol) at 0 °C. After stirring at room temperature for 18

[1720] -357- FH13323832.11Attorney Docket No.: LCH-03925

[1721] hours under N2, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. After concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-55 (496 mg, 85%). ESI-MS m / z: [M+H]+344.39, [M+Na]+366.38.

[1722] Preparation of Compound 2-56

[1723] Triphenylphosphine (416 mg, 1.59 mmol) was added to a solution of Compound 2-55 (496 mg, 1.44 mmol) in tetrahydrofuran (5 mL) at room temperature. After stirring for 30 minutes under N2, distilled water (0.52 mL, 28.89 mmol) was added thereto and the reaction mixture was refluxed for 4 hours. Then the reaction mixture was concentrated and purified by column chromatography to afford Compound 2-56 (415 mg, 90 %). ESI-MS m / z: [M+H]+318.39.

[1724] Example 49: Preparation of Compound 2-61

[1725]

[1726] -358- FH13323832.11Attorney Docket No.: LCH-03925

[1727]

[1728] Preparation of Compound 2-57

[1729] To a solution of Compound 1-12 (49 mg, 0.15 mmol) and Compound 2-56 (190 mg, 0.14 mmol) in / V. / V-di methylformamide (5 mL) were added M / V. / V’. A’-tetramethyl-O-i IH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.180 mmol) and N, N- diisopropylethylamine (0.059 mL, 0.42 mmol) at 0 °C. After stirring at room temperature for 3 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column

[1730] -359- FH13323832.11Attorney Docket No.: LCH-03925

[1731] chromatography to afford Compound 2-57 (214 mg, 92%). ESI-MS m / z: [M+H]+1658.50, [M / 2+H]+829.59.

[1732] Preparation of Compound 2-58

[1733] To a solution of Compound 2-57 (214 mg, 0.13 mmol) in methanol (3 mL) was added palladium / charcoal (10 wt. %, 40 mg). After stirring at room temperature for 3 hours under hydrogen atmosphere, the reaction mixture was filtered through a celite pad and washed with methanol (100 mL). The filtrate was concentrated to afford Compound 2-58 (170 mg), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1389.25, [M / 2+H]+695.42.

[1734] Preparation of Compound 2-59

[1735] To a solution of Compound 2-58 (90 mg, 0.065 mmol) and Compound 1-19 (128 mg, 0.14 mmol) in N, / V-di methylformamide (3 mL) were added A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 56 mg, 0.150 mmol) and N, N-diisopropylethylamine (0.045 mL, 0.26 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-59 (198 mg, 94%). ESI-MS m / z: [M / 2+H]+1623.54, [M / 3+H]+1082.69.

[1736] Preparation of Compound 2-60

[1737] To a solution of Compound 2-59 (198 mg, 0.061 mmol) in tetrahydrofuran / methanol (1.5 mL / 1.5 mL) was added lithium hydroxide monohydrate (20 mg, 0.49 mmol) in distilled water (1.5 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-60 (91 mg, 50%). ESI-MS m / z: [M / 2+H]+1483.23.

[1738] Preparation of Compound 2-61

[1739] To a solution of Compound 2-60 (91 mg, 0.031 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-61 (38 mg, 44%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1405.19, [M / 3+H]+937.17.

[1740] -360- FH13323832.11Attorney Docket No.: LCH-03925

[1741] Example 50: Preparation of Compound 2-65

[1742]

[1743] Preparation of Compound 2-62

[1744] To a solution of Compound 2-1 (1.0 g, 4.04 mmol) in diethyl ether (30 mL) was added lithium aluminum hydride (1.0 M in tetrahydrofuran, 8.08 mL, 8.08 mmol) at 0 °C under N2. After stirring at 0 °C for 3 hours, the reaction mixture was quenched by the addition of distilled water (1 mL). The suspension was filtered through a celite pad and washed with diethyl ether (30 mL). The filtrate was concentrated under reduced pressure to afford Compound 2-62 (700 mg, 84%), which was used for the next step without further purification.1H-NMR (400 MHz, CDCl3) δ3.40 (d, J = 7.2 Hz, 2H), 1.48 (s, 9H), 1.20 (s, 6H).

[1745] Preparation of Compound 2-63

[1746] To a solution of Compound 2-62 (600 mg, 2.92 mmol) in tetrahydrofuran (5 mL) was added sodium hydride (60 % dispersion in mineral oil, 1.09 g, 45.56 mmol) at 0 °C. After stirring at 0 °C for 0.5 hours, Compound 2-5 (650 mg, 2.28 mmol) was added to the reaction mixture at room temperature. After stirring for 16 hours, the reaction mixture was quenched by the addition of distilled water (5 mL) and extracted to ethyl acetate (30 mL x 4). The organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-63 (970 mg, 100 %).

[1747] Preparation of Compound 2-64

[1748] To a solution of Compound 2-63 (970 mg, 2.28 mmol) in tetrahydrofuran (5 mL) were added triphenylphosphine (787 mg, 3.0 mmol) and distilled water (0.41 mL, 22.8 mmol) at 0 °C under N2. The reaction mixture was stirred at 60 °C for 3 hours and then cooled to room temperature. Benzyl chloroformate (0.42 mL, 2.96 mmol) and A, A-diisopropylethylamine (0.8

[1749] -361- FH13323832.11Attorney Docket No.: LCH-03925

[1750] mL, 4.56 mmol) were added to the reaction mixture. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-64 (210 mg, 22%) as a brown oil. ESI-MS m / z: [M+H]+449.167.1H-NMR (400 MHz, CDCl3) 87.38-7.29 (m, 5H), 5.10 (d, J = 3.2 Hz, 2H), 3.68-3.45 (m, 6H), 3.41 (d, J = 13.1 Hz, 4H), 1.46 (d, J = 3.5 Hz, 9H), 1.21 (s, 6H).

[1751] Preparation of Compound 2-65

[1752] To a solution of Compound 2-64 (210 mg, 0.49 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 30 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-65 (136 mg, 94%) as a yellow oil. ESI-MS m / z:

[1753] [M+H]+293.27.

[1754] Example 51: Preparation of Compound 2-70

[1755]

[1756] 2-67

[1757] -362- FH13323832.11Attorney Docket No.: LCH-03925

[1758]

[1759] -363- FH13323832.11Attorney Docket No.: LCH-03925

[1760] Preparation of Compound 2-66

[1761] To a solution of Compound 1-12 (190 mg, 0.14 mmol) in / V. / V-dimethylformamide (5 mL) were added Compound 2-65 (45 mg, 0.15 mmol), A, A, A’, A’-tetramethyLO-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.18 mmol), and A, A-di isopropylethyl amine (0.06 mL, 0.42 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was concentrated, diluted with ethyl acetate (20 mL) and washed with saturated aq. NH4Cl solution (20 mL), saturated aq. NaHCO3 solution (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-66 (140 mg, 61%). ESI-MS m / z: [M+H]+1654.55.

[1762] Preparation of Compound 2-67

[1763] To a solution of Compound 2-66 (140 mg, 0.09 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 15 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-67 (90 mg, 77%) as a yellow oil. ESI-MS m / z:

[1764] [M+H]+1363.57.

[1765] Preparation of Compound 2-68

[1766] To a solution of Compound 2-67 (90 mg, 0.07 mmol) in A, A-dimethylformamide (3 mL) were added Compound 1-19 (131 mg, 0.14 mmol), A, A, A’, A’-tetramethyLO-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 58 mg, 0.15 mmol), and A. A-diisopropylethylamine (0.06 mL, 0.33 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-68 (140 mg, 66%) as an orange oil. ESI-MS m / z: [M / 2+H]+1610.08.

[1767] Preparation of Compound 2-69

[1768] To a solution of Compound 2-68 (140 mg, 0.04 mmol) in tetrahydrofuran (2 mL) and methanol (2 mL) was added lithium hydroxide monohydrate (14.6 mg, 0.35 mmol) in water (2 mL) at -78 °C. After stirring at -5 °C for 2 hours, the reaction mixture was adjusted to pH 4-5 with

[1769] -364- FH13323832.11Attorney Docket No.: LCH-03925

[1770] acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-69 (90 mg, 70%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1469.93.

[1771] Preparation of Compound 2-70

[1772] To a solution of Compound 2-69 (90 mg, 0.03 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 2-70 (60 mg, 78%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1391.97.

[1773] Example 52: Preparation of Compound 2-74

[1774]

[1775] Preparation of Compound 2-72

[1776] To a solution of Compound 2-71 (5.0 g, 13.42 mmol) in acetonitrile (100 mL) were added methyl propiolate (2.34 mL, 26.85 mmol) and N-methylmorpholine (0.30 mL, 2.68 mmol). After stirring at room temperature for 48 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-72 (3.82 g, 62%) as a yellow oil.

[1777] Preparation of Compound 2-73

[1778] To a solution of Compound 2-72 (3.82 g, 8.37 mmol) in methanol (70 mL) was added palladium / charcoal (10 wt. %, 400 mg) under hydrogen atmosphere. After stirring at room temperature for 16 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-73 (2.56 g, 65%) as a pale yellow oil. ESI-MS m / z: [M+H]+369.35.

[1779] Preparation of Compound 2-74

[1780] To a solution of Compound 2-73 (3.04 g, 8.25 mmol) in dichloromethane (30 mL) were added triethylamine (3.48 mL, 24.75 mmol) and -toluenesulfonyl chloride (1.89 g, 9.90 mmol)

[1781] -365- FH13323832.11Attorney Docket No.: LCH-03925

[1782] at 0 °C. After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. NaHCO3 solution (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-74 (2.93 g, 68%) as a pale yellow oil. ESI-MS m / z: [M+H]+523.35.

[1783] Example 53: Preparation of Compound 2-81

[1784]

[1785] Preparation of Compound 2-75

[1786] To a solution of Compound 1-9 (500 mg, 0.45 mmol) in tetrahydrofuran (3 mL) and methanol (1 mL) was added 1 N aq. NaOH (1.36 mL, 1.36 mmol) under N2. After 3 hours, the reaction mixture was titrated with 1 N aq. HCl solution to pH 3-4 and extracted with -366- FH13323832.11Attorney Docket No.: LCH-03925

[1787] dichloromethane (20 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-75 (475 mg, 96%), which was used for the next step without further purification. ESI-MS m / z:

[1788] [M+H]+1085.50.

[1789] Preparation of Compound 2-76

[1790] To a solution of Compound 2-75 (501 mg, 0.46 mmol) in A, N,N-dimethylformamide (10 mL) were added 3-azido-l-propanamine (126 mg, 0.92 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 262 mg, 0.69 mmol), and N, N-diisopropylethylamine (0.24 mL, 1.39 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL), and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-76 (520 mg, 96%) as a brown oil. ESI-MS m / z: [M+H]+1167.73.

[1791] Preparation of Compound 2-77

[1792] To a solution of Compound 2-76 (520 mg, 0.45 mmol) in dichloromethane (10 mL) were added anisole (0.72 mL, 6.68 mmol) and trifluoroacetic acid (0.34 mL, 4.45 mmol) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-77 (495 mg, quant.) as a pale yellow oil. ESI-MS m / z: [M+H]+1047.53.

[1793] Preparation of Compound 2-78

[1794] To a solution of Compound 2-77 (495 mg, 0.47 mmol) in N,N-dimethylformamide (6 mL) were added potassium carbonate (130 mg, 0.95 mmol) and Compound 2-74 (494 mg, 0.95 mmol) under N2. After stirring at 80 °C for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCO3 solution (30 mL), and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-78 (500 mg, 75%) as a brown oil.

[1795] Preparation of Compound 2-79

[1796] To a solution of Compound 2-78 (500 mg, 0.36 mmol) in tetrahydrofuran (10 mL) were added triphenylphosphine (141 mg, 0.54 mmol) and distilled water (0.06 mL, 3.58 mmol) at 0 °C

[1797] -367- FH13323832.11Attorney Docket No.: LCH-03925

[1798] under N2. After stirring at 80 °C for 6 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-79 (299 mg, 61%) as a pale yellow oil. ESI-MS m / z: [M+H]+1372.74, [M / 2+H]+686.82.

[1799] Preparation of Compound 2-80

[1800] To a solution of Compound 2-79 (299 mg, 0.22 mmol) in dichloromethane (10 mL) were added triethylamine (0.06 mL, 0.26 mmol) and di-terLbutyl dicarbonate (0.06 mL, 0.26 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-80 (295 mg, 92%).

[1801] Preparation of Compound 2-81

[1802] To a solution of Compound 2-80 (295 mg, 0.20 mmol) in methanol (7 mL) was added palladium / charcoal (10 wt. %, 100 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-81 (217 mg, 90%) as a yellow oil. ESI-MS m / z:

[1803] [M+H]+1203.78, [M / 2+H]+602.69.

[1804] Example 54: Preparation of Compound 2-86

[1805]

[1806] -368- FH13323832.11Attorney Docket No.: LCH-03925

[1807]

[1808] Preparation of Compound 2-82

[1809] To a solution of Compound 2-81 (217 mg, 0.18 mmol) and Compound 1-19 (375 mg, 0.40 mmol) in / V, / V-di methylformamide (5 mL) were added / V. / V. / V’. / V’-tetramethyl-O-i 17 / -

[1810] -369- FH13323832.11Attorney Docket No.: LCH-03925

[1811] benzotriazol- l-yl)uronium hexafluorophosphate (HBTU, 171 mg, 0.45 mmol) and N, N-diisopropylethylamine (0.16 mL, 0.90 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. NH4Cl solution (25 mL), saturated aq. NaHCO3 solution (25 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-82 (412 mg, 74%) as a beige solid. ESI-MS m / z: [M / 2+H]+1530.47, [M / 3+H]+1020.64.

[1812] Preparation of Compound 2-83

[1813] To a solution of Compound 2-82 (200 mg, 0.07 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1 mL) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was purified by HPLC to afford Compound 2-83 (200 mg, 99%). ESI-MS m / z: [M / 3+H]+987.19, [M / 2+H]+1480.01.

[1814] Preparation of Compound 2-85

[1815] To a solution of Compound 2-83 (200 mg, 0.07 mmol) and Compound 2-84 (DBCO- -PEG4-NHS ester, 85 mg, 0.13 mmol) in A, A-dimethylformamide (5 mL) was added N, N-diisopropylethylamine (0.11 mL, 0.65 mmol) under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. NH4Cl solution (25 mL) and distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-85 (106 mg, 46%) as a brown solid. ESI-MS m / z: [M / 3+H]+1165.50, [M / 2+H]+1747.75.

[1816] Preparation of Compound 2-86

[1817] To a solution of Compound 2-85 (106 mg, 0.03 mmol) in tetrahydrofuran (2 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (12.7 mg, 0.30 mmol) in water (2 mL) at -78 °C. After stirring at 5 °C for 6 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-86 (15 mg, 15%) as an ivory solid. ESI-MS m / z:

[1818] [M / 3+H]+1067.41, [M / 2+H]+1600.64.

[1819] Example 55: Preparation of Compound 2-89

[1820] -370- FH13323832.11Attorney Docket No.: LCH-03925

[1821]

[1822] Preparation of Compound 2-87

[1823] To a solution of Compound 1-46 (464 mg, 0.37 mmol) in / V, / V-dimethylformamide (5 mL) were added Compound 2-7 (228 mg, 0.75 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 212 mg, 0.56 mmol), and / V. / V-diisopropylethylamine (0.19 mL, 1.12 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL). The organic layer was washed with saturated aq. NH4Cl solution (50 mL), saturated aq. NaHCO3 solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under

[1824] -371- FH13323832.11Attorney Docket No.: LCH-03925

[1825] reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-87 (570 mg, 99%). ESI-MS m / z: [M+H]+1531.08, [M / 2+H]+765.86.

[1826] Preparation of Compound 2-88

[1827] To a solution of Compound 2-87 (570 mg, 0.37 mmol) in tetrahydrofuran (10 mL) was added tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 0.93 mL, 0.93 mmol). After stirring at 70 °C for 16 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by reversed phase column chromatography to afford Compound 2-88 (240 mg, 51%). ESI-MS m / z: [M+H]+1241.93, [M / 2+H]+621.88.

[1828] Preparation of Compound 2-89

[1829] To a solution of Compound 2-88 (240 mg, 0.19 mmol) in A, A-dimethylformamide (5 mL) were added Compound 1-19 (402 mg, 0.42 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 183 mg, 0.48 mmol), and N, / V-di isopropylethylamine (0.16 mL, 0.97 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (30 mL), saturated aq. NaHCCL solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-89 (574 mg, 95%) as a brown oil. ESI-MS m / z: [M / 2+H]+1548.78, [M / 3+H]+1033.22.

[1830] Example 56: Preparation of Compound 2-92

[1831]

[1832] -372- FH13323832.11Attorney Docket No.: LCH-03925

[1833]

[1834] -373- FH13323832.11Attorney Docket No.: LCH-03925

[1835] Preparation of Compound 2-90

[1836] To a solution of Compound 2-89 (574 mg, 0.18 mmol) in methanol (4 mL) and tetrahydrofuran (5 mL) was added lithium hydroxide monohydrate (62 mg, 1.48 mmol) in distilled water (5 mL) at -50 °C. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-90 (125 mg, 24%). ESI-MS m / z: [M / 2+H]+1408.89, [M / 3+H]+906.28.

[1837] Preparation of Compound 2-91

[1838] To a solution of Compound 2-90 (125 mg, 0.04 mmol) and Compound 1-50 (36 mg, 0.09 mmol), tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 7 mg, 0.05 mmol) in ethanol (2.5 mL) were added copper (II) sulfate pentahydrate (10.8 mg, 0.04 mmol) in distilled water (1.2 mL), and sodium L-ascorbate (16.1 mg, 0.08 mmol) in distilled water (1.2 mL) under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was dissolved in methanol (1 mL) and tetrahydrofuran (2 mL) was added lithium hydroxide monohydrate (9.3 mg, 0.22 mmol) in distilled water (1 mL) at -50 °C. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-91 (51.8 mg, 37% for 2 steps). ESI-MS m / z: [M / 2+H]+1540.91, [M / 3+H]+1027.30.

[1839] Preparation of Compound 2-92

[1840] To a solution of Compound 2-91 (51.4 mg, 0.017 mmol) in acetonitrile (1.5 mL) was added phosphoric acid (85%, 0.95 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-92 (28.8 mg, 49%). ESIMS m / z: [M / 2+H]+1615.50, [M / 3+H]+1077.11.

[1841] Example 57: Preparation of Compound 2-100

[1842] -374- FH13323832.11Attorney Docket No.: LCH-03925

[1843]

[1844] Preparation of Compound 2-94

[1845] To a solution of Compound 2-93 (1.1 g, 1.26 mmol; prepared by the method described in WO 2017 / 137553A1) in tetrahydrofuran (5 mL) were added triphosgene (150 mg, 0.51 mmol) and 1 -methylimidazole (0.3 mL, 3.79 mmol) at 0 °C under N2. After stirring at 0 °C for 1 hour, Compound 2-93-1 (753 mg, 1.39 mmol; prepared by the method described in US Patent No.

[1846] 11,654,197 B2) was added to the reaction mixture at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NaHCO3 solution (20 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-94 (912 mg, 49%). ESI-MS m / z: [M+H]+1477.36.

[1847] Preparation of Compound 2-95

[1848] -375- FH13323832.11Attorney Docket No.: LCH-03925

[1849] To a solution of Compound 2-94 (912 mg, 0.62 mmol) in dichloromethane (7 mL) were added tetrakis(triphenylphosphine)palladium (0) (71 mg, 0.06 mmol) and pyrrolidine (0.08 mL, 0.93 mmol) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was diluted with dichloromethane (50 mL) and washed with distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-95 (726 mg, 84%). ESI-MS m / z: [M+H]+1393.29.

[1850] Preparation of Compound 2-97

[1851] To a solution of Compound 2-95 (320 mg, 0.22 mmol) in dichloromethane (5 mL) were added triphosgene (27 mg, 0.09 mmol) and 1 -methylimidazole (0.05 mL, 0.68 mmol) at 0 °C under N2. After stirring at 0 °C for 30 minutes, Compound 2-96 (411 mg, 0.45 mmol; prepared by the method described in US Patent No. 11,654,197 B2) was added to the reaction mixture at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with saturated aq. NaHCO3 solution (20 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-97 (237 mg, 53%). ESI-MS m / z: [M+H]+1941.61.

[1852] Preparation of Compound 2-98

[1853] To a solution of Compound 2-97 (237 mg, 0.12 mmol) in tetrahydrofuran (1 mL) and water (1 mL) was added acetic acid (1 mL) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NaHCCh solution (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-98 (151 mg, 72%). ESI-MS m / z: [M+H]+1713.42

[1854] Preparation of Compound 2-99

[1855] To a solution of Compound 2-98 (151 mg, 0.08 mmol) in dichloromethane (3 mL) was added Dess-Martin periodinane (82 mg, 0.19 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with saturated aq. NaHCCL solution (10 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under

[1856] -376- FH13323832.11Attorney Docket No.: LCH-03925

[1857] reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-99 (148 mg, 98%). ESI-MS m / z: [M+H]+1710.26.

[1858] Preparation of Compound 2-100

[1859] To a solution of Compound 2-99 (148 mg, 0.08 mmol) in tetrahydrofuran (1 mL) and methanol (0.5 mL) was added lithium hydroxide monohydrate (25 mg, 0.60 mmol) in water (1.5 mL) at -78 °C. After stirring at 0 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-100 (53 mg, 42%). ESI-MS m / z: [M+H]+1678.20.

[1860] Example 58: Preparation of Compound 2-102

[1861]

[1862] -377- FH13323832.11Attorney Docket No.: LCH-03925

[1863]

[1864] Preparation of Compound 2-101

[1865] To a solution of Compound 2-100 (50 mg, 0.03 mmol) and Compound 2-25 (24 mg, 0.01 mmol) in ethanol (3.5 mL) were added tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 4.45 mg, 0.008 mmol), copper (II) sulfate pentahydrate (12 mg, 0.05 mmol), and sodium L-ascorbate (13 mg, 0.06 mmol) in distilled water (0.5 mL) under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 2-101 (49 mg, 68%). ESIMS m / z: [M / 3+H]+1429.30.

[1866] Preparation of Compound 2-102

[1867] To a solution of Compound 2-101 (49 mg, 0.01 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.2 mL) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was purified by HPLC to afford Compound 2-102 (21 mg, 44%). ESI-MS m / z: [M / 4+H+] 1033.65.

[1868] Example 59: Preparation of Compound 2-105

[1869] -378- FH13323832.11Attorney Docket No.: LCH-03925

[1870]

[1871] -379- FH13323832.11Attorney Docket No.: LCH-03925

[1872]

[1873] Preparation of Compound 2-103

[1874] To a solution of Compound 2-36 (204 mg, 0.07 mmol) in A-dimethylformamide (3 mL) were added DXd2 (99 mg, 0.15 mmol; prepared by the method described in US Patent No.

[1875] 10,117,952 B2) and A. A-diisopropylethylamine (0.05 mL, 0.29 mmol) under N2. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4Cl solution (10 mL), distilled water (10 mL), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-103 (254 mg, crude). [M / 2+H]+1702.09. [M / 3+H]+1135.05.

[1876] Preparation of Compound 2-104

[1877] To a solution of Compound 2-103 (254 mg, 0.07 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (25 mg, 0.59 mmol) in water (1 mL) at -78 °C. The reaction mixture was stirred at 5 °C for 4 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-104 (80 mg, 34% in 2 steps) as a yellow solid. ESI-MS m / z: [M / 2+H]+1561.83. [M / 3+H]+1041.60.

[1878] Preparation of Compound 2-105

[1879] To a solution of Compound 2-104 (80 mg, 0.03 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 0.4 mL) at 0 °C. After stirring at room temperature for 5 hours, the reaction

[1880] -380- FH13323832.11Attorney Docket No.: LCH-03925

[1881] mixture was purified by HPLC to afford Compound 2-105 (53 mg, 70%) as a yellow solid. ESIMS m / z: [M / 2+H]+1483.60, [M / 3+H]+989.53.

[1882] Example 60: Preparation of Compound 2-109

[1883]

[1884] -381- FH13323832.11Attorney Docket No.: LCH-03925

[1885]

[1886] Preparation of Compound 2-107

[1887] To a solution of Compound 2-36 (140 mg, 0.05 mmol) and Compound 2-106 (76.5 mg, 0.11 mmol; prepared by the method described in WO 2023 / 209441 Al) in N, N- dimethylformamide (5 mL) were added 1-hydroxy-7-azabenzotriazole (HOAt, 2.1 mg, 0.02 mmol) and A. A-diisopropylethylamine (0.04 mL, 0.26 mmol) at 0 °C under N2. The reaction mixture was warmed to room temperature and stirred for 12 hours. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4Cl solution (20 mL), distilled water (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column

[1888] -382- FH13323832.11Attorney Docket No.: LCH-03925

[1889] chromatography to afford Compound 2-107 (140 mg, 84%) as a white solid. ESI-MS m / z:

[1890] [M / 3+H]+1087.99.

[1891] Preparation of Compound 2-108

[1892] To a solution of Compound 2-107 (140 mg, 0.04 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (14 mg, 0.34 mmol) in water (1 mL) at -78 °C. After stirring at 0 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-108 (84 mg, 66%) as a white solid. ESI-MS m / z: [M / 3+H]+994.45.

[1893] Preparation of Compound 2-109

[1894] To a solution of Compound 2-108 (84 mg, 0.03 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.3 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-109 (61 mg, 77%) as a white solid. ESI-MS m / z: [M / 3+H]+942.53.

[1895] Example 61: Preparation of Compound 2-113

[1896]

[1897] -383- FH13323832.11Attorney Docket No.: LCH-03925

[1898]

[1899] -384- FH13323832.11Attorney Docket No.: LCH-03925

[1900] Preparation of Compound 2-111

[1901] To a solution of Compound 2-36 (140 mg, 0.05 mmol) in AW-dimethylformamide (5 mL) were added Compound 2-110 (68 mg, 0.11 mmol; prepared by the method described in WO 2023 / 209441 Al) and AW-diisopropylethylamine (0.09 mL, 0.51 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4Cl solution (10 mL), distilled water (10 mL), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-111 (100 mg, 62%) as a colorless oil. ESI-MS m / z: [M / 2+H]+1558.66, [M / 3+H]+1039.85.

[1902] Preparation of Compound 2-112

[1903] To a solution of Compound 2-111 (100 mg, 0.03 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (13 mg, 0.32 mmol) in water (2 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 2 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by prep-HPLC to afford Compound 2-112 (36 mg, 39%) as a white solid. ESI-MS m / z:

[1904] [M / 2+H]+1418.67, [M / 3+H]+946.54.

[1905] Preparation of Compound 2-113

[1906] To a solution of Compound 2-112 (36 mg, 0.01 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 1 mL) at 0 °C. After stirring at room temperature for 1 hour, the reaction mixture was purified by HPLC to afford Compound 2-113 (13.6 mg, 40%) as a white solid. ESIMS m / z: [M / 2+H]+1341.23, [M / 3+H]+894.43.

[1907] Example 62: Preparation of Compound 2-115

[1908]

[1909] -385- FH13323832.11Attorney Docket No.: LCH-03925

[1910] Preparation of Compound 2-114

[1911] To a solution of Compound 1-6 (1 g, 2.44 mmol) in dichloromethane (22 mL) was added Dess-Martin periodinane (1.55 g, 3.65 mmol) under N2. After stirring at room temperature for 16 hours, saturated aq. sodium thiosulfate pentahydrate solution (10 mL) and saturated aq. NaHCCL solution (20 mL) were added to the reaction mixture. The reaction mixture was stirred until the solid completely dissolved. The resulting mixture was diluted with dichloromethane (40 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, the resulting residue was purified by column chromatograph...

Claims

Attorney Docket No.: LCH-03925We claim:

1. A conjugate comprising a structure represented by formula I or a pharmaceutically acceptable salt thereof:whereinL1comprises an alkylene (e.g., an alkylene substituted with a reactive group, such as amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl);Y1, and Y3are each independently O, N(R3), or S;,X1is -N(R2)C(O)-, -C(O)N(R2)-, -C(O)N(R2)(CH2)Z-, -(CH2)ZC(O)N(R2) -C(O)-, -C(O)O-, -OC(O)-, -S(O2)N(R2)-, -N(R2)S(O2)-, -P(O)(R3)N(R2)-, -N(R2)P(O)(R3)-, -P(O)2N(R2)-, or -N(R2)P(O)2-;R1and R2are each independently H, alkyl, aryl, or aralkyl;each R3is independently alkyl, aryl, or aralkyl;z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; andLg is a ligand, an active agent, or a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl such as isoprenyl, or alkynyl).

2. The conjugate of claim 1, wherein Y2is H.

3. The conjugate of claim 1, comprising a structure represented by formula la or a pharmaceutically acceptable salt thereof:-763- FH13323832.11Attorney Docket No.: LCH-03925lawhereinL1comprises an alkylene (e.g., an alkylene substituted with a reactive group, such as amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl);Y1, Y2, and Y3are each independently O, N(R3), or S;X1is -N(R2)C(O)-, -C(O)N(R2)-, -C(O)N(R2)(CH2)Z-, -(CH2)ZC(O)N(R2) -, -C(O)-, -C(O)O-,R1, R2, and R3are each independently H, alkyl, aryl, or aralkyl;z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; andLg is a ligand, an active agent, or a reactive group (e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl such as isoprenyl, or alkynyl).

4. The conjugate of any one of claims 1-3, wherein the conjugate has a structure represented by formula lb or a pharmaceutically acceptable salt thereof:whereinL2, L3, and L4each independently comprise an alkylene;V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;T1, T2, and T3are each independently a bond, -O-, or a self-immolative moiety;-764- FH13323832.11Attorney Docket No.: LCH-03925B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamide, aryl, heteroaryl, or heterocyclyl; orV1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety; and ml, m2, and m3 are each independently 1, 2, or 3.

5. The conjugate of any one of claims 1-4, wherein Lg is an antibody.

6. The conjugate of claim 5, wherein the antibody is a humanized antibody or a human antibody.

7. The conjugate of claim 5 or 6, wherein the antibody is selected from a monoclonal antibody, a domain antibody (dAb), a single chain antibody (scAb), a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single chain variable fragment (scFv), an scFv-Fc fragment, a single domain heavy chain antibody, a single domain light chain antibody, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.

8. The conjugate of any one of claims 1-4, wherein Lg is a reactive group.

9. The conjugate of claim 8, wherein Lg is amino, azido, hydroxylamino, halo, keto, aldehyde, ester, amido, alkenyl, or alkynyl.

10. The conjugate of claim 9, wherein Lg is11. The conjugate of claim 8, wherein Lg is vinylpyridyl.

12. The conjugate of claim 8, wherein Lg is maleimidyl.

13. The conjugate of claim 8, wherein Lg is azido.-765- FH13323832.11Attorney Docket No.: LCH-0392514. The conjugate of claim 8, wherein Lg is alkynyl (e.g.,15. The conjugate of any one of claims 1-14, wherein Y1is O.

16. The conjugate of any one of claims 1-15, wherein Y2is O.

17. The conjugate of any one of claims 1-16, wherein Y3is O.

18. The conjugate of any one of claims 1-17, wherein X1is -N(R2)C(O)-.

19. The conjugate of any one of claims 1-17, wherein X1is -C(O)N(R2)-.

20. The conjugate of claim 18 or 19, wherein R2is H.

21. The conjugate of any one of claims 1-20, wherein L1comprises a Ci-Cioo alkylene.

22. The conjugate of any one of claims 1-20, wherein L1comprises a C1-C50 alkylene.

23. The conjugate of any one of claims 1-22, wherein L1further comprises an oligoethylene glycol.

24. The conjugate of claim 23, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

25. The conjugate of claim 23, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

26. The conjugate of any one of claims 1-25, wherein L1is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g.,-766- FH13323832.11Attorney Docket No.: LCH-03925hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide.

27. The conjugate of any one of claims 1-26, wherein L1is substituted with an oligoethylene glycol.

28. The conjugate of claim 27, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

29. The conjugate of claim 27, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

30. The conjugate of any one of claims 27-29, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl).

31. The conjugate of any one of claims 27-29, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

32. The conjugate of any one of claims 1-31, wherein L1further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties).

33. The conjugate of any one of claims 1-32, wherein L1further comprises a structure represented by formula Ila:IlawhereinA1represents a linkage to X1;A2represents a linkage to Lg;X4and X5are each independently O, S, or N(R7);-767- FH13323832.11Attorney Docket No.: LCH-03925R4and R5are each H or alkyl; or R4and R5combine to form a cycloalkyl;R6is H or alkyl; andR7is H, alkyl, aryl, or aralkyl.

34. The conjugate of claim 33, wherein X4is N(R7).

35. The conjugate of claim 34, wherein R7is H.

36. The conjugate of any one of claims 33-35, wherein X5is O.

37. The conjugate of any one of claims 33-36, wherein R4is alkyl ( e.g., methyl).

38. The conjugate of any one of claims 33-37, wherein R5is H.

39. The conjugate of any one of claims 33-37, wherein R5is alkyl ( e.g., methyl).

40. The conjugate of any one of claims 33-38, wherein R4and R5combine to form a cycloalkyl (e.g., cyclobutyl).

41. The conjugate of any one of claims 33-40, wherein R6is H.

42. The conjugate of any one of claims 33-40, wherein R6is alkyl.

43. The conjugate of any one of claims 4-32, wherein L1further comprises a structure represented by formula lib:libwhereinA1represents a linkage to X1;A2represents a linkage to Lg;R4and R5are each H or alkyl; or R4and R5combine to form a cycloalkyl; and-768- FH13323832.11Attorney Docket No.: LCH-03925R6is H or alkyl.

44. The conjugate of claim 43, wherein R4is alkyl (e.g., methyl).

45. The conjugate of claim 43 or 44, wherein R5is H.

46. The conjugate of claim 43 or 44, wherein R5is alkyl ( e.g., methyl).

47. The conjugate of claim 43, wherein R4and R5combine to form a cycloalkyl ( e.g., cyclobutyl).

48. The conjugate of any one of claims 43-47, wherein R6is H.

49. The conjugate of any one of claims 43-47, wherein R6is alkyl.

50. The conjugate of any one of claims 4-32, wherein L1further comprises a structure represented by formula lie:liewhereinA1represents a linkage to X1;A2represents a linkage to Lg; andR6is H or alkyl.

51. The conjugate of claim 50, wherein R6is H.

52. The conjugate of claim 50, wherein R6is alkyl.

53. The conjugate of any one of claims 1-52, wherein L1further comprises a structure represented by formula Illa, Illb, or IIIc:-769- FH13323832.11Attorney Docket No.: LCH-03925whereineach A1represents a linkage to X1;each A2represents a linkage to Lg.

54. The conjugate of any one of claims 1-53, wherein L1further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

55. The conjugate of any one of claims 1-54, wherein L1further comprises a structure represented by formula IVa or IVb:IVa IVbwhereineach A1represents a linkage to X1; andeach A2represents a linkage to Lg.

56. The conjugate of any one of claims 1-55, wherein L1further comprises a structure represented by formula V:Vwherein nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;each A1represents a linkage to X1; andeach A2represents a linkage to Lg.-770- FH13323832.11Attorney Docket No.: LCH-0392557. The conjugate of claim 56, wherein nl is 1, 2, 3, 4, or 5.

58. The conjugate of any one of claims 1-57, wherein L1further comprises an amino acid (e.g., a hydrophilic amino acid).

59. The conjugate of any one of claims 1-57, wherein L1further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

60. The conjugate of claim 58 or 59, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

61. The conjugate of claim 58 or 59, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine.

62. The conjugate of claim 58 or 59, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

63. The conjugate of claim 58 or 59, wherein the amino acid(s) are selected from aspartate and glutamate.

64. The conjugate of claim 58 or 59, wherein the amino acid(s) are sarcosine.

65. The conjugate of any one of claims 1-64, wherein L1further comprises a polypeptoid (e.g., polysarcosine).

66. The conjugate of any one of claims 4-65, wherein L2comprises a Ci-Cioo alkylene.

67. The conjugate of any one of claims 4-65, wherein L2comprises a C1-C50 alkylene.

68. The conjugate of any one of claims 4-67, wherein L2further comprises an oligoethylene glycol.-771- FH13323832.11Attorney Docket No.: LCH-0392569. The conjugate of claim 68, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties).

70. The conjugate of claim 68, wherein the oligoethylene glycol comprises 5 ethylene glycol moieties.

71. The conjugate of any one of claims 4-70, wherein L2further comprises amidoalkoxy (e.g., amidomethoxy) or carboxyalkoxy (e.g., carboxymethoxy).

72. The conjugate of any one of claims 4-71, wherein L2further comprises at least one amido moiety.

73. The conjugate of claim 72, wherein L2comprises 1, 2, 3, 4, 5, or 6 amido moieties.

74. The conjugate of claim 72, wherein L2comprises 1 or 2 amido moieties.

75. The conjugate of claim 74, wherein L2comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).

76. The conjugate of any one of claims 4-75, wherein L2further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

77. The conjugate of any one of claims 4-75, wherein L2further comprises a structure represented by formula Via or Vlb:whereineach Ax1represents a linkage to T1; andeach Ax2represents a linkage to V1.-772- FH13323832.11Attorney Docket No.: LCH-0392578. The conjugate of any one of claims 4-77, wherein L2is substituted with an oligoethylene glycol.

79. The conjugate of claim 78, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

80. The conjugate of claim 78, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

81. The conjugate of any one of claims 78-80, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl).

82. The conjugate of any one of claims 78-80, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

83. The conjugate of any one of claims 4-82, wherein L2further comprises an amino acid (e.g., a hydrophilic amino acid).

84. The conjugate of any one of claims 4-82, wherein L2further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

85. The conjugate of claim 83 or 84, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

86. The conjugate of claim 83 or 84, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

87. The conjugate of claim 83 or 84, wherein the amino acid(s) are selected from aspartate and glutamate.-773- FH13323832.11Attorney Docket No.: LCH-0392588. The conjugate of claim 83 or 84, wherein the amino acid(s) are sarcosine.

89. The conjugate of any one of claims 4-88, wherein L2further comprises a polypeptoid (e.g., polysarcosine).

90. The conjugate of any one of claims 4-89, wherein V1is a bond.

91. The conjugate of any one of claims 4-89, wherein V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by formula Vila or a pharmaceutically acceptable salt thereof:VilawhereinAx3represents a linkage to L2;Lx1and Lx2each independently comprise an alkylene;Tx1and Tx2are each independently a bond or a self-immolative moiety; andBx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

92. The conjugate of any one of claims 4-89, wherein V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula Vllb or a pharmaceutically acceptable salt thereof:VllbwhereinAx3represents a linkage to L2;Lx1and Lx2each independently comprise an alkylene;-774- FH13323832.11Attorney Docket No.: LCH-03925Tx1and Tx2are each independently a bond or a self-immolative moiety; andBx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

93. The conjugate of any one of claims 4-89, wherein V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula Vile or a pharmaceutically acceptable salt thereof:VilewhereinAx3represents a linkage to L2;Lx1and Lx2each independently comprise an alkylene;0 0Gx1, Gx2, and Gx3are each independently an alkylene,each Rx1is independently H, alkyl, or aralkyl;Tx1and Tx2are each independently a bond or a self-immolative moiety; andBx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

94. The conjugate of any one of claims 4-89, wherein V1is C and V1, T1and B1together represent a branched moiety having a structure represented by formula Vlld or a pharmaceutically acceptable salt thereof:-775- FH13323832.11Attorney Docket No.: LCH-03925VlldwhereinAx3represents a linkage to L2;Lx1, Lx2, and Lx3each independently comprise an alkylene;Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; andBx1, Bx2, and Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

95. The conjugate of claim 94, wherein the heteroaryl of Bx1, Bx2, or Bx3is further substituted with alkylene or amido.

96. The conjugate of claim 94, wherein the amido of Bx1, Bx2, or Bx3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

97. The conjugate of any one of claims 91-96, wherein Lx1comprises a Ci-Cioo alkylene.

98. The conjugate of any one of claims 91-96, wherein Lx1comprises a C1-C50 alkylene.

99. The conjugate of any one of claims 91-98, wherein Lx1further comprises a heteroaryl (e.g., triazolyl).

100. The conjugate of any one of claims 91-99, wherein Lx1further comprises an oligoethylene glycol.

101. The conjugate of claim 100, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

102. The conjugate of claim 100, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.-776- FH13323832.11Attorney Docket No.: LCH-03925103. The conjugate of claim 100, wherein the oligoethylene glycol comprises 4 ethylene glycol moieties.

104. The conjugate of any one of claims 91-103, wherein Lx2comprises a Ci-Cioo alkylene.

105. The conjugate of any one of claims 91-103, wherein Lx2comprises a C1-C50 alkylene.

106. The conjugate of any one of claims 91-105, wherein Lx2further comprises an oligoethylene glycol.

107. The conjugate of claim 106, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

108. The conjugate of claim 106, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

109. The conjugate of any one of claims 91-108, wherein Lx3comprises a C1-C100 alkylene.

110. The conjugate of any one of claims 91-109, wherein Lx3comprises a C1-C50 alkylene.

111. The conjugate of any one of claims 91-110, wherein Lx3further comprises an oligoethylene glycol.

112. The conjugate of claim 111, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

113. The conjugate of any one of claims 91-112, wherein Lx3further comprises a heteroaryl (e.g., triazolyl).

114. The conjugate of any one of claims 4-113, wherein T1, Tx1, Tx2, or Tx3have a structure represented by formula VIII or a pharmaceutically acceptable salt thereof:-777- FH13323832.11Attorney Docket No.: LCH-03925VIIIwhereineach Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;Wx1is -*C(O)-, -*C(O)N(Rx7)-, -*N(RX7)C(O)-, -*(CH2)tx1N(Rx7)C(O)-, -*C(O)O-, - *S(O2)N(Rx7)-, -*P(O)(RX8)N(RX7)-, -*S(O)N(RX7)-, or -*P(O2)N(Rx7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula VIII, Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Ja1is H or alkyl;Ja2is H or alkyl; orJa1and Ja2combine to form an oxo;tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nxl is 0, 1, 2, or 3;Ax4represents a linkage to B1, Bx Bx2, or Bx3; andAx5represents a linkage to L2, Lx1, Lx2, or Lx3.

115. The conjugate of any one of claims 4-114, wherein T1, Tx1, Tx2, or Tx3have a structure represented by formula VIII or a pharmaceutically acceptable salt thereof:-778- FH13323832.11Attorney Docket No.: LCH-03925VIIIwhereineach Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;Wx1is -*C(O)-, -*C(O)N(Rx7)-, -*N(RX7)C(O)-, -*(CH2)tx1N(Rx7)C(O)-, -*C(O)O-, - *S(O2)N(Rx7)-, -*P(O)(RX8)N(RX7)-, -*S(O)N(RX7)-, or -*P(O2)N(Rx7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula VIII, Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Ja1is H or alkyl;Ja2is H or alkyl; orJa1and Ja2combine to form an oxo;tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nxl is 0, 1, 2, or 3;Ax4represents a linkage to B1, Bx Bx2, or Bx3; andAx5represents a linkage to L2, Lx1, or Lx2.

116. The conjugate of claim 115, wherein Rx2is H.-779- FH13323832.11Attorney Docket No.: LCH-03925117. The conjugate of claim 115 or 116, wherein Rx3is H.

118. The conjugate of any one of claims 115-117, wherein Rx4is H.

119. The conjugate of any one of claims 115-118, wherein Rx5is H.

120. The conjugate of any one of claims 115-119, wherein nxl is 0.

121. The conjugate of any one of claims 115-120, wherein Wx1is -*C(O)N(Rx7)-.

122. The conjugate of claim 121, wherein Rx7is alkyl optionally substituted with heteroaryl (e.g., triazolyl).

123. The conjugate of claim 122, wherein when substituted, the heteroaryl of Rx7is substituted with oligoethylene glycol.

124. The conjugate of claim 122, wherein Rx7is substituted with oligoethylene glycol.

125. The conjugate of claim 123 or 124, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties.

126. The conjugate of claim 124, wherein the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl.

127. The conjugate of claim 126, wherein the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol.

128. The conjugate of claim 126, wherein the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine).

129. The conjugate of claim 128, wherein the polypeptoid is substituted with an acyl.-780- FH13323832.11Attorney Docket No.: LCH-03925130. The conjugate of claim 126, wherein the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol.

131. The conjugate of any one of claims 123-125, wherein the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

132. The conjugate of any one of claims 115-131, wherein Rx7is H.

133. The conjugate of any one of claims 115-132, wherein Ja1is H.

134. The conjugate of any one of claims 115-133, wherein Ja2is H.

135. The conjugate of any one of claims 116-132, wherein Ja1and Ja2combine to form oxo.

136. The conjugate of any one of claims 4-135, wherein B1is an active agent.

137. The conjugate of any one of claims 4-135, wherein ml is 1.

138. The conjugate of any one of claims 4-135, wherein ml is 2.

139. The conjugate of any one of claims 4-135, wherein ml is 3.

140. The conjugate of any one of claims 4-85, wherein each T1is a bond.

141. The conjugate of any one of claims 4-95 and 140, wherein each B1, Bx Bx2, and Bx3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

142. The conjugate of any one of claims 4-89, 140, and 141, wherein each B1is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

143. The conjugate of any one of claims 4-142, wherein L3comprises a Ci-Cioo alkylene.-781- FH13323832.11Attorney Docket No.: LCH-03925144. The conjugate of any one of claims 4-142, wherein L3comprises a C1-C50 alkylene.

145. The conjugate of any one of claims 4-144, wherein L3further comprises an oligoethylene glycol.

146. The conjugate of claim 145, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties).

147. The conjugate of claim 145, wherein the oligoethylene glycol comprises 5 ethylene glycol moieties.

148. The conjugate of claim 145, wherein the oligoethylene glycol comprises 6 ethylene glycol moieties.

149. The conjugate of any one of claims 4-148, wherein L3further comprises at least one amido moiety.

150. The conjugate of claim 149, wherein L3comprises 1, 2, 3, 4, 5, or 6 amido moieties.

151. The conjugate of claim 150, wherein L3comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxylamido).

152. The conjugate of claim 151, wherein L3comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).

153. The conjugate of any one of claims 2-152, wherein L3further comprises a heteroaryl (e.g., pyrazolyl, triazolyl).

154. The conjugate of any one of claims 2-153, wherein L3further comprises a structure represented by formula IXa or IXb:-782- FH13323832.11Attorney Docket No.: LCH-03925IXa IXbwhereineach Ay1represents a linkage to T2; andeach Ay2represents a linkage to V2.

155. The conjugate of any one of claims 4-154, wherein L3is substituted with an oligoethylene glycol.

156. The conjugate of claim 155, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

157. The conjugate of claim 156, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

158. The conjugate of any one of claims 155-157, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl).

159. The conjugate of any one of claims 155-157, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

160. The conjugate of any one of claims 4-159, wherein L3further comprises an amino acid (e.g., a hydrophilic amino acid).

161. The conjugate of any one of claims 4-159, wherein L3further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

162. The conjugate of claim 160 or 161, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.-783- FH13323832.11Attorney Docket No.: LCH-03925163. The conjugate of claim 160 or 161, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine.

164. The conjugate of claim 160 or 161, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

165. The conjugate of claim 160 or 161, wherein the amino acid(s) are selected from aspartate and glutamate.

166. The conjugate of claim 160 or 161, wherein the amino acid(s) are sarcosine.

167. The conjugate of any one of claims 4-166, wherein L3further comprises a polypeptoid (e.g., polysarcosine).

168. The conjugate of any one of claims 4-167, wherein V2is a bond.

169. The conjugate of any one of claims 4-167, wherein V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by formula Xa or a pharmaceutically acceptable salt thereof:XawhereinAy3represents a linkage to L3;Ly1and Ly2each independently comprise an alkylene;Ty1and Ty2are each independently a bond, or a self-immolative moiety; andBy1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.-784- FH13323832.11Attorney Docket No.: LCH-03925170. The conjugate of any one of claims 4-167, wherein V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula Xb or a pharmaceutically acceptable salt thereof:XbwhereinAy3represents a linkage to L3;Ly1and Ly2each independently comprise an alkylene;Ty1and Ty2are each independently a bond or a self-immolative moiety; andBy1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

171. The conjugate of any one of claims 4-167, wherein V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula Xc or a pharmaceutically acceptable salt thereof:XcwhereinAy3represents a linkage to L3; andLy1and Ly2each independently comprise an alkylene;0 0 / .yAGy1, Gy2, and Gy3are each independently an alkylene,, orRy;each Ry1is independently H, alkyl, or aralkyl;Ty1and Ty2are each independently a bond or a self-immolative moiety; and-785- FH13323832.11Attorney Docket No.: LCH-03925By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

172. The conjugate of any one of claims 4-167, wherein V2is C and V2, T2and B2together represent a branched moiety having a structure represented by formula Xd or a pharmaceutically acceptable salt thereof:XdwhereinAy3represents a linkage to L3;Ly1, Ly2, and Ly3each independently comprise an alkylene;Ty1, Ty2, and Ty3are each independently a bond or a self-immolative moiety; andBy1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

173. The conjugate of claim 172, wherein the heteroaryl of By1, By2, or By3is further substituted with alkylene or amido.

174. The conjugate of claim 172, wherein the amido of By1, By2, or By3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

175. The conjugate of any one of claims 169-174, wherein Ly1comprises a Ci-Cioo alkylene.

176. The conjugate of any one of claims 169-174, wherein Ly1comprises a C1-C50 alkylene.

177. The conjugate of any one of claims 169-176, wherein Ly1further comprises a heteroaryl (e.g., triazolyl).-786- FH13323832.11Attorney Docket No.: LCH-03925178. The conjugate of any one of claims 169-177, wherein Ly1further comprises an oligoethylene glycol.

179. The conjugate of claim 178, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

180. The conjugate of claim 178, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

181. The conjugate of any one of claims 169-180, wherein Ly2comprises a Ci-Cioo alkylene.

182. The conjugate of any one of claims 169-180, wherein Ly2comprises a C1-C50 alkylene.

183. The conjugate of any one of claims 169-180, wherein Ly2further comprises an oligoethylene glycol.

184. The conjugate of claim 183, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

185. The conjugate of claim 183, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

186. The conjugate of any one of claims 169-185, wherein Ly3comprises a C1-C100 alkylene.

187. The conjugate of any one of claims 169-186, wherein Ly3comprises a C1-C50 alkylene.

188. The conjugate of any one of claims 169-187, wherein Ly3further comprises an oligoethylene glycol.-787- FH13323832.11Attorney Docket No.: LCH-03925189. The conjugate of claim 188, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

190. The conjugate of any one of claims 169-189, wherein Ly3further comprises a heteroaryl (e.g., triazolyl).

191. The conjugate of any one of claims 4-190, wherein T2, Ty1, Ty2, or Ty3has a structure represented by formula XI or a pharmaceutically acceptable salt thereof:whereineach Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;each Wy1is independently - -*C(O)O-, -*S(O2)Nwherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XI,Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;-788- FH13323832.11Attorney Docket No.: LCH-03925Jb1is H or alkyl;Jb2is H or alkyl; orJb1and Jb2combine to form an oxo;ty1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;ny1 is 0, 1, 2, or 3;Ay4represents a linkage to B2, By1, By2, or By3; andAy5represents a linkage to L3, Ly1, Ly2, or Ly3.

192. The conjugate of claim 191, wherein each Ry2is H.

193. The conjugate of claim 191 or 192, wherein each Ry3is H.

194. The conjugate of any one of claims 191-193, wherein each Ry4is H.

195. The conjugate of any one of claims 191-194, wherein each Ry5is H.

196. The conjugate of any one of claims 191-195, wherein each nyl is 0.

197. The conjugate of any one of claims 191-196, wherein each Wy1is -*C(O)N(Ry7)-.

198. The conjugate of claim 197, wherein Ry7is alkyl optionally substituted with heteroaryl (e.g., triazolyl).

199. The conjugate of claim 198, wherein when substituted, the heteroaryl of Ry7is substituted with oligoethylene glycol.

200. The conjugate of claim 198, wherein Ry7is substituted with oligoethylene glycol.

201. The conjugate of claim 199 or 200, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties.

202. The conjugate of claim 200, wherein the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl.-789- FH13323832.11Attorney Docket No.: LCH-03925203. The conjugate of claim 202, wherein the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol.

204. The conjugate of claim 202, wherein the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine).

205. The conjugate of claim 204, wherein the polypeptoid is substituted with an acyl.

206. The conjugate of claim 202, wherein the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol.

207. The conjugate of any one of claims 179-201, wherein the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

208. The conjugate of any one of claims 191-207, wherein each Ry7is H.

209. The conjugate of any one of claims 191-208, wherein Jb1is H.

210. The conjugate of any one of claims 191-208, wherein Jb2is H.

211. The conjugate of any one of claims 191-209, wherein Jb1and Jb2combine to form oxo.

212. The conjugate of any one of claims 4-211, wherein B2is an active agent.

213. The conjugate of any one of claims 4-212, wherein m2 is 1.

214. The conjugate of any one of claims 4-212, wherein m2 is 2.

215. The conjugate of any one of claims 4-212, wherein m2 is 3.

216. The conjugate of any one of claims 4-212, wherein each T2is a bond.-790- FH13323832.11Attorney Docket No.: LCH-03925217. The conjugate of any one of claims 4-168 and 172, wherein each B2, By1, By2, and By3is independently H, hydroxyl, guanidyl, sulfate, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

218. The conjugate of claim 217, wherein each B2is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

219. The conjugate of any one of claims 4-168, wherein B2is alkyl (e.g., ethyl) substituted with phosphonatyl.

220. The conjugate of any one of claims 4-168, wherein B2is alkyl (e.g., ethyl) substituted with phosphatyl.

221. The conjugate of any one of claims 4-168, wherein B2is alkyl substituted with hydroxyl (e.g., 1, 2, 3, 4, 5, or 6 hydroxyl groups).

222. The conjugate of any one of claims 4-168 and 217, wherein B2is amido (e.g., piperazineamido).

223. The conjugate of any one of claims 4-168 and 217, wherein B2is heterocyclyl (e.g., piperazyl).

224. The conjugate of any one of claims 4-168 and 217, wherein B2is alkoxy (e.g., methoxy).

225. The conjugate of any one of claims 4-168 and 217, wherein B2is carboxyl.

226. The conjugate of any one of claims 4-168, wherein B2is heteroaryl (e.g., tetrazolyl).

227. The conjugate of any one of claims 4-168 and 217, wherein B2is hydroxyl.-791- FH13323832.11Attorney Docket No.: LCH-03925228. The conjugate of any one of claims 4-168 and 217, wherein B2is amino (e.g., dimethyl amino).

229. The conjugate of any one of claims 4-228, wherein L4comprises a Ci-Cioo alkylene.

230. The conjugate of any one of claims 4-229, wherein L4comprises a C1-C50 alkylene.

231. The conjugate of any one of claims 4-230, wherein L4further comprises an oligoethylene glycol.

232. The conjugate of claim 231, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties).

233. The conjugate of claim 232, wherein the oligoethylene glycol comprises 6 ethylene glycol moieties.

234. The conjugate of any one of claims 231-233, wherein the oligoethylene glycol further comprises an amido moiety.

235. The conjugate of claim 234, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, or 6 amido moieties.

236. The conjugate of claim 234, wherein the oligoethylene glycol comprises 1 or 2 amido moieties.

237. The conjugate of claim 236, wherein L4comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).

238. The conjugate of any one of claims 4-237, wherein L4further comprises a heteroaryl (e.g., pyrazolyl, triazolyl).-792- FH13323832.11Attorney Docket No.: LCH-03925239. The conjugate of any one of claims 4-237, wherein L4further comprises a structure represented by formula Xlla or Xllb:Xlla Xllbwhereineach Az1represents a linkage to T3; andeach Az2represents a linkage to V3.

240. The conjugate of any one of claims 4-239, wherein L4is substituted with an oligoethylene glycol.

241. The conjugate of claim 240, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

242. The conjugate of claim 240, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

243. The conjugate of any one of claims 240-242, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl).

244. The conjugate of any one of claims 240-243, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

245. The conjugate of any one of claims 4-244, wherein L4further comprises an amino acid (e.g., a hydrophilic amino acid).

246. The conjugate of any one of claims 4-245, wherein L4further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).-793- FH13323832.11Attorney Docket No.: LCH-03925247. The conjugate of claim 245 or 246, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

248. The conjugate of claim 245 or 246, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine.

249. The conjugate of claim 245 or 246, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

250. The conjugate of claim 245 or 246, wherein the amino acid(s) are selected from aspartate and glutamate.

251. The conjugate of claim 245 or 246, wherein the amino acid(s) are sarcosine.

252. The conjugate of any one of claims 4-251, wherein L4further comprises a polypeptoid (e.g., polysarcosine).

253. The conjugate of any one of claims 4-252, wherein V3is a bond.

254. The conjugate of any one of claims 4-252, wherein V3is N and V3, T3, and B3together represent a branched moiety having a structure represented by formula Xllla or a pharmaceutically acceptable salt thereof:XlllawhereinAz3represents a linkage to L4;Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a self-immolative moiety; and-794- FH13323832.11Attorney Docket No.: LCH-03925Bz1and Bz2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

255. The conjugate of any one of claims 4-252, wherein V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula Xlllb or a pharmaceutically acceptable salt thereof:XlllbwhereinAz3represents a linkage to L4;Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a self-immolative moiety; andBz1and Bz2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

256. The conjugate of any one of claims 4-252, wherein V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula XIIIc or a pharmaceutically acceptable salt thereof:XIIIcwhereinAz3represents a linkage to L4;Lz1and Lz2each independently comprise an alkylene;0 0Gz1, Gz2, and Gz3are each independently an alkylene,each Rz1is independently H, alkyl, or aralkyl;-795- FH13323832.11Attorney Docket No.: LCH-03925Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a self-immolative moiety; andBz1and Bz2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

257. The conjugate of any one of claims 4-252, wherein V3is C and V3, T3, and B3together represent a branched moiety having a structure represented by formula XIIId or a pharmaceutically acceptable salt thereof:XIIIdwhereinAz3represents a linkage to L4;Lz1, Lz2, and Lz3each independently comprise an alkylene;Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; andBz1, Bz2, and Bz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

258. The conjugate of claim 257, wherein the heteroaryl of Bz1, Bz2, or Bz3is further substituted with alkylene or amido.

259. The conjugate of claim 257, wherein the amido of Bz1, Bz2, or Bz3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

260. The conjugate of any one of claims 254-259, wherein Lz1comprises a Ci-Cioo alkylene.

261. The conjugate of any one of claims 254-259, wherein Lz1comprises a C1-C50 alkylene.-796- FH13323832.11Attorney Docket No.: LCH-03925262. The conjugate of any one of claims 254-259, wherein Lz1further comprises a heteroaryl (e.g., triazolyl).

263. The conjugate of any one of claims 254-259, wherein Lz1further comprises an oligoethylene glycol.

264. The conjugate of claim 263, wherein Lz1comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

265. The conjugate of claim 263, wherein Lz1comprises 1, 2, 3, or 4 ethylene glycol moieties.

266. The conjugate of any one of claims 254-265, wherein Lz2comprises a Ci-Cioo alkylene.

267. The conjugate of any one of claims 254-265, wherein Lz2comprises a C1-C50 alkylene.

268. The conjugate of any one of claims 254-265, wherein Lz2further comprises an oligoethylene glycol.

269. The conjugate of claim 268, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

270. The conjugate of claim 268, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

271. The conjugate of any one of claims 257-270, wherein Lz3comprises a C1-C100 alkylene.

272. The conjugate of any one of claims 229-270, wherein Lz3comprises a C1-C50 alkylene.

273. The conjugate of any one of claims 229-270, wherein Lz3further comprises an oligoethylene glycol.-797- FH13323832.11Attorney Docket No.: LCH-03925274. The conjugate of claim 273, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

275. The conjugate of any one of claims 259-274, wherein Lz3further comprises a heteroaryl (e.g., triazolyl).

276. The conjugate of any one of claims 4-275, wherein T3, Tz1, Tz2, or Tz3have a structure represented by formula XIV or a pharmaceutically acceptable salt thereof:whereineach Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;Wz1is -*C(O)-, -*C(O)N(Rz7)-, -*N(RZ7)C(O)-, -*(CH2)tziN(Rz7)C(O)-, -*C(O)O-, -*S(O2)N(Rz7)-, -*P(O)( RZ8)N(RZ7)-, -*S(O)N(RZ7)-, or -*P(O2)N(Rz7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XIV, Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jc1is H or alkyl;-798- FH13323832.11Attorney Docket No.: LCH-03925Jc2is H or alkyl; orJc1and Jc2combine to form an oxo;tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nzl is 0, 1, 2, or 3;Az4represents a linkage to B3, Bz1, Bz2, or Bz3; andAz5represents a linkage to L4, Lz1, Lz2, or Lz3.

277. The conjugate of claim 276, wherein T3, Tz1, Tz2, or Tz3have a structure represented by formula XIV or a pharmaceutically acceptable salt thereof:whereineach Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;)O-,-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XIV, Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jc1is H or alkyl;-799- FH13323832.11Attorney Docket No.: LCH-03925Jc2is H or alkyl; orJc1and Jc2combine to form an oxo;tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nzl is 0, 1, 2, or 3;Az4represents a linkage to B3, Bz1, or Bz2; andAz5represents a linkage to L4, Lz1, or Lz2.

278. The conjugate of claim 276 or 277, wherein Rz2is H.

279. The conjugate of any one of claims 276-278, wherein Rz3is H.

280. The conjugate of any one of claims 276-279, wherein Rz4is H.

281. The conjugate of any one of claims 276-280, wherein Rz5is H.

282. The conjugate of any one of claims 276-281, wherein nzl is 0.

283. The conjugate of any one of claims 276-282, wherein Wz1is -*C(O)N(Rz7)-.

284. The conjugate of claim 283, wherein Rz7is alkyl optionally substituted with heteroaryl (e.g., triazolyl).

285. The conjugate of claim 284, wherein when substituted, the heteroaryl of Rz7is substituted with an oligoethylene glycol.

286. The conjugate of claim 284, wherein Rz7is substituted with oligoethylene glycol.

287. The conjugate of claim 285 or 286, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties.

288. The conjugate of claim 286, wherein the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl.-800- FH13323832.11Attorney Docket No.: LCH-03925289. The conjugate of claim 288, wherein the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol.

290. The conjugate of claim 288, wherein the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine).

291. The conjugate of claim 290, wherein the polypeptoid is substituted with an acyl.

292. The conjugate of claim 288, wherein the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol.

293. The conjugate of any one of claims 286-288, wherein the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

294. The conjugate of any one of claims 276-293, wherein Rz7is H.

295. The conjugate of any one of claims 276-294, wherein Jc1is H.

296. The conjugate of any one of claims 276-295, wherein Jc2is H.

297. The conjugate of any one of claims 276-294, wherein Jc1and Jc2combine to form oxo.

298. The conjugate of any one of claims 276-297, wherein B3is an active agent.

299. The conjugate of any one of claims 276-298, wherein m3 is 1.

300. The conjugate of any one of claims 276-298, wherein m3 is 2.

301. The conjugate of any one of claims 276-298, wherein m3 is 3.

302. The conjugate of any one of claims 276-301, wherein each T3is a bond.-801- FH13323832.11Attorney Docket No.: LCH-03925303. The conjugate of any one of claims 4-253 and 302, wherein each B3, Bz1, Bz2, and Bz3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

304. The conjugate of claim 303, wherein each B3is H, hydroxyl, amino, ( e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

305. The conjugate of any one of claims 1-304, wherein the conjugate comprises a structure selected from:-802- FH13323832.11Attorney Docket No.: LCH-03925-803- FH13323832.11Attorney Docket No.: LCH-03925-804- FH13323832.11Attorney Docket No.: LCH-03925-805- FH13323832.11Attorney Docket No.: LCH-03925-806- FH13323832.11Attorney Docket No.: LCH-03925-807- FH13323832.11Attorney Docket No.: LCH-03925-808- FH13323832.11Attorney Docket No.: LCH-03925-809- FH13323832.11Attorney Docket No.: LCH-03925-810- FH13323832.11Attorney Docket No.: LCH-03925-811- FH13323832.11Attorney Docket No.: LCH-03925-812- FH13323832.11Attorney Docket No.: LCH-03925-813- FH13323832.11Attorney Docket No.: LCH-03925-814- FH13323832.11Attorney Docket No.: LCH-03925-815- FH13323832.11Attorney Docket No.: LCH-03925-816- FH13323832.11Attorney Docket No.: LCH-03925-817- FH13323832.11Attorney Docket No.: LCH-03925-818- FH13323832.11Attorney Docket No.: LCH-03925-819- FH13323832.11Attorney Docket No.: LCH-03925-820- FH13323832.11Attorney Docket No.: LCH-03925-821- FH13323832.11Attorney Docket No.: LCH-03925-822- FH13323832.11Attorney Docket No.: LCH-03925-823- FH13323832.11Attorney Docket No.: LCH-03925-824- FH13323832.11Attorney Docket No.: LCH-03925-825- FH13323832.11Attorney Docket No.: LCH-03925-826- FH13323832.11Attorney Docket No.: LCH-03925-827- FH13323832.11Attorney Docket No.: LCH-03925-828- FH13323832.11Attorney Docket No.: LCH-03925-829- FH13323832.11Attorney Docket No.: LCH-03925-830- FH13323832.11Attorney Docket No.: LCH-03925-831- FH13323832.11Attorney Docket No.: LCH-03925-832- FH13323832.11Attorney Docket No.: LCH-03925-833- FH13323832.11Attorney Docket No.: LCH-03925-834- FH13323832.11Attorney Docket No.: LCH-03925-835- FH13323832.11Attorney Docket No.: LCH-03925-836- FH13323832.11Attorney Docket No.: LCH-03925-837- FH13323832.11Attorney Docket No.: LCH-03925-838- FH13323832.11Attorney Docket No.: LCH-03925-839- FH13323832.11Attorney Docket No.: LCH-03925-840- FH13323832.11Attorney Docket No.: LCH-03925-841- FH13323832.11Attorney Docket No.: LCH-03925-842- FH13323832.11Attorney Docket No.: LCH-03925-843- FH13323832.11Attorney Docket No.: LCH-03925-844- FH13323832.11Attorney Docket No.: LCH-03925-845- FH13323832.11Attorney Docket No.: LCH-03925-846- FH13323832.11Attorney Docket No.: LCH-03925-847- FH13323832.11Attorney Docket No.: LCH-03925-848- FH13323832.11Attorney Docket No.: LCH-03925-849- FH13323832.11Attorney Docket No.: LCH-03925-850- FH13323832.11Attorney Docket No.: LCH-03925-851- FH13323832.11Attorney Docket No.: LCH-03925-852- FH13323832.11Attorney Docket No.: LCH-03925-853- FH13323832.11Attorney Docket No.: LCH-03925-854- FH13323832.11Attorney Docket No.: LCH-03925-855- FH13323832.11Attorney Docket No.: LCH-03925-856- FH13323832.11Attorney Docket No.: LCH-03925-857- FH13323832.11Attorney Docket No.: LCH-03925-858- FH13323832.11Attorney Docket No.: LCH-03925-859- FH13323832.11Attorney Docket No.: LCH-03925-861- FH13323832.11Attorney Docket No.: LCH-03925-862- FH13323832.11Attorney Docket No.: LCH-03925-863- FH13323832.11Attorney Docket No.: LCH-03925-864- FH13323832.11Attorney Docket No.: LCH-03925-865- FH13323832.11Attorney Docket No.: LCH-03925-866- FH13323832.11Attorney Docket No.: LCH-03925-867- FH13323832.11Attorney Docket No.: LCH-03925-868- FH13323832.11Attorney Docket No.: LCH-03925-869- FH13323832.11Attorney Docket No.: LCH-03925-870- FH13323832.11Attorney Docket No.: LCH-03925-871- FH13323832.11Attorney Docket No.: LCH-03925-872- FH13323832.11Attorney Docket No.: LCH-03925-873- FH13323832.11FH13323832.11Attorney Docket No.: LCH-03925-876- FH13323832.11Attorney Docket No.: LCH-03925-877- FH13323832.11Attorney Docket No.: LCH-03925-878- FH13323832.11Attorney Docket No.: LCH-03925-879- FH13323832.11Attorney Docket No.: LCH-03925-880- FH13323832.11Attorney Docket No.: LCH-03925-881- FH13323832.11Attorney Docket No.: LCH-03925-882- FH13323832.11Attorney Docket No.: LCH-03925-883- FH13323832.11Attorney Docket No.: LCH-03925-884- FH13323832.11Attorney Docket No.: LCH-03925-885- FH13323832.11Attorney Docket No.: LCH-03925-886- FH13323832.11Attorney Docket No.: LCH-03925-887- FH13323832.11Attorney Docket No.: LCH-03925-888- FH13323832.11Attorney Docket No.: LCH-03925-889- FH13323832.11Attorney Docket No.: LCH-03925-890- FH13323832.11Attorney Docket No.: LCH-03925-891- FH13323832.11Attorney Docket No.: LCH-03925-892- FH13323832.11Attorney Docket No.: LCH-03925-893- FH13323832.11Attorney Docket No.: LCH-03925-894- FH13323832.11Attorney Docket No.: LCH-03925-895- FH13323832.11Attorney Docket No.: LCH-03925-896- FH13323832.11Attorney Docket No.: LCH-03925-897- FH13323832.11Attorney Docket No.: LCH-03925-898- FH13323832.11Attorney Docket No.: LCH-03925-899- FH13323832.11Attorney Docket No.: LCH-03925-900- FH13323832.11Attorney Docket No.: LCH-03925-901- FH13323832.11Attorney Docket No.: LCH-03925-902- FH13323832.11Attorney Docket No.: LCH-03925-903- FH13323832.11Attorney Docket No.: LCH-03925-904- FH13323832.11Attorney Docket No.: LCH-03925-905- FH13323832.11Attorney Docket No.: LCH-03925-906- FH13323832.11Attorney Docket No.: LCH-03925-907- FH13323832.11Attorney Docket No.: LCH-03925-908- FH13323832.11Attorney Docket No.: LCH-03925-909- FH13323832.11Attorney Docket No.: LCH-03925-910- FH13323832.11Attorney Docket No.: LCH-03925-911- FH13323832.11Attorney Docket No.: LCH-03925-912- FH13323832.11Attorney Docket No.: LCH-03925-913- FH13323832.11Attorney Docket No.: LCH-03925-914- FH13323832.11Attorney Docket No.: LCH-03925-915- FH13323832.11Attorney Docket No.: LCH-03925-916- FH13323832.11Attorney Docket No.: LCH-03925-917- FH13323832.11Attorney Docket No.: LCH-03925-918- FH13323832.11Attorney Docket No.: LCH-03925-919- FH13323832.11Attorney Docket No.: LCH-03925-920- FH13323832.11Attorney Docket No.: LCH-03925-921- FH13323832.11Attorney Docket No.: LCH-03925-922- FH13323832.11Attorney Docket No.: LCH-03925-923- FH13323832.11Attorney Docket No.: LCH-03925-924- FH13323832.11Attorney Docket No.: LCH-03925-925- FH13323832.11Attorney Docket No.: LCH-03925-926- FH13323832.11Attorney Docket No.: LCH-03925-927- FH13323832.11Attorney Docket No.: LCH-03925-928- FH13323832.11Attorney Docket No.: LCH-03925-929- FH13323832.11Attorney Docket No.: LCH-03925-930- FH13323832.11Attorney Docket No.: LCH-03925-931- FH13323832.11Attorney Docket No.: LCH-03925-932- FH13323832.11Attorney Docket No.: LCH-03925-933- FH13323832.11Attorney Docket No.: LCH-03925-934- FH13323832.11Attorney Docket No.: LCH-03925-935- FH13323832.11Attorney Docket No.: LCH-03925-936- FH13323832.11Attorney Docket No.: LCH-03925-937- FH13323832.11Attorney Docket No.: LCH-03925-938- FH13323832.11Attorney Docket No.: LCH-03925-939- FH13323832.11Attorney Docket No.: LCH-03925-940- FH13323832.11Attorney Docket No.: LCH-03925-941- FH13323832.11Attorney Docket No.: LCH-03925-942- FH13323832.11Attorney Docket No.: LCH-03925-943- FH13323832.11Attorney Docket No.: LCH-03925-944- FH13323832.11Attorney Docket No.: LCH-03925-945- FH13323832.11Attorney Docket No.: LCH-03925-946- FH13323832.11Attorney Docket No.: LCH-03925-947- FH13323832.11Attorney Docket No.: LCH-03925-948- FH13323832.11Attorney Docket No.: LCH-03925-949- FH13323832.11Attorney Docket No.: LCH-03925-950- FH13323832.11Attorney Docket No.: LCH-03925-951- FH13323832.11Attorney Docket No.: LCH-03925-952- FH13323832.11Attorney Docket No.: LCH-03925-953- FH13323832.11Attorney Docket No.: LCH-03925-954- FH13323832.11Attorney Docket No.: LCH-03925-955- FH13323832.11Attorney Docket No.: LCH-03925-956- FH13323832.11Attorney Docket No.: LCH-03925-957- FH13323832.11Attorney Docket No.: LCH-03925-958- FH13323832.11Attorney Docket No.: LCH-03925FH13323832.11Attorney Docket No.: LCH-03925-960- FH13323832.11Attorney Docket No.: LCH-03925; or a pharmaceutically acceptable salt thereof.

306. The conjugate of any one of claims 4-305, wherein each active agent is independently a chemotherapeutic agent or a toxin, or a combination thereof.

307. The conjugate of any one of claims 4-305, wherein each active agent is independently a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, an antiparasitic agent, and a combination thereof.

308. The conjugate of claim 306 or 307, wherein each of B1, B2, B3, Bx1, Bx2, By1, By2, Bz1,or Bz2is independently selected from-961- FH13323832.11Attorney Docket No.: LCH-03925-962- FH13323832.11Attorney Docket No.: LCH-03925309. The conjugate of any one of claims 4-306, wherein each active agent is a cytotoxic compound selected from a mitotic inhibitor, a DNA alkylating agent, an RNA targeting agent and a topoisomerase inhibitor, or a combination thereof.

310. The conjugate of any one of claims 4-306, wherein the cytotoxic compound is a thailanstatin or an amatoxin.

311. The conjugate of claim 310, wherein the cytotoxic compound is selected from an auristatin, a maytansinoid, a tubulysin, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine, and a camptothecin, or a combination thereof.

312. The conjugate of any one of claims 4-306, wherein the active agent is selected from: (a) erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, ethylenimine,-963- FH13323832.11Attorney Docket No.: LCH-03925altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, topotecan, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, KW-2189, CB1- TM1, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotoxin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomysins, actinomycin, antimycin, azaserine, bleomycins, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholinodoxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, liposomal doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6- mercaptopurine, thiamiprine, thioguanine, ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatrexate, demecolcine, diaziquone, eflornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidanmol, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2, 2’, 2” -trichlorotriethylamine, T-2 toxin, verracurin A, roridin A, and anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, arabinoside, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, docetaxel, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, vincristine, vinorelbine, novantrone, teniposide,-964- FH13323832.11Attorney Docket No.: LCH-03925daunomycin, aminopterin, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, or pharmaceutically acceptable salts, solvates, or acids of any of the foregoing;(b) monokine, a lymphokine, a traditional polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a, tumor necrosis factor-p, Mullerian inhibiting substance, mouse gonadotropin associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, an osteoinductive factor, an interferon, interferon-oc, interferon-P, interferon-y, a colony stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, an interleukin (IL), IL-1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, polypeptide factor, LIF, kit ligand, or a combination of any of the foregoing;(c) diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, amanitin a- amanitin, pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, an auristatin, tubulysin, geldanamycin, maytansinoid, SG2285, cryptophycin, an enediyne antibiotic, epothilone, taltobulin, azonafide, a toxoid, or a combination of any of the foregoing;(d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, or a combination of any of the foregoing;(e) a radioactive label,32P,35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination of any of the foregoing; (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, and an anti-parasitic agent, or a combination of any of the foregoing;(g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, LY117018, onapristone, or toremifene;(h) 4(5)-imidazoles, megestrol acetate, exemestane, or anastrozole;(i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine;-965- FH13323832.11Attorney Docket No.: LCH-03925(j) an aromatase inhibitor;(k) a protein kinase inhibitor;(l) a lipid kinase inhibitor;(m) an antisense oligonucleotide;(n) a ribozyme;(o) a vaccine; and(p) an anti-angiogenic agent.

313. The conjugate of claim 312, wherein the active agent is pyrrolobenzodiazepine.

314. The conjugate of any one of claims 4-306, wherein each active agent is selected from GENZ-644282, exatecan, monomethyl auristatin (e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FL118, Dxd derivative (e.g., Dxd2), a stimulator of interferon genes agonist, and a Toll-like receptor agonist (e.g., TLR7 / 8 agonist), or a combination thereof.

315. The conjugate of claim 314, wherein each active agent is selected from exatecan, monomethyl auristatin (e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FLU 8, Dxd derivative (e.g., Dxd2), and a stimulator of interferon genes agonist, or a combination thereof.

316. The conjugate of any one of claims 4-306, wherein each active agent is exatecan.

317. The conjugate of any one of claims 4-306, wherein each active agent is a monomethyl auristatin.

318. The conjugate of any one of claims 4-306, wherein each active agent is monomethyl auristatin E (MMAE).

319. The conjugate of any one of claims 4-306, wherein each active agent is monomethyl auristatin F (MMAF).-966- FH13323832.11Attorney Docket No.: LCH-03925320. The conjugate of any one of claims 4-306, wherein each active agent is FL118.

321. The conjugate of any one of claims 4-306, wherein each active agent is a stimulator of interferon genes agonist (STINGa).

322. The conjugate of claim 314, wherein the Toll-like receptor agonist is a TLR7 / 8 agonist.

323. The conjugate of claim 314, wherein the Toll-like receptor agonist is a TLR7 agonist.

324. The conjugate of claim 314, wherein the Toll-like receptor agonist is a TLR8 agonist.

325. The conjugate of any one of claims 4-306, wherein a first active agent is exatecan and a second active agent is a STINGa.

326. The conjugate of any one of claims 4-306, wherein a first active agent is MMAE and a second active agent is a STINGa.

327. The conjugate of any one of claims 4-306, wherein a first active agent is MMAF and a second active agent is a STINGa.

328. The conjugate of any one of claims 4-306, wherein a first active agent issecond active agent is a STINGa.

329. The conjugate of any one of claims 4-306, wherein a first active agent is MMAE and a second active agent is exatecan.-967- FH13323832.11Attorney Docket No.: LCH-03925330. The conjugate of any one of claims 4-306, wherein a first active agent is GENZ-644282 and a second active agent is a STINGa.

331. The conjugate of any one of claims 4-306, wherein a first active agent is taltobulin and a second active agent is a STINGa.

332. The conjugate of any one of claims 4-306, wherein the conjugate comprises at least 3 active agents.

333. The conjugate of any one of claims 4-306, wherein a first active agent is STINGa and a second active agent and a third active agent are each exatecan.

334. The conjugate of any one of claims 4-306, wherein a first active agent is STINGa and a second active agent and a third active agent are each MMAE.

335. The conjugate of any one of claims 4-306, wherein a first active agent is STINGa and a second active agent and a third active agent are each MMAF.

336. The conjugate of any one of claims 4-306, wherein a first active agent is MMAE and a second active agent and a third active agent are each exatecan.

337. The conjugate of any one of claims 4-306, wherein a first active agent is MMAF and a second active agent and a third active agent are each exatecan.

338. The conjugate of any one of claims 4-306, wherein a first active agent is MMAE and a second active agent and a third active agent are each a TLR7 / 8 agonist.-968- FH13323832.11Attorney Docket No.: LCH-03925339. The conjugate of any one of claims 4-306, wherein a first active agent is MMAE and asecond active agent and a third active agent are each340. The conjugate of any one of claims 4-306, wherein a first active agent is MMAF and a second active agent and a third active agent are each a TLR7 / 8 agonist.

341. A pharmaceutical composition comprising the conjugate of any one of claims 1-340 and a pharmaceutically acceptable excipient.

342. A method of treating a disease or disorder in a subject comprising administering a conjugate or composition of any one of claims 1-340 to the subject.

343. The method of claim 342, wherein the disease or disorder is cancer.

344. A method of conjugating an agent ( e.g., a ligand) to a branched linker comprising contacting the agent with the conjugate of any one of claims 1, 3, 4, and 12-340, wherein Lg is a reactive group ( e.g., amino, azido, hydroxylamino, halo, keto, aldehyde, ester, amido, alkenyl, or alkynyl).-969- FH13323832.11Attorney Docket No.: LCH-03925 345. The conjugate of claim 4, wherein the conjugate is selected from:-970- FH13323832.11Attorney Docket No.: LCH-03925-971- FH13323832.11Attorney Docket No.: LCH-03925-972- FH13323832.11Attorney Docket No.: LCH-03925-973- FH13323832.11Attorney Docket No.: LCH-03925-974- FH13323832.11Attorney Docket No.: LCH-03925-975- FH13323832.11Attorney Docket No.: LCH-03925-976- FH13323832.11Attorney Docket No.: LCH-03925-977- FH13323832.11Attorney Docket No.: LCH-03925-978- FH13323832.11Attorney Docket No.: LCH-03925-979- FH13323832.11Attorney Docket No.: LCH-03925-980- FH13323832.11Attorney Docket No.: LCH-03925-981- FH13323832.11Attorney Docket No.: LCH-03925-982- FH13323832.11Attorney Docket No.: LCH-03925-983- FH13323832.11Attorney Docket No.: LCH-03925-984- FH13323832.11Attorney Docket No.: LCH-03925-985- FH13323832.11Attorney Docket No.: LCH-03925-986- FH13323832.11Attorney Docket No.: LCH-03925-987- FH13323832.11Attorney Docket No.: LCH-03925-988- FH13323832.11Attorney Docket No.: LCH-03925-989- FH13323832.11Attorney Docket No.: LCH-03925FH13323832.11Attorney Docket No.: LCH-03925-991- FH13323832.11Attorney Docket No.: LCH-03925-992- FH13323832.11Attorney Docket No.: LCH-03925-993- FH13323832.11Attorney Docket No.: LCH-03925-994- FH13323832.11Attorney Docket No.: LCH-03925-995- FH13323832.11Attorney Docket No.: LCH-03925-996- FH13323832.11Attorney Docket No.: LCH-03925-997- FH13323832.11Attorney Docket No.: LCH-03925FH13323832.11Attorney Docket No.: LCH-03925or a pharmaceutically acceptable salt thereof.

346. The conjugate of claim 1, wherein the conjugate is selected from:-999- FH13323832.11Attorney Docket No.: LCH-03925-1000- FH13323832.11Attorney Docket No.: LCH-03925-1001- FH13323832.11Attorney Docket No.: LCH-03925-1002- FH13323832.11Attorney Docket No.: LCH-03925-1003- FH13323832.11